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iv. ABSTRACT 
Dermal bone is the oldest of vertebrate hard tissues; despite its evolutionary 
and developmental significance, its histogenesis is poorly understood. The 
present thesis investigates aspects of frontal bone and clavicle formation 
including layer morphogenesis, vasculogenesis, biomineralization and 
muscle:bone connectivity. I apply an array of molecular markers in a 3D 
time-course at single-cell resolution to genetically tracked and mutated 
mouse cell lineages. I uncover a growth mode not commensurate with 
traditional models of intramembranous ossification, whereby two molecularly 
distinct generative layers (external and internal) intercalate cells into the 
intervening cancellous/spongious layer, which elaborates with time. Cells in 
the external layer organize into rosette formations that act as archetypal units 
of cellular introgression, bearing the hallmarks of a tangential convergence-
extension movement. Both osteoblasts and endothelia enter into the 
spongious bone from the generative layers, forming an osteoblast-
endothelial interface in the cancellous layer and de novo vasculature in the 
maturing bone. Ablation of Hand2 in the neural crest lineage abrogates this 
internal sheet formation, substantiating the notion of ingression from the 
outer and inner (Hand2+) layers; Hand2 mediates this process in vivo by 
regulating the nuclear import of Runx2 protein, at the post-transcriptional 
level. The highly dynamic processes of layer formation and vascularization 
are related to bone mineralization using a time-course of matrix labeling, 
examined ex vivo and in vivo; this reveals extensive remodeling of existing 
mineral by osteoblasts and endothelial cells, which modulate the collagen 
scaffolds along which hydroxyapatite crystals are assembled in the absence 
of osteoclasts. This sheds light on possible mechanisms of skeletogenesis in 
acellular bone among jawed vertebrate ancestors. I finally investigate 
endochondral ossification of classically mesodermal occipital regions and 
find an additional neural crest-based invasion in those tissues. This sheds 
light onto the etiology of neurocristopathies and prompts a modification of 
present fate maps. 
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Fibroblastic growth factor receptor 1 
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genomic DNA 
green fluorescent protein 
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intracranial pressure 
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in situ hybridisation 
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polymerase chain reaction 
pectoralis muscle 
paraformaldehyde 
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a-Smooth muscle actin 
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v. OVERVIEW· GENERAL INTRODUCTION TO THESIS CONTENTS 
Dermal bone is the oldest form of ossification in evolutionary history, and one 
of the key novelties of jawed vertebrates, displaying a three-layered (diploe) 
organisation in the earliest known taxa. Two layers, one external (underneath 
the dermis, herein termed Layer 1) and one internal (adjacent to the brain, 
termed Layer 3 in this study) sandwich an intervening spongious/cancellar 
area, denoted Layer 2. During early paleontological studies the spongious 
layer was considered a passive 'bystander' of other biomineralisation 
processes, therefore, the underlying developmental processes responsible 
for bone layering, and the resulting three-dimensional bone architecture, has 
remained poorly understood. Although a large corpus of literature -genetic 
and developmental- exists, these studies rarely examined co-expression of 
relevant genes nor were they examined in 3D at high resolution (Abzhanov 
et al. 2007; Bandyopadhyay et al 2008; Franz-Odendaal et al. 2006; 
Buckwalter et al. 1995; Hall 2005; Paic et al. 2009). Therefore, molecular 
identities, fates and lineage origins of cells participating in dermal bone 
formation have not been studied in a comprehensive fashion and the gamut 
of literature describing intramembranous ossification is highly contradictory. 
While many studies have focused on sutures as places of lateral dermal 
bone expansion, the mechanism of how dermal bones grow in thickness has 
remained almost entirely obscure (Johnson et al. 2000; Lana-Elola et al. 
2007; Opperman et al. 2000; Ting et al. 2009). Instead, endochondral bone 
formation is often used as a proxy for understanding the ontogeny of dermal 
bones; patterns observed in studies of intramembranous bones are usually 
reconciled with the formation of the endochondral skeleton (Lieberman & 
Friedlaender 2005; Buckwalter 1995; Hall 2005). For example, the process of 
appositional addition of osteoblasts and matrix to the bone front in dermal 
bone was originally modelled based on what is known about mesodermal 
long bone formation. This co-opting of endochondral formation to resolve 
dermal bone formation means that the exact mechanism of intramembranous 
ossification is unresolved. 
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Work for this thesis aims to explore the entire process of dermal bone 
formation, from the condensed mesenchyme stage in murine embryonic 
development, through early post-natal maturation. In order to fully explore 
bone development an array of molecular markers was employed, chosen to 
encompass those traditionally associated with the four key processes in 
bone formation: Chapter 1. the establishment of layer morphogenesis as 
dictated by the osteoblastic cells within the bone; Chapter 2. the process of 
angiogenesis in bone growth thus the emergence of an 
osteoblastic/endothelial interface; Chapter 3. the mechanism by which the 
osteoid is calcified and the mineral phase is formed; and finally, Chapter 4. 
the generation of the bone:skeletal muscle interface. These features of bone 
maturation were concurrently 'explored utilising 3D reconstructions to 
visualise marker expression at the single-cell level in wild-type and 
genetically labelled and/or mutated murine tissues. 
The establishment of layer morphogenesis in dermal bone is explored in 
Chapter 1. There I will examine the number and location of generative 
(growth) surfaces in the frontal and clavicle bones in a time-course of 
development (sections 1.1-1.2). I discover that, in contrast to the traditional 
model of intramembranous ossification, the bone anlagen comprise two 
generative layers each of which remain contiguous from mid-way through 
murine gestation (E13) though postnatal development (P8) (section 1.1). I 
will describe how new cells, osteoblasts and endothelial cells, become part of 
growing layers and I provide molecular markers and genetiC (ablation) 
evidence pointing towards an unusual process of cells percolating into the 
inner (previously called 'spongious' or cancellar') layer of the dermal bone 
from both sides and (re)forming osteoblastic-endothelial sheets inside that 
inner layer, which generates the increasingly complex cancellous bone 
(sections 1.2-1.4). The process by which this occurs is similar to what is 
known in embryology as a convergence-extension/sheet migration process 
(section 1.5). 
The incorporation of new cells into the growing middle layer appears to take 
place at specific privileged places where cells organize in a rosette-type 
fashion in the external layer (L 1) (section 1.3). I will describe the molecular 
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and cellular nature of these rosettes, as well as evidence that rosettes are 
archetypal units of dermal thickness growth. Surprisingly, a (hitherto 
unrecognized) key process for regulated cell invasion appears to be the post-
transcriptional modification of transcription factors inside rosette cells. In 
section 1.4 I describe a new process of tethering by which the transcription 
factor Hand2 regulates the Runx2 protein's nuclear localization. I show how 
genetic ablation of Hand2 abrogates this process, which has fundamental 
implications for sheet formation, layer morphogenesis and ensuing 
biomineralisation. 
In Chapter 2 I test the validity of the traditionally held notion that dermal 
bones are pre-patterned by existing vasculature in the overlying dermis, 
which becomes encompassed by the growing bone (section 2.1). Contrasting 
this, I find the generative layers introducing osteoblasts to the nascent bone 
also provide the bone vasculature (section 2.2). There is de novo vessel 
formation in the bone and a unique relationship whereby osteoblasts and 
vasculature develop concurrently in direct juxtaposition to one another, 
preventing precocious ossification impinging on vascular formation (section 
2.2.2). Furthermore, the rosettes discovered during experiments of Chapter 1 
are shown to act as the mammalian counterpart to the pore canal system of 
basal vertebrates (section 2.2.3). 
The formation of the mineral phase of dermal bones is analysed in Chapter 3 
with specific regard to how layer morphogenesis affects the process of 
mineralisation. I examine how the spongious Layer 2 grows as a mineral 
entity using a time-course of both ex vivo (section 3.2) and in vivo (section 
3.3) labelling of the biomineralising zone. Traditionally (and to date) only 
matrix apposition from the outside (by osteoblasts) was considered, as 
mineral decay is believed to be established by osteoclasts. In contrast to this, 
results in Chapter 3 indicate younger matrix is found on the inside of older 
matrix, thus matrix is continually remodelled by reshaping the collagenous 
scaffolds upon which hydroxyapatite crystals are built (section 3.4); 
surprisingly this is achieved by osteoblasts that etch themselves into 
previously mineralised areas, cleave the collagen scaffolds on which mineral 
is laid, and expand mineralised areas from within (section 3.5). This 
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remodelling by cells from both generative layers leads to an amorphous core 
of mineral that is only later surrounded by late appositional matrix after birth 
(section 3.3). This sheds new light on the temporal sequence and 
directionality of mineralization. 
Having established the layer morphogenesis, vascularisation and 
biomineralisation in Chapters 1, 2 and 3, respectively, in Chapter 4 I examine 
the means by which musculoskeletal attachments can form, without 
impinging on the thickness growth of the bone. I find a unique subdivision of 
the most external periost-like tissue forms the enthesis (section 4.2.1) and I 
establish molecular marker signatures for the cells within the attachment 
region responsible for muscle connectivity (section 4.2.2), a finding that 
explains how the muscle scaffold can remain stable over long evolutionary 
periods while the process of ossification of attachment pOints might change. 
Results from Chapters 1 to 4 lead to the formation of a new model of dermal 
bone formation, the synopsis of which is found in Chapter 5. The 
coordination of layer morphogenesis, vasculogenesis, biomineralisation and 
enthesis formation are all dependent on the behaviours of highly invasive 
neural crest cells that form an osteoblastic-endothelial interface through 
sheet neogenesis. The continual expansion of the bone relies on perpetual 
integration of new cellular material; in the frontal bone both the osteoblastic 
and endothelial cells are found to derive from the neural crest and 
mesoderm. 
The discovery of a new contribution of neural crest to endothelia led to the 
final work of my PhD, where I re-examine the potential contribution of the 
neural crest to endochondral ossification in the cranial base. The 
development of this anatomical region holds significance for understanding 
the process of indirect ossification and has direct relevance to human 
diseases such as the Chiari malformation, as recent studies have indicated 
areas of the cranial base that are primarily affected in Chiari malformations 
are neural crest in origin. I map the previous evidence that the neural crest 
contributes cells to regions of the cranial base affected in Chiari "" in 
Chapter 6, where the etiological origins of affected areas is shown to be the 
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first unifying feature for the multitude of incongruent symptoms of the 
condition. 
In Chapter 7 I continue to explore the possibility that Chiari is a 
neurocristopathy and map the contributions of the neural crest to the late 
development of the posterior cranial fossa, the chief anatomical region 
affected in Chiari malformations. I find that cartilages that have previously 
been mapped as mesodermal (somitic) - namely the occipitals - become 
later invaded by an osteoblastic-endothelial front of neural crest origin. The 
surprising contribution of neural crest-derived endothelia to regions including 
the occipital protuberance, suprocciput, atlas and clivus, at late stages of 
murine pre-natal development, as well as the arachnoids, pericytes, and 
endothelia of the cortex indicate previously established fate maps may need 
to be amended as aspects of a wider time time-course (section 7.2). 
Finally, results from single cell transcriptome analyses of several neural 
crest-derived regions in the cranial base are presented in Chapter 8, 
supporting Chiari as a potential vasculogenic neurocristopathy and/or a 
connective tissue disorder (section 8.2). 
The work conducted in this thesis aimed to explore the generative 
architecture of intramembranous ossification and the role of the neural crest 
in the development of the cranial base. Each chapter inc\udes the re\evant 
introduction, results and an independent discussion, and each part (I and II) 
concludes with a summarising discussion pertaining to dermal bone 
formation (Chapter 5) and establishing Chiari as a neurocristopathy (Chapter 
9), respectively. 
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PART I: 
THE GENERATIVE ARCHITECTURE OF 
DERMAL BONE DEVELOPMENT 
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1. Cell biological foundations of dermal bone development 
1.1 The generative architecture of dermal bone formation 
1.1.1 Introduction 
The vertebrate skeleton comprises two types of bone, dermal and 
endochondral: dermal bone is the oldest form of ossification in evolutionary 
history, with the craniofacial region being the most primitive skeleton 
(Donoghue et al. 2006). Despite its ancient origins, the process of dermal 
bone development remains poorly understood (Hall and Miyake 2000; 
Donoghue and Sansom 2002; Janvier 2008). Dermal bone arises directly 
from mesenchymal cells in direct or intramembranous ossification; a process 
that differs dramatically from the extensively studied mechanism by which in-
direct/endochondral bones are formed. 
In the traditional model of intramembranous ossification, dermal bone 
formation is preceded by an increase in vascularisation at the site of future 
skeletogenesis, after which mesenchymal cells migrate to the area and are 
subjected to epithelial-mesenchymal interactions (Hall and Miyake 2000). 
These interactions lead to the condensation of the mesenchyme into 
trabeculae (Hall and Miyake 1992). Proper osteogenesis intitates when a 
sheet of mesenchymal cells in the trabecle differentiate into the osteoblastic 
lineage, as indicated by the expression of genes associated with a pre-
osteoblastic condition, namely Runx2 and Collagen I (Abzhanov et al. 2007). 
Next, a single layer of osteoblastic precursors further differentiate from pre-
osteoblasts into osteoblasts (a transition reportedly indicated by the 
expression of Osteopontin, and SSP II) and these cells start prodUCing 
osteoid (Figure 1.1), which mineralises to form the hardened calcified tissue 
(Lieberman and Friedlaender 2005; Abzhanov et al. 2007). Some 
osteoblasts become engulfed by the matrix they secrete and further 
differentiate into osteocytes capable of small amounts of rapid osteolysis 
(Soukhechba et al. 2009); at this stage the next layer of pre-osteoblasts 
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differentiates into osteoblasts and a second layer of osteoid is deposited 
(Figure 1.1). The osteogenic front thus continues to move through the 
mesenchyme, with successive layers of cells depositing new osteoid on top 
of the existing mineralized surface, growing the bone by apposition 
(Buckwalter et al. 1995). This arrangement results in the most mature 
mineralisation found at the deepest margin, with the superficial aspects of 
the bone being the most recently mineralised. Bone formation is completed 
by the addition of the inner and outer compacta, establishing the periosteum 
(Birnbaum et al. 2001; Hall 2005). Any further remodelling to the bone (to 
accommodate additional vasculature, bone resorption, etc.) is accomplished 
via osteoclasts arising from the bone marrow from monocyte and 
megakaryocyte precursors (Cohen 2006). Unlike endochondral bone 
formation, dermal bone develops from the mesenchyme without any cartilage 
precursor as a template. The architecture of the intramembranous anlagen 
is, therefore, dictated by two features: the pre-existing vasculature, around 
which the bone must form, and the generative layer of osteoblasts secreting 
the osteoid and mineralising the matrix (Figure 1.1). 
Dermal bone gives rise to the majority of the craniofacial skeleton (Gans and 
Northcutt 1983; Noden 1983; Couly et al. 1993; Le Douarin et al. 1993) and 
the histogenetic mechanism by which the bones form while accommodating 
the simultaneous expansion of the brain is poorly understood. Specifically of 
interest in the current study was elucidating the mechanism by which the 
dermal bones of the cranial vault expand in thickness without compromising 
cerebro-cortical development. 
The current study aimed to examine the validity of the traditional model of 
intramembranous ossification (described above), and explore the generative 
architecture and molecular characteristics of the cells involved in direct 
ossification. The study employed a wide-array of molecular markers to probe 
bone maturation and resolve the widely conflicting expression domains of 
these markers as reported in dermal bone development literature (Abzhanov 
et al. 2003; Hall 2005; Franz-Odendaal et al. 2006; Abzhanov et al. 2007; 
Bandyopadhyay et al. 2008). Markers were chosen such that they would 
assess the progression of overall bone formation and also the development 
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of cells through various stages of osteoblastic lineages (expected to advance 
from pre-osteoblast to osteoblast to osteocyte) (Table 1.1). 
The formation of the mesenchymal anlagen would be monitored using 
Fibronectin, a cell adhesion molecule and marker of sheet migration 
downstream of TGFj31 required for mesenchymal condensation formation, 
secreted by cells depositing a basal membrane (Bilezikian et a/. 2008) and 
expressed by early pre-osteoblasts (Franz-Odendaal et a/. 2006). Traditional 
pre-osteoblastic markers also included Runx2 (widely expressed in 
fibroblasts), as well as Collagen I and Collagen II (Franz-Odendaal et a/. 
2006). The previously identified transition to osteoblasts would be marked by 
Osteopontin and Osteocalcin expression (Franz-Odendaal et a/. 2006). 
Finally, the end stage of bone development, when bone is encased by a 
periosteum, would be indicated by the presence of CRABP1 and Undulin 
(Collagen XIV) (Bandyopadhyay et a/. 2008). Periostin (POSTN), or 
Osteoblast Specific Factor-2, is an additional marker of the periosteum which 
may also be expressed by pre-osteoblasts and has been found to regulate 
sheet migration of cells, a phenomenon well described for neural crest cells 
migrating into branchial arches or into the developing heart outflow tracts 
(Horiuchi et a/. 1999; Franz-Odendaal et a/. 2006; Zhu et a/. 2008). 
The current study mapped murine intramembranous ossification using high 
resolution imaging, which enables the structures to be recapitulated in 3D at 
single cell resolution. This approach would allow the bone maturation 
process to be examined in situ as any alternative approach (such as explant 
studies and in vitro bone growth) may have unknown consequences on the 
normal progression of dermal bone development. Double and triple 
immunohistochemistry (IHC) was favoured over RNA in situ hybridisation in 
order to monitor changes in protein localization (ex: nuclear versus 
cytoplasmic); the ramifications of using this methodology could not be 
predicted as high resolution imaging combined with IHC has not been 
previously utilised for in vivo analysis of dermal bone formation. 
1.1.2 Results 
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The traditional model of dermal bone formation describes differentiation 
progressing through the condensed mesenchyme, organising the anlage into 
layers of pre-osteoblasts (Runx2-positive, no osteoid secretion) and fully 
functioning osteoblasts that deposit osteoid and then calcify the matrix. In 
this model, at a given time-point there is only a single generative layer of fully 
differentiated osteoblasts, which abuts the pre-osteoblastic layer (Figure1.1). 
In addition to the expression of several characteristic markers, the 
progression through the osteoblastic lineages is accompanied by 
morphological changes (Table 1.1); mesenchymal cells of the dermis have 
the flattened morphology of fibroblasts, pre-osteoblasts have a relatively 
more rounded shape, and osteoblasts are expected to be round or cuboidal 
during their growth phase and pyramidal with extensive cellular processes 
thereafter (Lieberman and Friedlaender 2005; Lerner 2006; Schiavi 2006). In 
the traditional model of intramembranous ossification, cells percolate at 
random from the single osteoblastic front into the matrix. 
My initial analysis focused on a time-point midway through murine gestation 
when the characteristic architecture of the frontal bone would be established 
but bone development is incomplete, such that territories of the different cell 
lineages (pre-osteoblasts vs. osteoblasts) should be easily defined. In 
contrast to the expectation of a single generative (outer) surface, I find a tri-
layered architecture of the immature frontal bone where two laminae of thin, 
flattened cells sandwich an intervening space populated by larger, more 
rounded cells (Figure 1.2). Progressing from the dermis side, the external 
lamina is hitherto referred to as Layer 1 (L 1), the internal space as Layer 2 
(L2), and the internal lamina as Layer 3 (L3) (Figure 1.2A). Although 
containing morphogenically similar cells, Layers 1 and 3 are molecularly 
distinct. 
L 1, the external layer of flattened cells at the dermis-bone interface, 
expresses markers associated with the pre-osteoblastic condition, namely 
Runx2 and Collagen II (Figure 1.2). Notably, Runx2 expression is largely 
localised to the cytoplasm. In contrast, L3, the internal layer of flattened cells 
at the dura-bone interface, expresses markers associated with mature 
osteoblasts, namely Osteopontin and Collagen I (Figure 1.2), but is negative 
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for Runx2 and Collagen II proteins. Despite the flattened cell morphology, 
this finding may imply L3 contains the most mature (osteoblast) cells, while 
L 1 comprises the pre-osteoblasts; this formation would be consistent with a 
traditional model where the oldest layers are considered to be at the bottom 
of the bone and the youngest areas as the most superficial. 
However, contradicting this model of spatial segregation of pre-osteoblasts 
and osteoblasts, both layers 1 and 3 are populated by cells expressing 
proteins associated with the various stages of osteoblast maturation. The 
external layer, L 1, and the dermis display a wide expression of Osteocalcin, 
a marker traditionally associated with late osteoblasts in intramembranous 
ossification and osteocytes in endochondral ossification (Figure 1.3A) 
(Franz-Odendaal et al. 2006). Cells of both L 1 and L3 express the 
osteoblast/osteocyte marker J3-Catenin required for proper osteogenesis 
(Figure 1.3B) (Chen et al. 2007; Kramer et al. 2010). Conversely, Hand2, a 
gene associated with both heart and limb formation whose abrogation leads 
to craniofacial abnormalities (Yanagisawa et al. 2003), is more widely 
expressed by cells of L3, although focal expression of Hand2 in L 1 is noted 
(Figure 1.3C). 
Further complicating the characterisation of the laminar layers, both L 1 and 
L3 carry markers of the periosteum and/or perichondrium, which would not 
be expected to be present until the final stages of bone maturation. L 1 
strongly expresses CRABP1 and Undulin, with weaker expression of both 
found in L3; contrarily, L3 expression of POSTN is more marked than 
POSTN expression in L 1 (Figure 1.4). The perichondrium and periosteum 
are fundamental to endochondral bone development; they act as a cambial 
growth zone and a source of osteoblasts, they regulate differentiation of 
adjacent tissues and are critical for the growth and maintenance of the bones 
they encapsulate (Col not et al. 2004; Bandyopadhyay et al. 2008). The 
current results may indicate periosteal-like tissues are critical for early dermal 
bone formation. 
In addition to being periosteum-like, L 1 and L3 contain cells with high lateral 
mobility potential as they express Fibronectin, as well as F-Actin, a 
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component of lamellipodia and filopodia and a marker of cellular motility 
(Figure 1.5) (Fujii et al. 2010). The potential motility of cells within L 1 and L3 
is consistent with recent Oil labelling experiments exhibiting extensive lateral 
spreading from areas corresponding to the location of the laminar layers of 
the frontal bone (Figure 1.5 C-D) (Morriss-Kay 2001). 
The complexity of markers expressed in Layers 1 and 3 means neither can 
easily be ruled the single generative osteoblast layer, and there is a 
complete incongruence with traditional classification as both express pre-
osteoblastic, osteoblastic, osteocytic and non-osteoblastic markers; this 
raises the possibility that both layers could act as generative surfaces. To 
explore the roles of Layers 1 and 3 in bone development, the spatial and 
ontogenetic development of the diploe architecture of intramembranous 
bones was closely examined. 
1.1.2.1 Spatial maturation of the frontal bone 
Dermal bone maturation progresses in a vectorial manner: along the dorso-
ventral axis the youngest bone lies closest to the coronal suture (separating 
the frontal and parietal bones) while at the nasal end the mature bone has 
acquired a characteristic trabeculated appearance (within L2) (Figure 1.6). 
This growth pattern ensures that in sagittal cross-section, a snapshot of the 
various stages of bone development is available at a single time-point of 
analYSis (Yoshida et al. 2008). 
At a semi-mature stage of frontal bone development, at a late period of 
murine gestation between E17-18, the bone has a tripartite structure; in a 
sagittal cross-section through the bone the cancellous core is sandwiched 
between two laminar layers (L 1 and L3) of thin, flattened cells that fully line 
the length of the bone (Figure 1.6). The two border layers of cells are 
contiguous sheets across the expanding length of the bone. Molecular 
analysis confirms the two laminar layers are L 1 and L3, and there is a 
continuity of gene expressing along the dorso-ventral axis within the layers: 
L 1 contains Runx2(+)/Osteocalcin(+)/j3-Catenin{+) cells, while L3 contains 
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Osteopontin(+)/Hand2(+)/I3-Catenin(+) cells and both layers are positive for 
periosteal/perichondrial markers and markers of sheet mobility (Figure 1.7). 
Despite the morphological and molecular continuity of Layers 1 and 3, the 
intervening Layer 2 becomes more elaborate with time and along the dorso-
venral axis. Near the coronal suture, L2 is a nascent layer only a single to a 
few cells thick and sparsely populated. Progressing toward the nasal end, L2 
increases in complexity and carries the matrix and cancellous bone structure. 
Within L2 the distinctive layered appearance of the developing bone, as 
predicted by the traditional model of dermal bone development, was not 
evident. Instead Layer 2 was a patchwork of cells that carried the hallmarks 
of either Layer 1 or Layer 3 (Figures 1.3, 1.4, 1.5, 1.7). This could suggest 
that L 1 and L3 are indeed both generative layers and cells from them that 
are in Layer 2 have maintained the unique combination of gene expression 
from the layer with which that cell is associated. This single time-point 
analysis cannot, however, rule out the possibility that transitory gene 
expression may mean cells alternate marker expression within L2, and a 
time-course analysiS necessary to confirm the uninterrupted expression of 
the marker combinations throughout dermal bone formation. 
1.1.2.2 Ontogeny of frontal bone development 
The time-course analysis of layer formation in dermal bone focused on the 
development of the frontal bone from a stage mid-way through foetal 
development (at the condensed mesenchyme stage) through embryonic 
maturation and birth. Frontal bone formation is initiated at embryonic day 
E12-13 when the primordia to the frontal bone consists of a loose 
mesenchyme encasing the developing telencephalon (Yoshida et al. 2008) 
(Figure 1.8). The mesenchyme, which is in the process of condensing, lies 
beneath a thin layer of dermis and above the forebrain. At this stage, the 
dermis expresses the markers associated with Layer 1, namely Runx2, 
Osteocalcin, F-Actin, I3-Catenin and Fibronectin (Figure 1.9). Conversely, the 
forebrain expresses Hand2, and POSTN, akin to Layer 3 (Figure 1.10). The 
brain also expresses an activated form of Notch (nuclear) and I3-Catenin 
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(Figure 1.10). The margin of the forebrain is delineated by a border of cells 
expressing the endothelial marker CD31, indicating the boundary of the 
developing meninges and the medial margin of the condensed mesenchyme 
(Figure 1.1 OG). 
Utilising the same molecular markers as in the single time-point study, I find 
the condensed sheet of mesenchyme, while morphological indistinct, is 
already a bi-Iayered system carrying the hallmarks of L 1 and L3 (Figure.J. 
Cells adjacent to the dermis express cytoplasmic l3-Catenin and Runx2; 
while cells abutting the meninges express POSTN and Hand2 (Figure 1.11). 
Within the next day of embryological development (through late day E13 in 
gestation), the mesenchymal condensation rapidly expands. The population 
of cells within L 1 is extremely dense and cells have a variety of morphologies 
with the majority having acquired a slightly flattened shape (Figure 1.12). The 
expression of Runx2 is ubiquitous within L 1 (Figure 1.12). Conversely, L3 
and the forebrain express Osteopontin, with expression in the brain being 
markedly more pronounced than that in L3 (Figure 1.12). At this young stage 
the two layers, L 1 and L3, are directly juxtaposed to one another without the 
intervening physical space, L2. 
At the next time-point examined, E16, near the coronal suture, the bone has 
acquires the same architecture as displayed at E18, whereby L1 and L3 
remain continuous layers lining the bone; their characteristic composition 
includes their molecular signatures, as well as the thin-flattened morphology 
of the cells within them. The morphological and gene-expression signatures 
of Layer 1 and 3 continue to be unbroken in the final stages of analysis, at 
the first day of postnatal development. 
1.1.3 Conclusion 
Results from the time-course study of frontal bone ontogeny reveal Layer 1 
and Layer 3 are incipient layers of bone formation between the dermis and 
brain, respectively. These layers are a continual presence within the frontal 
bone, lining it on either side. The molecular expression patterns of Layers 1 
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and 3 are unchanged from E13 through birth, and morphologically by E16 
the cells within them have achieved a thin-flattened appearance that is 
constant through all prenatal development. Contrasting this, L2 expands with 
time to become the spongious bone and it is the continually increasing 
complexity of this layer (and the subsequently increasing separation of L 1 
and L3) that is responsible for expanding the thickness of the frontal bone. 
The mechanism by which L2 becomes populated was further explored in the 
next study, utilising genetic lineage labelling in transgenic strains of mice. 
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Figure 1.1: Diagrammatic representation of the traditional model of dermal ossification 
The process of intramembranous ossification occurs when a condensed mesenchyme forms a bone, without a 
cartilage template, in a process termed direct ossification. Condensed mesenchymal cells (yellow) differentiate into 
pre-osteoblasts (teal) which further differentiate into fully functioning osteoblasts (white), which secrete osteoid (grey) 
and subsequently mineralise the matrix (green). In this model the area where the dermal bone will form is highly 
vascularised and the bone is pre-pattered by the existing blood vessels (red) , which the bone must engulf and 
accommodate. 
A. A single layer of osteoblasts acts as the generative front, depositing matrix appositionally; the wave of 
differentiation continues through the mesenchyme, so the next layer of pre-osteoblasts differentiates into osteoblasts 
(8) and cells are oriented around the blood vessels as the osteoid is continually mineralised (C). In the next stage, a 
second layer of mineral will be deposited as the process repeats (D) and the bone will grow by apposition and 
layering of the mineral on top of the previously laid calcifications. In the resulting architecture the oldest bone will be 
at the bottom and the most immature regions are the most superficial. 
A-O Modified from Bruder & Scaduto in Bone Regeneration and Repair, 2005, Human Press Inc. Lieberman & Friedlaender, eds. 
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Table 1.1: Marker expression as mapped in dermal bone development in published studies and the expected 
morphology of each type of cell in the osteoblastic lineage (see text for details & references) 
Expected Expression Patterns 
, 
Periosteum/ Pre~Osteoblast Osteoblast Osteocyte 
Perichondrium 
Fibronectin x x x 
Run x2 x 
Col/agen" x 
Periostin x x x 
Collagen I I x x 
Osteopontin x x 
Osteocalcin i x x 
p~Catenin I x x 
Undulin x 
CRABP·I x 
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Figure 1.2: The immature frontal bone has a diploe architecture 
Sagittal sections through the frontal bone at embryonic day E18 after conception; Wnt1-Cre+J.. x Rosa26lacZ-I-
specimen. IHe· for Runx2 (red, B-C), Collagen II (green, e), Collagen I (red, D), and Osteopontin (white, e,E); 
nuclear counterstain DAP' (blue). Layers 1, 2, and 3 are indicated as L 1, L2, and L3. respectively. 
A. Near the coronal suture. the most immature area of the bone. the frontal bone has a tri-partite (diploe) architecture; 
two extemallaminar layers (L 1 and L3) sandwich an intervening space that is cell sparse (12). 
8-0. The external laminar layers are molecularly different. Cells of layer 1 express Runx2 (B-C) and Collagen II (B) 
while cells of Layer 3 express Collagen I (D) and Osteopontin (e, E). The dermis expresses Runx2 (B-C) and 
Collagen' (D). whife cells of the forebrain express Collagen I (D) and Osteopontin (E). 
The spatial expression of the traditional pre~steoblast markers (Runx2 and Collagen II) are notably defined from and 
complimentary to the expression area of the osteoblast markers (OPN and Collagen I) in the immature bone (B) and 
a slightly more mature region from the same section (e) • 
d Dermis, b Brain 
Scale bar indicates 50lJm. 
• Conditions for IHe, image acquisition and analysis can be found in Material and Methods, Chapter 11. 
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Figure 1.3: Layers 1 and 3 both express markers of osteoblasts 
Sagittal sections through the frontal bone at embryonic day E18 after conception; Wnt1-Cre+l- x Rosa26 LacZ-I-
specimen. IHe for Osteocalcin (red, A) , f3-Catenin (green, B) and Hand2 (red, C); nuclear counterstain DAPI (blue). 
Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. 
A-B. Layer 1 expresses markers traditionally associated with fully mature osteoblasts: Osteocalcin (A) is expressed in 
a nascent area of diploe architecture, and f3-Cantenin (B) expression is in Layer 1 and in Layers 2-3. 
C. Bird's-eye view of Hand2 expression in an immature region of the frontal bone (L2 is not visible); expression in the 
dermis is also noted. 
d Dermis, b Brain 
Scale bar indicates 50j..Jm. 
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Figure 1.4: Layers 1 and 3 are periosteum/perichondrium-like tissues 
Sagittal sections through the frontal bone at embryonic day E 18; Wnt1-Cre+l- x Rosa26LacZ-I- specimen. IHC for 
CRABP1 (red, A), Undulin (red, B) and Periostin (red, C); nuclear counterstain DAPI (blue). Layers 1, 2, and 3 are 
indicated as L 1, L2, and L3, respectively. 
A, B. Layer 1 and the dermis strongly expresses markers associated with the fibroblastic layer of the 
periostium/perichondrium (CRABP1 in A; Undul in in B). Layer 3 is weakly positive for both markers. C. Periostin, is 
strongly expressed by Layer 3, weakly expressed in Layer 1, and also present in the dermis. 
Scale bar indicates 50l-lm . 
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Figure 1.5: Cells of layers 1 and 3 have high mobility potential 
A-B. Sagittal sections through the frontal bone at embryonic day E 18 after conception (positive vaginal plug is taken 
as EO); wild-type specimen. IHe for F-Actin (red. A) and Fibronectin (red. B) specimen; nuclear counterstain DAPI 
(blue) (A-B). layers 1, 2, and 3 are indicated as L 1. L2. and L3. respectively. 
The cells of layers 1 and 3 both ubiquitously express markers associated with sheet mobility. F-Actin (A) and 
Fibronectin (B). 
C-D. The possibility that cells from l1 and l3 are capable of lateral motility supports results of Oil labelling 
experiments performed by Yoshida et. al. (C-D. coronal section from animals 120 hours after Dil injection) where cells 
in areas corresponding to l1 and l3 exhibit extensive spreading. The calcified area of the frontal bone is indicated 
with arrow in C; the injection site of 0 indicated with arrow and cells have migrated into the frontal bone and to the tip 
of the head. indicated with a white arrowhead. Modified from Yoshida et. al. 2008. Figure 6. 
d Dermis. b Brain 
A-B Scale bar indicates 50!-,rn. C Scale bar indicates 100!-,m. 
4&6 "- - ~'"---- ------ -'.---'_ .. ,. -.-~ -'--'- --._--------"-------
IdVO 
~ 
-C/) 
o 
0:: 
Figure 1.6: The murine frontal bone at embryonic day E18, a bi-layered architecture 
Sagittal sedion through the frontal bone at embryonic day E18 after conception (positive vaginal plug is taken as EO); 
Wnt1-Cre+1- x Rosa26lacZ-I- specimen. Nuclear stain (DAPI) in blue. Section lines in insert of A indicate the relative 
position of 8-0. layers 1. 2, and 3 are indicated as L 1. L2, and L3, respectively. 
A. Anatomical overview of the cranial region (image obtained on an Aperio microscope); insert: low magnification 
image of the frontal bone from the coronal suture to the nasal bone. 
B. Magnification the coronal suture. 
c. The most immature frontal bone, adjacent to the coronal suture. The cells of layers 1 (area between white dotted 
lines) and 3 (area between red dotted lines) have physically separated and acquired a thin, flat morphology. The 
intervening space between the layers, which is initially very cell sparse, is termed layer 2. 
D. At a mature area of the frontal bone, the cancellous, trabeculated core of l2 remains sandwiched between L 1 and 
L3, which are contiguous along the bone's length. Blood vessels are indicated (*). 
d Dermis, b Brain, s Suture, f Frontal, p Parietal 
Scale bar indicates 50jJm. 
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Figure 1.7: Expression of markers in Layer 1 and 3 persist along the ventro-dorsal axis of the frontal bone at 
E18 
Sagittal sections through the frontal bone at embryonic day E18 after conception (positive vaginal plug is taken as 
EO); WnM -Cre+1- x Rosa26LacZ4- specimen. IHe for Runx2 (red, A-C), Osteopontin (green, A-B), Osteocalcin (red, 
D), Periostin (red, E), and l3-Catenin (green, F); nuclear counterstain DAPI (blue). Layers 1, 2, and 3 are indicated as 
L 1, L2, and L3, respectively. 
Along the length of the ventr(Hjorsal axis the expression of molecular markers in Layers 1 and 3 remains continuous, 
indicating expression within these layers, observed in the immature bone, is not a transient feature. 
Layer 1 expresses Runx2 near the coronal suture (A) and at the most mature (highly trabeculated region) area of the 
frontal bone (B); this contrasts Layer 3, which expresses Osteopontin. 
The expression domain of Osteocalin in a mature region of the frontal bone extends from Layer 1 to the Layer 213 
border (D). 
Layers 1 and 3 express the osteoblast marker J3-Catenin (F) and the pre-osteoblasUosteoblasUperiosteal maker 
Periostin (E). 
d Dermis, b Brain, s Suture 
Scale bar indicates 50lJm. 
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Figure 1.8: The murine frontal bone primordium at embryonic 
day E13 
Sagittal section through the anlagen to the frontal bone at the 
condensed mesenchyme stage, embryonic day E13 after 
conception (positive vaginal plug is taken as EO); wild-type 
specimen. Nuclear stain (DAPI) in blue. Section line in A indicates 
the relative position of B. 
A. Anatom ical overview of the forebrain encased in the 
condensing mesenchyme at a low magnification. 
B. Magnification of the condensing mesenchyme comprising the 
frontal bone anlage. The dermis comprises a single layer of 
aligned cells at the external margin of the tissue (indicated with 
white dotted line). The boundary of the forebrain is denoted with a 
dashed line and the single line of meningeal cells is indicated with 
an arrow. Cells within the condensation are morphologically 
indistinct and are largely blast-like. 
Scale bar indicates 50~m. Dermis ~ Rostral 
Brain 
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Figure 1.9: Dermal expression of several markers at 
embryonic day E13 
Sagitta l sections through the anlage of the frontal bone at 
the condensed mesenchyme stage, embryonic day E 13 
after concept ion; wild-type specimen. IHC for Runx2 (red, 
A), F-Actin (red, 8 ), Osteocalcin (red, C), ~-Catenin 
(green, 0 ), Fibronectin (green, E); nuclear counterstain 
DAP I (blue). 
A-E: Expression in derm is, indicated with white 
arrowhead. Red denotes expression in dermis and 
condensing mesenchyme; green denotes expression in 
dermis, condensing mesenchyme and meninges. 
Scale bar indicates 50~m . 
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Figure 1.10: Expression patterns of several markers in the forebrain and meninges at embryonic day E13 
Sagittal sections through the forebrain and meninges at the condensed mesenchyme stage, embryonic day E13 after 
conception; wild-type specimen. IHe for activated Notch (red, B), Hand2 (red, C), Periostin (yellow, D), J3-Catenin 
(green, E). Fibronectin (green, F), CD31 (green, G); nuclear counterstain DAPI (blue). 
A. Anatomical overview of the forebrain encased in the condensing mesenchyme at a low magnification. Section lines 
indicate the relative positions of B-G. 
B-G: Expression of Notch (B). Hand2 (C) and Periostin (D) in the developing forebrain (red box); expression of 13-
Catenin (E), Fibronedin (F) and CD31 (G) in early meningeal layer (green box). 
The extent of the forebrain is indicated with a dotted line. In F the dense expression of Fibronedin in the condensing 
mesenchyme is indicated (*). 
Scale bar indicates 50~m. 
54 
- -------- ... - .,-,. 
~-CATENIN HAND2 
NIN31V'J-9 
NOISS3HdX3 £1/t1 
POSTN HAND2 
N1SOd 
NOISS3HdX3 £1 
----------------- ldVO ----------------
o.n 
o.n 
Figure 1.11: The frontal bone primordium is a bi-layered system at embryonic day E13 Dermis 
Rostral ~ 
Brain 
Sagittal sections through the frontal bone primordium at the condensed mesenchyme stage, embryonic day E13 after 
conception (positive vaginal plug is taken as EO); wild-type specimen. IHe for ~atenin (green, A, A+B), Hand2 (red, 
B, B+C), Periostin (green, C, B+C); nuclear counterstain (OAPI, blue). Images are oriented cranial to the top and 
ventral to the left. 
A. J3-(;atenin is expressed in the dermis (arrowhead in A-C, A+B, B+C), the meninges (*) and the most anterior 
region of the condensed mesenchyme; contrarily Hand2 (B) is expressed in a thin layer of cells at the posterior 
margin of the mesenchyme, as well as the meninges and brain. Similarly, Periost in (C) is expressed in posterior 
mesenchyme, meninges and brain. 
A+B Displays the largely non-{)verlaping expression domains of ~-Catenin and Hand2; while B+C shows the 
overlapping expression domain of Hand2 and Periost in. The anterior region is here defined as Layer 1, while the 
posterior compartment is termed Layer 3. Layer 1 comprises a wider physical area (white line) than Layer 3 (red line); 
while Layer 3 Is a more tightly packed tissue. 
Scale bar indicates 50j.Jm. 
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Figure 1.12: The bi-layered anlage of the frontal bone has differential expression of osteoblastic markers at 
embryonic day E13.5 
Sagittal section through the frontal bone primordium at the condensed mesenchyme stage, embryonic day E 13.5 after 
conception (positive vaginal plug is taken as EO); WnM -Cre·/- x Rosa26lacZ-I- mouse. IHe for Runx2 (red), and 
Osteopontin (green); nuclear counterstain (DAPI) in blue. layers 1 and 3 are indicated as L 1 and L3, respectively. 
A, C. Runx2 and Osteopontin have mutually exclusive expression pattems in the developing forbrain (OPN positive) 
and condensed mesenchyme (Runx2) except for the extemal margin of the dermis. Many of the cells of the 
mesenchyme have flattened and taken on a sheet-like appearance (B). Runx2 is expressed cytoplasmically 
throughout l1, with some cells in which expression is translocated into the nucleus. Osteopontin is strongly 
expressed in the brain and more weakly expressed in l3. 
B. Within the area of the mesenchymal condensation comprising the precursor to Layer 1 (Runx2+) cells have 
acquired a slightly flattened morphology 
Scale bar indicates 50l-lm. 
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1.2. Populating L2: Exploring lineage heterogeneity of the frontal bone 
1.2.1 Introduction 
The vertebral head skeleton is divided into the neurocranium, the skeleton of 
the central nervous system, and the splachno- or viscerocranium, the 
skeleton of the lower face and branchial arches (Le Douarin and Kalcheim 
1999). Within these divisions, the skeletal elements arise from either paraxial 
mesoderm or neural crest progenitors. The location of the neural 
crest:mesoderm boundary within the neurocranium has been heatedly 
disputed, with the margin of the neural crest territory alternatively 
hypothesized to be the frontal:parietal interface (Morriss-Kay 2001) or the 
parietal:occipital junction (Couly et al. 1993) The composition of the frontal 
bone has been argued to be entirely neural crest (Couly et al. 1993) or 
primarily mesodermal (Evans and Noden 2006). Notably, Couly et al., who 
argue for an entirely neural crest-derived frontal bone, employ a standard 
grafting technique (quail-chick chimera) in their analysis, however, the final 
time-point of their study Oust over mid-way through incubation) preceded 
definitive osteogenesis in the frontal and parietal areas examined. As such, 
their fate maps were generated at stage similar to E13 in murine 
development, as presented above, where the diplo~ architecture of the 
frontal bone is not yet established and any late invasion or contribution of 
mesodermal cells could not be analysed. Conversely, Evans and Noden 
maintain there is a large contribution of the mesoderm to calvarial tissues 
and their analyses occur at a slightly later time-point than Couly; however, 
their use of targeted injection of replication-incomplete retroviruses is not a 
de rigueur technique due to potential concerns over cross 
mesodermal:neural crest contamination. 
Establishing a time-course of the contributions of the neural crest and 
mesoderm to both the generative layers (L 1 and L3) and the fully formed L2 
is a key component of understanding the cellular origins and histogenesis of 
the frontal bone, a bone for which homologies across vertebrates are well 
established (Rice 2008). As such, in addition to mapping the generative 
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architecture of dermal bone formation, the current study also aimed to 
resolve the widely contested issue of lineage origins of the frontal bone. 
To examine the contributions of the neural crest and mesoderm to the frontal 
bone, lineage analysis was undertaken using Cre-mediated recombination: 
the Wnt1 dorsal neural tube enhancer is expressed in the neural crest 
precursor population, and a Wnt1-Cre+l- strain of mouse will confer transgene 
expression to all neural crest cells and their resulting progeny, with the 
exception of neural crest from rhombomere 1 (Jiang et al. 2000; Ferguson 
and Graham 2004). When combined with Cre-reporter mice, carrying floxed 
resistance-pA cassettes, an excision event will occur and the neural crest 
cells can be permanently visualised. For the current study, lineage analyses 
were conducted using two strains of reporter mice: ROSA26LacZ-I- mice in 
which LacZ is under the control of the Rosa26 locus (Soriano 1999); and XZ-
DR-I- mice with GFP under the control of the human Ubiquitin C minimal 
promoter (hUbC), shown to drive strong expression in mice (Zhang and 
Koentges unpublished; Schorpp et al. 1996; Lois et al. 2002). 
1.2.2 Results 
From the earliest time-point analysed, E13, etiologically Layer 1 is neural 
crest, while Layer 3 is of mixed neural crest and mesodermal origins; the 
neural crest contributions to L3 are discernibly more minimal than the 
mesodermal component to that layer (Figure 1.13). From E13 through birth, 
the lineage composition of the layers is undisturbed: L 1 remains neural crest 
and L3 is a mosaic of neural crest and mesoderm. The lineage heterogeneity 
in Layer 3 is reflected in Layer 2, which -from the most immature through 
mature states- contains cells of both origins (Figure 1.14). Notably, the 
mesodermal contributions to the neural crest do not appear to be confined to 
the vascular spaces (Figure 1.14). 
The lineage mosaicism of the frontal bone was utilised to explore how L2 
matures, as cells within L2 could derive from adjacent layers (1 and 3) and/or 
via endogenous cell division within l2. Within the most immature l2 the 
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sparse cells populating this intermediary layer carry the molecular signatures 
of either Layer 1 or 3 and have a rounded, blast-like morphology (Figure 
1.15). The implication that these cells entered Layer 2 via direct deposition of 
cells from a generative layer would indicate an appositional mechanism of L2 
maturation. A traditional model of appositional growth, developed for 
mesodermal long bones, would imply that cells percolate from a generative 
surface or surfaces directly into L2 without any constrained entry points as 
each mother cell within the respective layer would yield a daughter cell 
delving into the underlying matrix. This delamination of cells would lead to a 
columnar organisation of the expanding bone (Figure 1.16), akin to basic 
columnar organisation of progenitor cells migrating radially from a ventricular 
generative surface in the developing central nervous system (Price et al. 
1987; Rakic 1988; Walsh and Cepko 1992; Walsh and Cepko 1993; 
Mountcastle 1997). This arrangement would yield bone matrix deposition in 
parallel sheets. 
Cells within Layer 2 could alternatively (or in conjunction with apposition) 
experience clonal expansion; this mechanism of increasing L2 complexity 
would lead to the expectation of clonal nests or islands of cells derived from 
either mesodermal or crest progenitors, with little mixing between them within 
L2 (Figure 1.16). Furthermore, clonal expansion should lead to extensive 
amounts of discernable cells undergoing division within L2. 
Contrasting with both these models, in an ontogenetic analysis, there does 
not appear to be homogenous deposition of cells from surfaces of either 
Layers 1 or 3, nor evidence of clonal expansion within L2. Instead, from E16 
(the earliest time-point with a discernable L2), at specific points across the 
length of the developing bone, cells from L 1 and L3 appear to invade the L2 
space. Three-dimensional reconstructions of the developing bone show 
strings of neural crest cells (labelled) extending from L 1 into L2 and touching 
the surface of L3, thus neural crest cells from one side extend across the 
different layers (Figure 1.17). The same is evident for mesodermal cell (non-
labelled) from L3. Unusually, within this bee-line the cells in L2 continue to 
express the unique combination of markers of either Layer 1 or Layer 3 
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(Figure 1.18): i.e. Runx2+ cells from Layer 1 connect to Run2+ cells in Layer 
2 and OPN+ cells in Layer 3 connect to OPN+ cells in Layer 2. 
The lateral connections between L 1 and L3 (across L2) are accomplished in 
the immature bone by only a single or few cells (Figures 1.17-1.19): cells 
from L 1 enter L2 and form a bridge between the laminar layers in an 
organisation that appears akin to a handshake; these handshakes are 
hitherto referred to as 'clasps'. 
Within the clasps, a physical link to the generative layers (L 1 or L3) is 
maintained via cell-cell connections (Figures 1.17-1.19). The entry of cells 
into the L2 system does not appear to be confined to an immature phase of 
bone development, as the clasps are found along the length of the dorso-
ventral axis from E16 through foetal and early post-natal development to P2 
(the final time-point analysed). As L2 becomes increasingly trabeculated, 
clasps are maintained by increasing numbers of cells forming entire sheets 
inside L2 of the maturing bone (Figures 1.19-1.20). As the frontal bone 
increases in complexity, the lateral connections between layers also 
experience horizontal elaborations, however they are not engulfed directly by 
matrix (for details on aspects of biomineralisation refer to Chapter 3) (Figure 
1.20). In this way, cells of both neural crest and mesodermal origins (both 
carrying markers of osteoblast lineages) intermingle and contemporaneously 
contribute to L2 development. 
1.2.3 Conclusion 
The molecular and morphogenic properties of L 1 and L3 indicate their 
potential as generative layers of the frontal bone; the intervening space -L2-
matures with bone development, increasing in cell density and thickness with 
time and carrying the osteoid and mineralised matrix (Described in Chapter 
3). The mechanism by which L2 maturation occurs is at the heart of how 
dermal bones form. Evidence from the analysiS of Wnt1-Cre+l- mice does not 
support either an appositional or clonal expansion model of L2 maturation , 
but instead favours the bidirectional intercalation of cells from L 1 and l3 
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(Figure 1.21). The introduction of cells from the generative layers is highly 
constrained and accomplished via a 'threading in' mechanism whereby 
clasps act as conveyor belts, delivering new cells to L2. Continuous sheets 
of cells are formed within L2, while cells maintain the molecular profiles of 
the generative layer from which they originate. Although de novo expression 
of the markers from L 1 or L3 within L2 cannot be ruled out, the traditional 
'percolation' model of appositional growth from an internal surface is 
excluded on the basis that no columns of mesodermal cells (from L3) or 
neural crest cells (from L 1 or L3) are observed. Instead, single cells appear 
to enter and expand L2 and at no point does either of the generative layers 
involute as whole entities, which would break the continuity of L 1 and L3. 
Furthermore, the intriguing expression of markers of cellular mobility 
(Fibronectin, F-Actin, Periostin) and the periosteum (which are attractant to 
osteoblastic cells) in L 1 and L3 is resolved when the migratory behaviour of 
L 1 and L3 cells is understood. If L 1 and L3 act as generative layers, cells 
within them must be capable of both integrating into L2 and performing the 
role of osteoblasts. The means by which the points of cellular entry into L2 
are initiated and maintained are examined in Section 1.3, below. 
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Figure 1.13: The bi-Iayered anlage to the frontal bone is of mosaic lineage at embryonic day E13.5 
Sagittal section through the frontal bone primordium at the condensed mesenchyme stage, embryonic day E13.5 after 
conception (positive vaginal plug is taken as EO); Wnt1-Cre+l- x Rosa26LacZ-I- mouse. IHe for ~-Galactosidase 
indicating the neural crest cells (green, A; white, B), Runx2 (red, B), and Osteopontin (light blue, B); nuclear 
counterstain DAPI (blue). Layers 1 and 3 are indicated as L 1 and L3, respectively. 
A. L 1 (the region corresponding to Runx2 expressing cells in B) contains neural crest cells; at the external margin of 
the condensed mesenchyme, as well as within L3, cells of mesodermal origin are noted (*, in dermis), as indicated by 
a lack of ~-Galactosidase activity. 
B. Runx2 and Osteopontin expression domains are almost entirely mutually exclusive with a few noted exceptions ("). 
The forebrain is of neural crest origin and morphologically distinct from L3, although both express OPN. The extent of 
L3 is indicated with dashed lines. 
Scale bar indicates 50iJm. 
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Figure 1.14: The frontal bone is of dual neural crest and mesodermal origin 
Sagittal sections through the frontal bone at embryonic day E18 after conception (positive vaginal plug is taken as 
EO); Wnt1-Cre+l- x Rosa26LacZ-I- specimen A-D, Wnt1-Cre+l- x XZ-DR-I- specimen E-F. Layers 1, 2, and 3 are 
indicated as L 1, L2 and L3, respectively. 
X-gal stain (A-C) and IHC (O-F) for ~-Galactosidase showing neural crest cells in blue A-C and green D·F. Nuclear 
counterstain DAPI (blue) in O-F. 
A-C. X-Gal stain of progressively more mature regions of the frontal bone. L 1 and L3 regions sandwich the 
mineralised core of L2. A. Off the coronal suture, areas of non-reactivity, indicating tissues of mesodermal origin or 
those from rhombomere 1, are noted (white arrowhead) within L2. 
B-C. In mature areas of the frontal bone areas without X-Gal labelling are not confined to blood vessel lining as they 
are within the bone matrix. 
D-F. IHC of I3-Gal (0) and GFP (E-F). L 1 contains neural crest cells, while L2 and L3 have mosaic expression of the 
neural crest marker. 
Scale bar indicates 50~m. 
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Figure 1.15: L2 is initially populated by blast-like cells expressing Runx2 or OPN 
Dermis 
Rostral ( I 
Brain 
Sagittal sections through the most immature frontal bone displaying a diploe architecture at embryonic day E16 after 
conception (positive vaginal plug is taken as EO); Wnt1-Cre+l - x Rosa26LacZ-I- mouse. IHC for Runx2 (green, A-B) , 
and Osteopontin (red, C); nuclear counterstain DAPI (blue). Layers 1, 2, and 3 are indicated as L 1, L2 and L3, 
respectively. 
A-B. The initial cells on the L 1-side of L2 are large and blast-like and express Runx2; this contrasts to many cells on 
the L2:L3 border (C) that have a similar morphology (blast-l ike) but express OPN (*). The external boundary between 
L3 and the brain is indicated in C (red dashed line). 
Scale bar indicates SOf.Jm . 
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Figure 1.16: Competing models of the 
mechanisms for L2 growth 
A. Schematic representation of an immature 
frontal bone at E16-18 as found in the current 
study. Layer 1 is entirely of neural crest origin , 
while L3 is a mosaic of neural crest and 
mesodermal cells. L2 is initially cell-sparse with 
cells of both lineages. In time L2 becomes more 
complex (not shown). 
B. The appositional/clonal expansion model of 
L2 maturation. Cells from Layer 1 and 3 
experience no lateral spread and deposit cells 
into L2 via direct apposition; these leads to 
clonal columns and a parallel-sheet organisation 
of L2. Cells within L2 could also divide, leading 
to clonal islands of cells within L2. 
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Figure 1.17: Evidence of bi-directional involution of cells from L 1 and L3 
Sagittal section through the frontal bone at embryonic day E18 after conception; Wnt1-Cre+l- x Rosa26LacZ-I-
specimen. IHC for ~-Galactosidase showing neural crest cells (green) and Periostin (red); nuclear counterstain DAPI 
(blue). Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. 
A. Cells from L 1 and L3 invade L2 and form a bridge connecting the two generative layers. Red box indicates the 
location of B. 
B. Optical section of the interaction between cells invading L2 from L 1 and L3; this interaction is referred to as a 
'clasp'. The cells within the clasp are sheet-like and maintain contact with the layer from which they originate. 
Scale bar indicates 50\Jm. 
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Figure 1.18: Clasp structures are formed by Runx2 and Osteopontin expressing cells 
Dermis 
~ Rostral 
Brain 
Sagitta l sect ion through the frontal bone at embryonic day E18 after conception; Wnt1-Cre+l- x Rosa26LacZ-I-
specimen. IHC Runx2 (red) and Osteopontin (white); nuclear counterstain DAPI (blue). Layers 1, 2, and 3 are 
indicated as L 1, l2, and l3, respectively. 
Cells form a bee-l ine across L2, connecting L 1 to L3; within this clasp cells are Runx2-positive, akin to Layer 1, or 
Osteopontin posit ive, akin to Layer 3. In less mature regions of the frontal bone clasps are formed by relatively few 
cells (* in A) , compared to a fully trabeculated area from the same section where the clasps is maintained by 
significantly more cells and there appear to be horizontal extensions (**) from the predominant lateral clasp (*) 
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Figure 1.19: Following clasp formation L2 elaborates via continual cell involution 
Sagittal section through the frontal bone at embryonic day E18 after conception (positive vaginal plug is taken as EO); 
WnM-Cre+l - x Rosa26LacZ-I- specimen. IHC for ~-Galactosidase showing neural crest cells (green) and Runx2 (red); 
nuclear counterstain DAP I (blue). Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. 
A. Neural crest cells from L 1, expressing Runx2, enter L2 and the clasp elaborates. Runx2 expression continues 
down the majority of the clasp (8) until it meets non-Runx2 expressing cells, which have lost expression or originated 
in L3. A nascent clasp is being formed by a cell intercalating into L2 (empty arrowhead). Large, blast-like cells are 
found encased in the clasp (white *) and associating with the outside of the clasp (red *); these cells are of mixed 
neural crest and mesodermal origin. 
Scale bar indicates 50~m. 
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Figure 1.20: In increasingly mature areas clasps experience vertical and horizontal elaborations 
Sagittal section through the frontal bone at embryonic day E18 after conception (positive vaginal plug is taken as EO); 
Wnt1-Cre+l- x Rosa26LacZ-I- specimen. IHC for (3-Galactosidase showing neural crest cells (green) and Runx2 (red) ; 
nuclear counterstain DAPI (blue). Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. 
A. In a semi-mature region of the frontal bone, long connections of cells forming sheets inside L2 are visible. Within 
these sheets cells are adjacent to other cells expressing the same marker (e.g. Runx2, B) and/or cells of the same 
etiological origin (e.g. neural crest versus mesodermal C). 
In 0 a bee-line of cells of mesodermal origin can be see extending across the entire lateral space of L2, connecting 
the generative layers (line of cells indicated in yellow dashed line). This line is also bisected by a line of neural crest 
cells that all express Runx2 (outlined in orange dashed line) that are a horizontal elaboration of a clasp. At one point, 
cells of L 1 (NC cells expressing Runx2) can be seen beginning to intercalate into L2 and sliding past the pre-exiting 
sheet of mesodermal cells (*). 
Scale bar in A indicates SOJ.jm. 
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Figure 1.21: Contrasting modes of expanding 
L2 
A. Schematic representation of an immature 
frontal bone at E 16-18 as found in the current 
study. Layer 1 is entirely of neural crest origin, 
while L3 is a mosaic of neural crest and 
mesodermal cells. L2 is initially cell-sparse with 
cells of both lineages. In time L2 becomes more 
complex . 
B. The appositional/clonal expansion model of 
L2 maturation. Cells from Layer 1 and 3 
experience no lateral spread and deposit cells 
into L2 via direct apposition; these leads to 
clonal columns and a parallel-sheet organisation 
of L2. Cells within L2 could also divide, leading 
to clonal islands of cells within L2. 
C. The bi-directional involution model of L2 
maturation. Cells from Layers 1 and 3 spread 
laterally (purple arrows) and thread cells into L2 
in a conveyor-belt delivery system. Cellular 
involution into L2 in constrained to specific notes 
and cells enter and form sheets on the inside of 
L2. 
1.3 Discovery of the rosette system in dermal bone development 
Having established the clasps as the point of initial contact between L 1 and 
L3, my analysis subsequently focused on the process by which cells initiate 
their invasion of L2 from the generative layers. Three-dimensional 
reconstructions of the privileged points of cellular entry from L 1 into L2 led to 
the discovery of a unique assembly of cells at the surface of L 1. Cells around 
the entry point from L 1 to L2 are oriented in a rosette-like architecture 
comprising -6-8 flattened neural crest cells (Figure 1.22). These rosettes are 
observed along the length of the frontal bone at all places where cells from 
L2 connect to the generative layers. 
1.3.1 Molecular composition of rosettes 
The organisation of cells into a rosette formation is reminiscent of 
arrangements found among stem cell populations during neuromast 
formation in zebrafish (Hava et a/. 2009) and mammalian neural stem cells 
on the surface of the ventricular zone (Mirzadeh et a/. 2008). Within the 
mammalian eNS rosette-like architectures contain both stem cells and their 
supporting cells, which are molecularly distinct. I probed the molecular 
character of dermal bone rosettes and confirmed heterogeneity among the 
individual single cells contributing to the rosettes. 
Within the rosette assembly, cells widely express cytoplasmic Runx2, which 
is polarised such that nuclei of rosettes (DAPI counterstained) appear to sit 
on a cloud of cytoplasmic Runx2 expression (Figure 1.228). Notch co-
expression in the Runx2-positive cells was also observed (Figure 1.22C), 
and was an interesting finding given that Notch activation acts as a 
mechanism by which osteoblastic cells have been shown to regulate 
haematopoietic stem cell niches in vivo (Calvi et a/. 2003). Intriguingly. 
among the cells of the rosette assembly, one cell expresses nuclear_ 
localised Runx2; the same cell co-expressed nuclear Osteopontin (Figure 
1.22A). This co-localization was unexpected as results from dissociated 
calvaria concluded that double positivity of Runx2 and OPN does not exist; 
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indeed, such double positivity is also found within L2 (discussed in Chapter 
3.4.2). The previously observed focal expression of Hand2 within L 1 was 
also mapped to rosettes (Figure 1.220), and nuclear Hand2 is found to be 
co-expressed in the nucleus of the Runx2/0steopontin expressing cell. 
Hand2 has previously been found to be required for flattening up of cells in 
Drosophila, and a phylogenetically ancient role for the gene may be to 
coordinate the movements of cells in relation to one another (Ruest et al. 
2003; Liu et al. 2009; Liu et al. 2009; Xiong et al. 2009). Hand2 also 
regulates Runx2, acting to supress intramembranous ossification by 
physically interacting with Runx2 and prohibiting proper osteoblast 
maturation via a mechanism that remains unclear (Funato et al. 2009). 
Therefore, Hand2, in the context of expression among dermal bone rosettes, 
may act to help cells of L 1 coordinate their localised migration into L2 and 
prevent precocious osteogenesis from taking place within the rosettes. 
1.3.2 Rosettes as a generative architectural component of frontal bone 
development 
Beyond the molecular properties of the rosettes, their physical properties 
also indicated a role for them in coordinating the growth of dermal bones. An 
architectural feature of rosettes is they are organised around a physical hole, 
through which cells could thread into L2 (Figure 1.23). The single high-
columnar Runx2/0steopontin/Hand2-nuciear cell is located at the apex of a 
rosette, often creating the initial contact with L3 across L2 (Figure 1.24). This 
single Runx2/0steopontin/Hand2-nuclear cell retains its position in the 
rosette as the clasp becomes more elaborate and non-rosette cells from L 1 
seem to use the rosette as the entry point to slide into L2 (Figure 1.24). The 
structure of the rosette, acting as a scaffold system coordinating cellular 
migration, is akin to radial glial cells acting as guideposts along which cells 
from the mammalian ventricular zone enter the cortex (Rakic 1972; Price et 
al. 1987; Rakic 1988; Walsh and Cepko 1992; Cepko et al. 1993; Walsh and 
Cepko 1993; Mountcastle 1997). The conceptual link between dermal bone 
rosettes and radial glial cells suggests a morphogenetic similarity, 
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underscoring the potential importance of rosettes in coordinating the 
\ 
structure of the frontal bone. 
The startling finding of these rosettes. and the possibility that they might ad 
as generative architectural components of bone formation coordinating the 
intercalation of cells from the generative layers into L2. necessitated a 
rigorous time-course analysis of rosette formation. 
1.3.3 Ontogeny of rosette formation in the frontal bone 
Rosettes are observed in the earliest formation of murine frontal bone 
development (E13) and can be identified in all stages of foetal development 
through birth (Figure 1.24). The rosettes act as points of cell invasion for 
cells of both the osteoblastic and vascular lineages (discussed further in 
Chapter 2.2). Rosettes were not identified within L3. potentially due to the 
higher cellular density of L3 compared to L 1 complicating three-dimensional 
reconstruction of the L3 region. 
To explore if rosettes persist as entities after birth. they were examined in the 
context of the two-dimensional space of L 1 after a week of postnatal 
development. In addition to adding a later time-point of analysis. this Would 
assess the relationship between cellular invasion and definitive matrix 
mineral deposition (the spatial relationship between rosettes and bone matrix 
deposition is detailed in Chapter 3). For these reasons I dissected the 
cranial region of a one-week old wild-type mouse: the frontal and parietal 
region was isolated and the frontal bone was flat-mounted; this was 
challenging as overlying dermis is difficult to remove. however. it is possible 
to confocal through the entire bone and reconstruct it in small 3D stacks. 
Using reflection imaging to exploit the birefringence of collagen fibres 
• 
rosettes can be seen sitting in distinct craters on the surface of L 1 (Figure 
1.25). In the centre of these craters small pores are visible (Figure 1.25). 
presumably the location through which other cells of L 1 enter L2. 
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1.3.4 Rosettes: a common feature to both the frontal and clavicle bones 
The implication that rosettes may be essential to dermal bone development 
would necessitate their presence not only across the entirety of dermal bone 
maturation, but also in all dermal bones. I confirmed the presence of rosettes 
in the dermal component of the murine clavicle. The clavicle undergoes both 
dermal and endochondral ossification (Figure 1.26). At the lateral end, where 
the clavicle meets the acromion, the bone develops via direct dermal 
ossification; more medially an endochondral core develops under a second 
dermal bone covering (Huang et a/. 1997); with time the two dermal sheaths 
grow together. In addition to two forms of ossification, the clavicle derives 
from both mesodermal and neural crest precursors; an anterior neural crest 
component serves as the attachment regions of the sternocleidomastoid 
(SCM) and the coracobranchial muscles (Matsuoka et ai, 2005), while the 
posterior dermal bone (serving as attachment region of pectoralis and other 
mesodermal muscles) is entirely mesodermal in origin. I focused my analysis 
on the neural crest-derived components of the dermal clavicle. The SCM was 
previously shown to be of neural crest origin (Matsuoka et a/. 2005), and 
following the connectivity-rule I expected the underlying bone to be neural 
crest; as such my analyses focused on the area of the clavicle with SCM 
insertion pOints. 
Investigations of the clavicle at the SCM lead to the identification of rosettes 
within L 1 (Figure 1.27). Three-dimensional reconstructions again displayed 
the rosettes to be sitting in and along the walls of craters (Figure 1.27), which 
are shown to be Periostin positive with a discernible polarisation of POSTN 
localisation. The cells forming the rosettes of the clavicle displayed a similar 
molecular heterogeneity (with regard to Runx2 and Hand2) to those in frontal 
bone rosettes. 
1.3.5 Conclusion 
Rosette formations are located at the highly constrained points of cellular 
invasion from L 1 to L2; this feature is conserved throughout bone 
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development into the postnatal condition. This supports the notion that that 
rosettes provide the basic units of cellular involution and ingrowth of cells 
necessary for the formation of L2. 
Individual cells could enter L2 through the holes in rosettes (Le. at focal 
places) and involution or invagination of the entire generative layer (similar to 
neurulation) is not observed. Furthermore, post-translational modification and 
protein re-Iocalisation of Runx2 into the nucleus is a hallmark of single cells 
within the rosette formations at the apices of the observed rosette 
architectures and may be critical for the early establishment of L 1 to L3 
connections. This cell, at the apex of the rosette, expresses nuclear 
Osteopontin, Runx2 and Hand2, the implication of this co-expression being a 
fundamental role of Hand2 in the development of dermal bone. Hand2 is a 
known regulator of Runx2, although the mechanism by which this occurs is 
unclear: biochemical studies have identified the interaction domain of the two 
proteins, suggesting Hand2 prevents Runx2 from binding (Funato et a/. 
2009), but other (additional) means of in vivo control are possible. 
Hand2 may play a role in coordinating the invasion of cells from L 1 and L3 
into L2, a requirement of layer-like elaboration of L2. While gene expression 
may be highly variable, the heterogeneity of marker expression within the 
rosettes appears to have significance for how the rosettes function. 
In order to further elucidate the role of Hand2 in dermal bone formation, I 
analysed the phenotypes of two previously established strains of Hand2-
transgenic mice, with specific regard to intramembranous ossification. 
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Figure 1.22: Cells at the apex of clasps are arranged in a pinwheel/rosette organisation 
Sagittal sections through the frontal bone at embryonic days E13.5 (A) and E18 (B-D) after conception (positive 
vaginal plug is taken as EO); Wnt1-Cre+l• x Rosa26lacZ-I· specimen. IHC for Runx2 (red, A-B), Osteopontin (green, 
A), Hand2 (green, B) and Notch intra-cellular domain (green, C); nuclear counterstain DAPI (blue). Layers 1, 2, and 3 
are indicated as L 1, L2, and L3, respectively. 
A. Cells organised into a pinwheeVrosette formation are found within l1 where clasps terminate. Rosettes contain a 
single cell with nuclear Runx2 and OPN expression (arrow in A), the remaining cells express cytoplasmic Runx2, 
polarised such that the cells appear to sit on clouds of Runx2 expression (8 & D). 
B. The cells that expresses nuclear Runx2 also co-expresses nuclear Hand2 (D and arrow to that nucleus in D) 
C. Cells within the rosette also express an activated form of Notch 1 , as do the cells of the clasp across L2 connecting 
to the L 1 rosette (*). 
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Figure 1.23: Rosettes are organised around a physical hole 
8 
Sagittal sections through the frontal bone at embryonic days E13.5 (A) and E18 (B-C) after conception; Wnt1-Cre+l- x 
Rosa26 LacZ-I- specimen. Nuclear counterstain DAPI (blue). 
Cells of rosettes are organised around a physical hole (indicated with **). The orientation of the plane is indicate at the 
top of each image (A and Care bird's eye views; versus B, an oblique view of a rosette as rosettes appear in 
tangential cross sections; rosettes are only visible using 3D reconstructions as they are in the L 1 plane and not visible 
in 20). 
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Figure 1.24: Rosettes express the markers of L 1 and L3 
Sagittal sections through the frontal bone at embryonic days E13.5 (A) and E18 (8) after conception (positive vaginal 
plug is taken as EO); Wnt1-Cre+/- x Rosa26LacZ-I- specimen. IHe for Runx2 (red, A-B), Osteopontin (white, B), and 
J3-Galactosidase showing neural crest cells (green, A-B); nuclear counterstain DAPI (blue). Layers 1, 2, and 3 are 
indicated as L 1, L2, and L3, respectively. 
Rosettes are first identified in Layer 1 of the condensed mesenchymal precursor to the frontal bone at E13.5. The 
orientation of five cells into a rosette is visible in the DAPI channel in B. Within the rosette, a single cell expresses 
nuclear Runx2 and Osteopontin, as indicated by the sectional view of the nucleus in C-D, cut through the section line 
indicated in A. All cells of the rosettes, in the Runx2+/0PN+ cell, are of neural crest origin (A, D). 
E. A rosette in L 1 of an immature region of the frontal bone in an E18 mouse, where the majority of cells sit on a 
'cloud' of Runx2 cytoplasmic expression. A Single cell in the rosette with Runx2 nuclear expression has a cellular 
process extending into L2 .. 
Scale bar indicates 251Jm. 
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Figure 1.25: Surface view of rosettes in L 1 
Flat mount of the frontal eminence of a wild-type mouse at postnatal day 3 (P2). Nuclear counterstain DAPI (blue) and 
reflection imaging to examine bone topography. Images are a surface view of L 1, oriented rostral to the frontal suture 
to the left. 
A. Low magnification of area of L 1 near the frontal suture where rosettes sit along the entire image plane; the image 
series was acquired through a depth of 25J..1m of L 1. The nuclei and reflection imaging were reconstructed in 3D, 
revealing rosettes sit along the walls of depressions in the bone; white boxes indicate the locations of subsequent 
panels. 
8-D. The overlay of the DAPI and reflection channels and each individual channel. A cluster of three rosettes sit in 
craters. The three rosettes are at slightly different depths in the bone, such that the top right crater is imaged at a 
more superficial stage than the rosette to its left, which is imaged at the bottom of the crater and a small pore is 
visible at the base of the depression housing the rosette (red arrowhead, C). 
E-G. The overlay of the DAPI and reflection channels and each individual channel. A rosette of several nuclei imaged 
at the bottom of the crater where a pore is visible (red arrowhead, F). 
Scale bar indicates 50~m. 
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Figure 1.26: Diagrammatic representation of the clavicle 
A. Coronal overview of the right murine clavicle (white). At the lateral end (left), toward the acromion, the clavicle 
undergoes direct dermal ossificat ion; at the medial position, toward the sternum, an endochondral core develops 
under a dermal outer covering. The clavicle comprises cells from the neural crest (near the anterior 
sternocleidomastoid (SCM) muscle attachment) and lateral plate mesoderm (near the posterior attachment of the 
pectoralis (PE) muscle). A boundary between these zones is indicated with a dashed line. The omohyoideus 'sling' 
wraps around the clavicle (OM). The SCM, PE and OM are in pink. The section line (black) indicates the relative 
position of B. 
B. A cross-sect ion through the clavicle at the attachment of the SCM (orange and brown); the omohyodius is 
perpendicular to the SCM, dark brown). In the diagram , the endochondral core of the clavicle is dark grey and 
processing toward the external face are L3, L2 and L 1. 
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Figure 1.27: Rosettes within L 1 of the dermal clavicle 
Sagittal section through the dermal clavicle bone at embryonic day E18 after conception; Wnt1-Cre+l- x Rosa26LacZ-I-
specimen. IHC for Periostin (green, A-C); nuclear counterstain DAPI (blue); IHC performed by B. Ryll, image 
acquisition and analysis performed by K Jordan. Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. A 
schematic representation of the clavicle at the attachment point of the SCM indicates the position of A. In the diagram 
L 1 is light blue, L2 is blue/grey and Layers 3 is white. 
A. Rosettes, first identified in the frontal bone, are also present in Layer 1 of the dermal clavicle at a region where the 
SCM inserts into the bone (attachment area is superficial to the area of A). Rosettes sit in craters, the walls of which 
are Periostin positive, allowing the depth of the craters to be assessed in 3D. VVhite boxes indicate the locations of B-
C. 
B-C. The 3D reconstruction of A was rotated 1800 to view the rosettes from behind, allowing visualisation of the pore 
at the base of the craters (**). 
Scale bar indicates 2Sj.Jm. 
92 
,_.'-./---' ----,- ---.. 
1.4 Hand2 mutant analysis: Disrupted layer morphogenesis 
1.4.1 Introduction 
The role of Hand2 in dermal bone formation was investigated using two 
previously established strains of mice in which Hand2 expression is ablated. 
The Hancrillfl-Wnt1-Cre strain is a knockout transgenic which lacks Hand2 
expression specifically in neural crest cells (Hendershot et al. 2008). To 
visualise the Hand2-/- cells, Handillfl-Wnt1-Cre mice were crossed with the 
ROSA26LacZ reporter. This cross enables the discrimination between cell-
autonomous effects (in LacZ+ cells lacking Hand2) and non-autonomous 
phenotypic effects. To further specify if any observed effects of Hand2 
deletion were the results of the loss of Hand2 function conferred by the so-
called branchial arch enhancer (BAenh), I examined a strain of transgenic 
mouse lacking the BAenh region (Hand2BAenh) in parallel with the Hand2.f1Ifl-
Wnt1-Cre strain. Specimen from both strains were isolated for analysis at the 
day of birth (PO) to assess the resulting phenotype of Hand2 ablation during 
the processes of bone development previously analysed in the wild-type 
condition. 
Prior to investigating the effects of Hand2 deletion on dermal bone 
development, the endogenous expression of Hand2 was confirmed in the 
system in question, namely the murine frontal bone and dermal clavicle. 
Immunohistochemistry results indicated that in immature dermal bones, 
expression of Hand2 is prolific in Layer 3; while in more mature areas Hand2 
is widely expressed by cells populating Layer 2. Cytoplasmic Hand2 was 
also found to be expressed in the cells participating in rosettes, and crucially 
one cell of a rosette has a nuclear co-localisation of Runx2 and Hand2. In 
situ hybridisation (performed by B. Ryll) confirmed Hand2 expression in an 
early condensation of L3 in the clavicle of an E14 Hand2-Cre+l- x 
ROSA26Lacz-l- animal (Figure 1.28) (Ruest et a/. 2003); similarly to the 
frontal bone anlagen, the early condensation of L 1 in the clavicle comprises 
more cell layers than L3 and L 1 in the mature bone. Hand2 mRNA 
expression at this stage was also observed at the muscle-bone interface in 
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the presumptive L 1, in a less homogenous pattern than within L3 (Figure 
1.28). Coronal sections through a more mature frontal bone (E16) show a 
wide expression of Hand2 transcripts in L2 (primarily within osteoblasts, but 
also in the lining of blood vessels), and the dermis (Figure 1.28). Expression 
of Hand2 mRNA in L 1 and L3 at this stage is focal. Previous work in the 
laboratory confirmed the overlap of the endogenous and transgene 
expression patterns in craniofacial and clavicular structures of the Hand2-
Cre+l• x ROSA26Lacz·l. transgenic strain (Ryll & Koentges, unpublished). For 
the purpose of the current study, only the endogenous mRNA expression 
and protein localisation of Hand2 was analysed. 
1.4.2 Results 
In Hand2ft/ll-Wnt1-Cre x ROSA26LacZ specimen, Layers 1 and 3 are 
discernible by the alternating expression of Runx2 and OPN/Collagen I, 
respectively. 
At the medial margin of the clavicle, there is an extreme proliferation of cells 
within Layer 1. Runx2 expression is considerably up-regulated and is entirely 
translocated to the nucleus, suggesting a cytoplasmic tethering of Runx2 by 
Hand2 protein in vivo (Figure 1.29B) occurs in the non-mutant condition. 
Cells along the external margin of the clavicle have achieved the thin, sheet-
like morphology, which precedes L2 involution in the wild-type condition; 
however rosettes and their accompanying clasps are not evident and round, 
globular Runx2+ cells from L 1 have filled the entire physical space up to L3. 
These cells are neural crest in origin (LacZ+) and appear unable to form 
sheets within L2. This appearance is akin to what is expected from a 
traditional 'percolation' model where cells would enter L2 without constraint. 
The L 1 to L3 boundary is discernible by the strong expression of Collagen I 
in L3 (Figure 1.29A); which also indicates the location of the dermal cover of 
the endochondral core as Collagen I is expressed by cells of osteobloastic 
but not cartilaginous lineages (Mundlos et al. 1990; Huang et a/. 1997). 
There does not appear to be an extension of Collagen I expression into l2 , 
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an expression profile indicating that cells within the initial generative layer L3 
. may be confined to this area in the mutant and not able to enter L2. Some 
cells of L3, akin to the external area of L 1 cells, have flattened, however the 
characteristic bi-involution process is not evident and appears to be 
truncated by Hand2 ablation. 
The attachment site of the SCM per se, where direct dermal ossification 
occurs, appears unaffected in Hand2f1Ifl-Wnt1-Cre x ROSA26LacZ mice 
(Figure 1.30), suggesting that the molecular mechanisms determining 
attachment regions are distinct from those responsible for the histogenesis 
(dermal or endochondral) of the underlying bone. This genetiC separability 
might have relevance for the changes in ossification type within the shoulder 
region of tetrapods (Matsuoka et al. 2005). 
Contrasting this, the organisation of the dermal bone layer along the 
diaphysis is severally disrupted. In the Hand2 knockout, cells of both L 1 and 
L3 remain globular; the domain of L 1 has expanded in the absence of a well-
defined L2, while L3 consists of a single layer of cells (Figure 1.30). The 
organisation of POSTN expression becomes haphazard, with fibres spanning 
across the L 1-L3 region, where clearly defined borders into what should be 
L2 are not evident (Figure 1.30). Within L 1 rosettes are conspicuously absent 
and the cells' F-Actin fibres are radial giving the cells the appearance of 
being aligned along a vertical axis, further exaggerating that L 1 cells have 
lost their horizontal-sheet arrangement (Figure 1.20). 
An examination of the Hand2BAenh-l- strain yielded results indicating the 
Hand2BAenhancer ablation replicates the phenotype of crest-specific Hand2 
deletion (Figure 1.31). 
In the frontal bone of Hand2f1Ifl-Wnt1-Cre transgenic mice mirrors the 
condition of the clavicle with an expansion of L 1 and L3 cells and arrest of L2 
elaboration. Within L 1 semi-flattened cells (LacZ-negative) sit adjacent to 
LacZ+ neural crest cells of globular morphology (Figure 1.32). Given that 
there is a successive invasion of neural crest from L 1 into Layer 2 in the wild-
type condition (see above), the globular cells within L2 at the L 1/L2 interface 
might derive from L 1 but be unable to form sheets within L2. Layer 1 is many 
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cell layers thick and the bone is lacking the characteristic clasp features 
connecting Layers 1 and 3. At points along the bone, single radial cancellar 
walls are formed in L2 of the mutants, largely by LacZ- cells, but these 
simple walls lack any further horizontal and radial elaboration (Figures 1.32-
1.33). Where connections between the generative layers does occur, they 
are achieved by LacZ- cells, which do not carry the hallmarks of L 1 given 
they are both Runx2 and OPN negative indicating these 'clasps' may be 
mesodermal blood vessels (Figure 1.33). The expression domains of Runx2 
and OPN in the frontal have expanded, such that cytoplasmic Runx2 is found 
in L3, while OPN expression is observed in L 1 and the dermis (Figure 1.33). 
Cells adjacent to the mesodermal vasculature are found to be large, round 
cells expressing both OPN and Runx2 (Figure 1.33). 
1.4.3 Conclusion 
The overall appearance of the dermal bones in both the Hand2 f11f1-Wnt1-Cre 
and Hand2BAenh-l- strains are characteristic of an appositional growth mode 
via expansion of L 1, while L3 cells appear to be more inhibited in their 
invasion of L2. In the mutants, cells are unable to enter L2 in a regulated 
manner, leading to many blast-like cells that are Runx2-nuclear within the 
space corresponding to Layer 2; the overabundance of L 1 cells in the L2 
space suggest either invasion of L2 from L 1 or cells within L2 are undergoing 
rapid and unregulated division. Previous data suggested that Runx2 is a key 
regulator of invasion processes under metastatic conditions leading to 
osteolytic disease (Barnes et al. 2004; Pratap et al. 2006; Akech et al. 2010) 
and the invasive potential of Runx2+ cells seems to be maximised in the 
Hand2-mutant condition. 
The regulators of confined entry into the developing L2 system, namely the 
rosettes, are not evident in either Hand2-mutant strain of mouse analysed, 
nor are there properly elaborated clasps. In the frontal bone, some areas 
with single canceller walls of cells within L2 are found, however, they are 
comprised mainly of cells of non-neural crest origin (LacZ-negative), in which 
Hand2 would not have been ablated. This implies an attempt at a 
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compensatory mechanism of the mesodermal cells, which contributes to the 
subtlety of the phenotype. 
Interestingly, while the majority of cells are positive for LacZ, indicating they 
are Hand2-1- cells, the remarkable effect of Hand2 ablation on layer 
formation is most likely due to the loss of Hand2 function in coordinating 
cellular movements through the rosettes, established by the single 
Runx2/Hand2-nuclear expressing cell in each rosette. The consequence of 
the inability of cells to form proper laminae on vascularisation and 
biomineralisation are discussed in Chapters 2 and 3, respectively. 
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Figure 1.28: Endogenous expression of Hand2 mRNA in dermal bone 
Sagittal section through the dermal clavicle bone at embryonic day E14 (A) after conception, and coronal section 
through the frontal bone at postnatal day 1 (PO) (positive vaginal plug is taken as EO); Hands2-Cre+l- x Rosa26LacZ-I-
specimen. RNA fluorescent in situ hybridisation for hand2 (red); nuclear counterstain DAPI (blue); in situ performed by 
B Ryll, image acquisition and analysis performed by K Jordan. Layers 1, 2, and 3 are indicated as L 1, L2, and L3, 
respectively. 
A. At E 14 the hand2 transcripts are detected throughout L3 of the clavicle, as well as along the external margin of L 1 
and weaker expression is detected within the endochondral core of the clavicle. 
B. Overview of the cranial region of a PO, the frontal bone is outlined (white dashed line). 
c. Within the PO frontal bone, hand2 transcripts are detected in L2, as well as at focal points in L 1 and L3. The 
majority of the hand2 expression in L2 is confined to the bone proper, although weak expression in the lining of the 
vasculature is observed (blood vessels indicated, *). 
d Derm is, b Brain 
Scale bar indicates 50l-lm. 
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Figure 1.29: Loss of Hand2 leads to expansion of L 1 and nuclear translocation of Runx2 expression 
Sagittal section through the medial clavicle of postnatal day 1 (PO) transgenic knockout mouse; Hand2f1lf-l-/; Wnt1-
Cre+l- x Rosa26LacZ-I- specimen. IHC for Collagen I (red, A, C), Runx2 (green in B-C); nuclear counterstain DAPI 
(blue. Layers 1 and 3 are indicated as L 1 and L3, respectively. Anatomical overview of counterstain, including the 
location of A-C, is indicated at bottom right. 
Loss of Hand2 has resulted in a clavicle where L 1 is expanded and L3 confined to a single layer of cells at the margin 
of the endodermal core; there is no discernable L2 space. 
A. Collagen I expression is found in flattened cells at the external margin of L 1 and within L3. Expression of Collagen 
I in a single layer of cells on the L 1 side of L3 may indicate some cells from L3 have deposited via apposition into the 
area that should comprise L2. 
B. Runx2 expression in L 1 is ubiquitous and has been translocated into the nucleus in the absence of Hand2, 
indicating Hand2 may regulate Runx2 via a tethering mechanism. Within L3 there are some areas of Runx2 
cytoplasmic expression. 
C. Overlay of Collagen I and Runx2. 
Scale bar indicates 50l-lm. 
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Figure 1.30: Loss of Hand2 disrupts layer formation of the dermal clavicle 
Comparison of Hand2 knockout and control clavicles. A-C, Sagittal section through the dermal clavicle of postnatal day 1 (PO) 
transgenic knockout mouse in SCM attachment regions; Hand2M1; Wnt1-Cre+l- x Rosa26LacZ-I-. D-E, Sagittal section through 
the dermal clavicle of a non-mutant E18 mouse; Wnt1-Cre+l- x Rosa26LacZ-I- specimen. IHC for [3-Galactosidase indicate neural 
crest cells in which Hand2 has been ablated (white in A, light blue in B, pink in C), Periostin (green in A, B, D), F-Actin (red in A, 
C, E); nuclear counterstain DAPI (blue). A schematic representation of the clavicle at the attachment point of the SCM indicates 
the position of A-E. 
Loss of Hand2 has resulted in a clavicle where layer formation is disrupted. L 1 is expanded and cells have not flattened up and 
involuted into an L2 region. The attachment region is notably unaffected. The region that should contain L2 is noted with a 
dashed green line in A-C. 
A. Overlay of F-Actin, Periostin and [3-Gal in the mutant clavicle. 
B. The Periostin fibre system is disrupted in the mutant. Periostin fibres span the L 1-L3 region and do not form the walls of 
craters as POSTN does in the presence of Hand2 (D); flattened cells that are POSTN+ and line l2 are no longer visible. Cells 
orienting themselves in circular formations, indicative of an attempt at crater formation, are noted (*) and are mainly negative for 
[3-Gal indicating they have not had Hand2 ablated. 
c. Cells in Layer 2 have acquired a vertical orientation in the Hand2 knockout mouse and appear more isolated from one 
another and have not created a meshwork of cells in a parallel sheet organisation (E). 
Scale bar indicates 50~m. 
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Figure 1.31: Loss of the Hand2 branchial arch enhancer disrupts layer formation of the dermal clavicle 
Comparison of the clavicles of Hand2 knockout and Hand2BAenhancer knockout transgenic strains. A-B, Sagittal section through the 
dermal clavicle of postnatal day 1 (PO) transgenic knockout mouse in SCM attachment regions; Hand2f11f1; Wnt1-Cre+/- x Rosa26LacZ-
/- . C-D, Sagittal sections through the dermal clavicle of a Hand2BAenh-l- specimen. IHC for /3-Galactosidase indicate neural crest cells 
in which Hand2 has been ablated (pink in A. light blue in B), Periostin (green in B, 0), F-Actin (red in A, C), v\NF (green in C), and 
Runx2 (red in 0); nuclear counterstain DAPI (blue). Layers 1 and 3 are indicated as L 1 and L3, respectively. A schematic 
representation of the clavicle at the attachment point of the SCM indicates the position of A-D. 
Loss of the Hand2 branchial arch enhancer has resulted in a clavicle with a similar layer disorganisation as in the Hand2 knockout. L 1 
is expanded and cells have not flattened up and intercalated into an L2 region. The region that should contain L2 is noted with a 
dashed green line in A-D. The attachment region is notably unaffected. 
A. Cells of Layer 1 are organised in a vertical manner and there is a total absence of flattened cells lining an L2 region; in the 
Hand2BAenh-l knockout the L 1 organisation in a columnar fashion is further exaggerated (C). 
B. Periostin disorganisation in Hand2 knockout mice where POSTN fibres span L 1-L3 and are strongest in the disorganised region 
between L 1 and L3 that should contain L2. In the Hand2BAenh-l mice POSTN is expressed at the margin of the attachment region 
and along the L 1/L3 border (note: the globular appearance of POSTN in 0 is due to the antibody and not a phenotypic feature of the 
mutant). 
C. The attachment region comprises a subsection of L 1 'Nith a meshwork of F-Actin expression and a high level of vascularisation. 
Contrasting this, L 1 in non-attachment areas consists of cells in a vertical arrangement. Vascularisation of the L 1 and L3 areas is 
impaired. 
O. Runx2 expression in Hand2BAenh'" animals is both nuclear and cytoplasmic in L 1-L3. Cells of the layers remain round and blast-
like and have not flattened. A nascent 'clasp' formation is noted (*), which is noticeably cell-poor and aberrantly constructed. 
Scale bar indicates 50~m. 
IHC in A-B performed by B. Ryll, IHe in c-o performed by K Jordan, all image acquisition and analysis performed by K Jordan. 
105 
~ 
co 
-1 
CD 
N 
cr: 
X 
Q) 
~ () 
I 
~ 
...... 
~ 
~ 
-CI) 
o 
0:: 
Figure 1.32: Loss of the Hand2 disrupts layer formation in the frontal bone 
Comparison of Hand2 knockout and control frontal bone. A, Sagittal section through the frontal bone of a non-mutant 
E18 mouse; Wnt1-Cre+l- x Rosa26LacZ-I- . B-C, Sagittal section through the frontal bone of postnatal day 1 (PO) 
transgenic knockout mouse; Hand2f11f1; Wnt1-Cre+l- x Rosa26LacZ-I-. Nuclear counterstain DAPI (blue). Images are 
oriented cranial to the top and ventral to the left. Layers 1 and 3 are indicated as L 1 and L3, respectively. 
A. Anatomical overview of the frontal bone from the coronal suture to the nasal bone in a non mutant mouse. The 
bone becomes progressive more complex along the horizontal axis as it progresses toward the nasal bone. 
B-C. In the mutant condition the layer formation is disrupted. At the coronal suture (B) the bone does not immediately 
resolve into L 1, L2 and L3. The external margins of L 1 and L3 are noted (white and red dotted lines, respectively), 
however their inner margins cannot be determ ined. 
C. In the Hand2 knockout the bone becomes progressively less complex along its horizontal axis. C. is taken from a 
region adjacent to the nasal end, which should correspond to the most highly cancellous area of the bone. Layer 1 
has expanded and a thin space, presumably L2, is noted between Layers 1 and 3. 
d Dermis, b Brain, s Suture 
Scale bar indicates 50lJm. 
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Figure 1.33: Layer formation in the Hand2 knockout is achieved by mesodermal cells 
Sagittal sections through the frontal bone of a postnatal day 1 (PO) transgenic knockout mouse; Hand2f1/f/; Wnt1-
Cre+l- x Rosa26LacZ-I- . IHe for J3-Galactosidase indicate neural crest cells in which Hand2 has been ablated (green in 
A, 0), Runx2 (red in B, E), Osteopontin (green in C, red in 0, blue in E); nuclear counterstain DAPI (blue). Images are 
oriented cranial to the top and ventral to the left. Layers 1 and 3 are indicated as L 1 and L3, respectively. 
A. Cells of Layer 1 that have achieved a flattened morphology are negative for j3-Gal indicating their non-neural crest 
origin meaning Hand2 has not been ablated in these cells. Horizontal elaborations within L2 are not found. Cells of 
Layer 2 forming a 'clasp' are not positive for Runx2 (8) or OPN (C) indicating they are likely to be blood vessels. 
Large, globular cells neural crest cells, positive for both Runx2 and OPN are noted within L2 (* in 0, E). 
B-C. The expression domains of Runx2 and OPN in the frontal have expanded. Cytoplasmic Runx2 is found in L3 
(B), while OPN expression is observed in L 1 and the dermis (C). 
d Dermis 
Scale bar indicates 50JJm. 
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1.5 The PCP/non-canonical Wnt signalling pathway in dermal bone 
development 
1.5.1 Introduction 
The Hand2 mutants display a phenotype whereby the constrained cellular 
entry from L 1 and L3 into L2 required for normal intramembranous formation 
of the frontal and clavicle bones is abrogated. 
In the non-mutant condition, entry of cells from generative Layers 1 and 3 
appears to involve the cells in closest proximity to the rosette scaffolds 
threading into the underlying L2, which is elaborated in time by the continual 
addition of new cellular material. The morphogenetic arrangements of sheets 
of cells threading into rosettes at defined places requires coordinated 
migration patterns and is a behaviour reminiscent of classically defined 
convergent extension movements, often regulated by the non-canonical 
Wnt/Planar Cell Polarity (PCP) pathway, usually associated with cellular 
polarisation (Darken et al. 2002; Wang et al. 2006; Simons and Mlodzik 
2008). The PCP pathway regulates the organisation of cells along an 
epithelial plane and is involved in a diverse range of tissue formations, 
including gastrulation and neurulation, regulating aspects of development in 
an array of speCies including Drosophilia, Xenopus, zebrafish and mammals 
(Darken et al. 2002; Fanto and McNeill 2004; Karner et al. 2006; Karner et a/. 
2006; Simons and Mlodzik 2008). Components of the PCP pathway ensure 
proper sheet formation and overall cellular coordination (Myers et al. 2002). 
Mutations in this pathway lead to an inability of cells to coordinate their 
respective migration behaviours in groups, leading to the abolition of sheets 
and the isolation of cells that remain blast-like (Myers et al. 2002; Wu and 
Mlodzik 2009; Wansleeben and Meijlink 2011). This phenotype is replicated 
in the Hand2 mutants in the current study; the finding that LacZ+ cells lacking 
Hand2 remain blast-like and lose the polarisation of the markers they 
express (ex: Runx2, OPN, POSTN) indicate the membership of Hand2 in the 
PCP pathway. Although Hand2 is not a known member of PCP pathway, it is 
necessary for sheet formation in both zebrafish myocardial epithelium 
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outflow tract formation and murine palatal tissue development (Trinh et al. 
2005; Xiong et al. 2009). 
1.5.2 Results 
The possibility that the PCP pathway is involved in layer morphogenesis of 
dermal bones is supported by our findings that components of the non-
canonical WntlPCP pathway are expressed during the development of 
Layers 1, 2 and 3. 
An activated form of Notch is widely expressed by cells of Layers 1 and 3 
during early layer morphogenesis, including in cells participating in rosette 
formations and those cells that connect to the rosette and form a clasp 
across L2 (Figure 1.34). In epithelial tissues, the Notch pathway, in 
convergence with Wnt signalling and the BMP pathway, is transduced to the 
non-canonical Wnt pathway to control cell polarity and the canonical Wnt 
pathway to control tissue differentiation (Katoh 2007). Wnt5a is a key 
regulator of non-canonical Wnt signalling also known to direct cellular 
movements in the developing palate and is necessary for proper cranio-facial 
development (Oishi et al. 2003; He et al. 2008); this protein is expressed at 
focal points in Layer 1, within the majority of Layer 3 and, most interestingly, 
by cells that have intercalated into Layer 2 on both the L 1 and L3 margins 
(Figure 1.34), further supporting the notion that cells invade L2 from the 
generative layers. Interestingly, a recent report describing a PCP-mutant 
phenotype (lacking PKC-delta) speculated that this pathway may regulate 
the more subtle features of osteogenesis beyond the final differentiation of 
osteocytes, a postulation supported by the current findings (Tu et al. 2007). 
The finding that the non-canonical Wnt pathway is involved in regulating the 
stacking of chondrocytes in endochondral ossification (Li and Dudley 2009) 
implies this pathway serves as a universal mediator of cellular orientation 
allowing cells to organise themselves with regard to their neighbours, a 
feature that would be required for the coordinated elaboration of sheets of 
cells forming L2. While the PCP-pathway has previously been linked to the 
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proper formation of cartilaginous elements of the cranio-facial skeleton (Dale 
et al. 2009), results from the current study indicate it may also be necessary 
for dermal bone development. 
1.5.3 Conclusion 
Taken together, results presented here in indicate the role of the PCP 
pathway in in establishing Layers 1 and 3 as sheets capable of intercalating 
cells into L2. This process is disrupted upon ablation of either Hand2 or the 
Hand2 branchial arch enhancer in neural crest cells, resulting in a columnar 
organisation of the dermal bones indicative of an appositional growth mode, 
supporting Hand2 as a possible component of the PCP/non-canonical Wnt 
signalling pathway under in vivo conditions. Thus the previously posited 
model for appositional growth most strikingly resembles what is observed in 
the Hand2 mutants - cells are able to percolate into L2 but are unable to 
self-organize within L2, nor able to establish proper communication to the 
underlying Layer 3. 
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Figure 1.34: The non-canonical WntiPCP pathway is active in the 
generative layers of the frontal bone 
Sagittal sections through the frontal bone at embryonic day E18 after 
conception; Wnt1-Cre+l - x Rosa26LacZ-l- - specimen. IHC for activated Notch 
(red, A), and WntSa (green, B); nuclear counterstain DAPI (blue). Layers 1, 2, 
and 3 are indicated as L 1, L2, and L3, respectively. 
Expression of markers of the non-canonical WntlPCP pathway in progressively 
more mature stages of frontal bone development. 
A. An activated form of Notch is expressed by Layers 1 and 3 from the earliest 
stage of layer formation , as well as within cells of L2 and clasps that have 
achieved a flattened morphology. Notch is not expressed in cells that have 
remained round and not flattened up in Layer 2, as well as in the dermis. 
B. WntSa is expressed focally in Layer 1, ubiquitously in Layer 3 and in cells 
that have entered L2. 
d dermis, b brain Dermis 
Scale bar indicates SOl-lm . Rostral ~ 
Brain 
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1. 6 Summary of findings 
- The frontal bone primordium is a bilayered system comprising molecularly 
heterogeneous cells. External Layer 1 is neural crest in origin, while Layer 3 
is a mosaic of neural crest and mesodermal cells; 
- With time cells of Layers 1 and 3 flatten into laminar sheets and separate 
with the intervening space, termed L2, constituting the future cancellous 
bone structure that growths in thickness and complexity; 
- During the elaboration of Layer 2, Layers 1 and 3 remain unchanged and 
continue to express the molecular markers combinations that serve as their 
signatures through bone maturation; 
- Lineage mosaicism is used to explore the mechanism of L2 development 
and neither apposition nor clonal expansion is found to be the primary growth 
mode. Instead L2 is populated in time by the bi-directional movement of cells 
from L 1 and L3 into L2 as a convergence extension process, and the 
horizontal elaboration of the sheets of cells in L2; 
- There is no evidence of entire layer involution (neurulation-type behaviour) 
from L 1 or L3 into L2; 
- Cellular intercalation from L 1 and L3 into L2 is constrained to specific nodes 
of entry; at these entry points in L 1 cells are organised into rosette-like 
architectures; 
- Rosettes have polarised POSTN expression and contain one high columnar 
cell with translocation of Runx2 into the nucleus, as well as nuclear 
Osteopontin and nuclear Hand2 expression; 
- Loss of Hand2 in dermal structures results in disrupted layer formation and 
an organisation suggesting apposition from highly proliferative Layer 1 as the 
mechanism of bone growth in the mutants; 
- Genetic evidence from Hand2 mutants and marker states (OPN+, Coli 1+) 
also suggest invasion from Layer 3 into Layer 2 under wild-type conditions is 
blocked in the mutants. 
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- Translocation of Runx2 into the nucleus of Hand2-/- cells implies post-
transcriptional tethering of Runx2 in the cytoplasm by Hand2 as the 
mechanism for regulation Runx2's action. Preventing Runx2 from entering 
the nucleus would deprive it from binding target genes. Such a mode of 
regulation is not dissimilar to the action of Twist and other transcription 
factors (Twist code); 
- The PCP pathway is activated in Layers 1 and 3 and responsible for the 
convergent extension behaviours of cells threading from the generative 
layers into L2 in a highly regulated fashion; 
- Hand2 is implicated as potential new component of the non-canonical 
WntlPCP pathway. 
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2. Vascularising dermal bone 
2.1 Introduction 
Bones are highly vascularised entities and angiogenesis is a key component 
of both endochondral and dermal ossification (Hall and Miyake 1992; 
Kanczler and Oreffo 2008). Proper bone development and maintenance 
requires a close physical proximity between vasculature and the osteogenic 
surface, without which bone integrity is lost and bone formation is abrogated 
(Coskun and Hirschi 2010). While initial stages of endochondral bone 
development occur under a-vascular conditions, dermal bone is believed to 
form around pre-existing vasculature (Figure 2.1) (Lieberman and 
Friedlaender 2005). In this model, the intramembranous skeleton arises from 
mesenchymal condensations that are highly populated by blood vessels; in 
the craniofacial skeleton this vasculature matures earlier in organogenesis 
from the cephalic mesoderm (Le Douarin and Kalcheim 1999). This means 
vasculature has temporal precedent and dictates the architecture of dermal 
bones in the conventional model of direct ossification: as mesenchymal cells 
differentiate into osteoblastic lineages they need to arrange themselves in 
close proximity to the blood vessels, without impinging upon the vasculature 
with capricious osteoid production (Figure 2.1) (Lieberman and Friedlaender 
2005). 
This model, whereby existing vasculature becomes enveloped by 
osteoblastic layers, is irreconcilable with results presented in Chapter 1, 
where Layer 2 is initially cell sparse and could not accommodate pre-existing 
vasculature nor does Layer 1 secondarily engulf vasculature in the overlying 
dermis. Moreover, it was previously assumed that blood vessel endothelia of 
dermal bones are mesodermal in origin within neural crest-derived skeletal 
elements on the basis of QH 1 immunoreactivity and how mesodermal 
vasculature enters into a predominantly neural crest area has not been 
previously reconciled (Etchevers et al. 2001). Therefore, it became 
necessary to explore how vascular development is integrated into dermal 
bone formation. To accomplish this, the same technique was employed as 
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was used to explore layer morphogenesis: namely, a three dimensional time-
course study of bone development from E13 through murine birth using 
molecular markers of vascular development. 
Blood vessels (with the exception of capillaries) comprise three layers 
associated with both their function and the cell types within them (Figure 
2.1 C) (Lee 1989): at the internal (luminal) face the endothelial cells form the 
tunica intima. The tunica intima is ensheathed by the smooth muscle cells of 
the tunica media, reinforced by layers of the elastic laminae. The external 
adventia layer is composed of connective tissue and nerve fibres. Vascular 
development in dermal bones was analysed using three molecular markers, 
which preferentially labelled either the endothelia or smooth muscle lining of 
the vessels. 
Endothelial cells were identified using the well-established markers von 
Willibrand factor (Factor VIII related factor) (vWF) and CD31 (PECAM1). 
vWF is synthesised by endothelial cells and megakaryocytes and is stored in 
intracellular granules or secreted into plasma; vWF is a component involved 
in plateletvessel wall interactions (Denis 2002). Under some conditions, for 
example during tumorigenic angiogenesis, vWF immunolabelling is 
insufficient to identify all vessels, whereas CD31 has shown a wider area of 
expression among endothelial cells (8aderca et al. 2005). CD31 is produced 
by platelets and leukocytes, concentrated at the borders between endothelial 
cells (Simmons et al. 1990). Pericytes (or vascular mural cells) are 
embedded in the vascular basement membrane and their cytoskeleton can 
be labelled with a-smooth muscle actin (SMA); pericyte reactivity for SMA is 
not, however, entirely consistent brain pericytes of chicken reportedly 
express SMA, while those in mice were unlabelled; even within individual 
micro-vessels SMA expression is patchy (Armulik et al. 2005). 
A combinatorial approach, whereby markers of vasculature were examined 
in parallel with osteblastic markers, allowed a thorough investigation into the 
generation of the osteoblast-vasculature interface and the role of 
angiogenesis in dermal bone development. 
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Figure 2.1 Vascularising dermal bones 
A-B. Diagrammatic representation of the traditional model of intramembranous ossification in which the bone forms 
around pre-exisiting vasculature. The blood vessels (red) are engulfed by the growing bone front and osteoblasts 
(white) surround the vasculature and secrete osteoid (grey) and mineralised matrix (green) away from the vessels so 
as not to impinge upon them with precocious ossification. 
Modified from Bruder & Scaduto in Bone Regeneration and Repair, 2005, Human Press Inc. Lieberman & Friedlaender, eds. 
c. The structure of a blood vessel has three layers, separated by thin, elastic lamina (dark grey). At the internal 
(luminal) space, endothelial cells (light grey) of the tunica intima completely line the vessel. Endothelial cells are then 
sheathed on their external side by the smooth muscle cells of the tunica media (red). The most external area of the 
vessel is the connective tissue of tunica adventitia (pink). 
Modified from Podell & DiGergorio. available at: httpJIwww.freewebs.com/circulatorysystem/aboutbloodsystems.htm 
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2.2 Results 
2.2.1 Generating the vasculature-osteoblast interface 
Results presented in Chapter 1.1 indicate the mesenchymal condensation 
yielding the frontal bone is a bi-Iayered anlage comprising L 1 and L3. At E13, 
the frontal bone primordium has a spatial molecular heterogeneity, with the 
lateral and medial aspects expressing the signature of L 1 and L3, 
respectively. At this stage there is no intervening L2 nor any morphogenic 
evidence of pre-existing vasculature in the condensed mesenchyme. 
Expression of vascular markers at E13 is restricted to a border of cells at the 
margin of the brain (presumably the meninx) and to individual, blast like cells 
within L 1 (Figure 2.2). 
As foetal maturation progresses and rudimentary L2 is formed, there remains 
no evidence of fully formed vasculature within immature Layer 2 by day E 16 
(Figure 2.2). Conversely, Layer 1 and Layer 3 are extremely heterogeneous 
and comprise both osteoblastic and vascular CD31/vWF+ precursors (Figure 
2.2). Analysis of Wnt1-Cre x ROSA26LacZ and Wnt1-Cre x XZ-DR mice 
indicate the CD31/vWF-positive cells are two populations: mesodermally-
derived and neural crest-derived endothelia. The latter is surprising given 
that studies by LeDouarin et al. had not found neural crest to be able to form 
endothelia (Le Douarin and Kalcheim 1999). 
If L 1 and L3 are closed systems that provide osteoblastic cells to populate 
L2, without pre-existing vasculature there is the possibility that L 1 and L3 
also act as generative layers for the endothelia. Indeed, examining early 
clasp formations in Wnt1-Cre+l- x XZ-DR/-/ROSA26LacZ-I- mice reveals pairs 
of neural crest (LacZlGFP-positive) cells entering L2 from the generative 
layer L 1; these pairs contain cells of two separate fates, osteoblasts that are 
Runx2+/CD31- and Runx2-/CD31+ endothelial precursor cells (Figure 2.3), 
in direct proximity to each other. This is the first time, to our knowledge, 
neural crest cells have been shown to form endothelia in the frontal bone, 
although they have been previously documented within the bone marrow of 
119 
adult animals (Nagoshi et al. 2008). The mosaic expression of bone and 
vascular markers in L 1 is reflected in L3, indicating L3 may also contribute 
both osteoblastic (OPN+) and vascular (C031+/vWF+) cells to L2 (Figure 
2.2). 
As cells continue to invade L2, the bone structure becomes continually more 
elaborate along the dorsa-ventral axis and through a time-course of 
development. Osteoblastic cells in L2 contribute to matrix deposition while 
C031/vWF-positive cells participate in angiogenesis. The proximity of the 
osteoblastic and vascular cells is continually maintained such that the 
vascular and bone architectures develop concurrently (Figure 2.4). The de 
novo formation of the bone vasculature from C031/vWF-positive cells from 
L 1 and L3 results in a mature frontal bone containing both neural crest and 
mesoderm-derived vasculature (Figure 2.5). In areas with advanced stages 
of bone maturation, L3 becomes increasingly vascularised and is many cell 
layers thick, with the cells in a parallel-sheet orientation (Figure 2.5). 
Contrasting this, L 1 only ever comprises 1-3 cell sheets and the relative 
proportion of osteoblast and vascular cells remains stable from E16 through 
birth. 
2.2.2 Rosettes and the pore-canal system 
Results from Chapter 1.3 indicate rosettes are the entry point for the 
osteoblastic cells, and additional evidence supports them being the 
introduction site of the endothelia. Intriguingly, when examined with vascular 
markers, single cells within rosettes were also found to be positive for 
endothelial markers (Figure 2.6). In early ontogeny, rosettes were not the exit 
or sprouting points of pre-existing dermal vasculature, but were hubs of 
endothelial intercalation. At a future time-point, late in ontogeny (E18 and 
beyond), rosettes appear to also be docking points, connecting vasculature 
in the dermis to the generative layer (Figure 2.7). 
The physical topography of the rosette environment, namely a pore in the 
centre of a crater at the bone-dermis interface, are reminiscent of the pore-
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canal system of fossil fish (Gross 1956; Donoghue and Sansom 2002; Le 
Guellec et al. 2004). A schematic representation of the pore-canal system in 
the basal jawed-vertebrate osteostracans displays a remarkable similarity to 
the surface view of rosettes in L 1 (Figure 2.8). The pore canal system exists 
in heterostracans, osteostracans and lungfish, where the dermoskeletan is 
laced with canals that communicates with the external surface via a series of 
pores whose morphogenetic significance has remained elusive (Donoghue 
and Sansom 2002); these canals were initially believed to act as 
electroreceptive organs (given the similarity between the pore-canal 
morphology and ampullary organs in chondrichthyans) or spacing agents for 
mechanoreceptors and later understood in the classical framework of 
ossification as a secondary consequence of vascular involution and 
remodelling (Gans and Northcutt 1983; Northcutt and Gans 1983; Maderson 
1987; Gans 1988; Gans 1989; Hanken and Hall 1993). This notion was 
problematic as only placoderms display clear evidence of bone remodelling. 
If, however, the system has been retained through evolution and now 
comprises rosettes and their scaffolds, the pore canal system can be 
understood not as a consequence of remodelling, but part of dermal bone 
development involving active and constant insertion of new cellular material 
(osteoblastic and vascular) in the initial modelling process. Under these 
conditions one can start to re-examine classical acellular bone such as that 
found in heterostracans where classical 'remodelling' has not been found. 
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Figure 2.2: Location of endothelial cells in the developing frontal bone from E13-E18 
Sagittal sections through the frontal bone at embryonic day E13 (A-B) and E18 (C-D) after conception; Wnt1-Cre+l- x 
Rosa26LacZ-I-. IHC for CD31 (green, A-B; red, C), and vWF (red, D), indicating endothelial cells; nuclear counterstain 
DAP I (blue). Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. 
Location of endothelial cells in the developing frontal bone. 
In the mesenchymal anlage to the frontal bone (A-B) CD31 expression is confined to a single layer of cells at the 
brain:mesenchyme interface (presumably the meninges) and to a few cells within the mesenchyme. Notably, none of 
these cells has achieved the flattened appearance of fully differentiated endothelial cell. 
C-D. In immature regions of the frontal bone at E18 there are very few endothelial cells within L2, instead L 1 and L3 
are both populated by vascular cells, intermingled with non-vascular cells (presumably osteoblasts). 
d Dermis, b Brain 
Scale bar indicates 50~m. 
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Figure 2.3: Osteoblastic and vascular cells enter L2 via clasps in a twinned manner 
Sagittal section through the frontal bone at embryonic day E 18 after conception; Wnt1-Cre+l- x Rosa26LacZ-I-
specimen. IHC for f3-Galactosidase showing neural crest cells (green), Runx2 ( red in A, D) and CD31 (white A, red 
in C); nuclear counterstain DAPI (blue). Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. 
A. In an immature region of the frontal bone clasps can be seen in different stages of development. Mature clasps 
(filled arrowhead) are interspersed with nascent clasps (empty arrow head). Red box indicates the location of C and 
D. 
B. Anatomical overview of L 1, L2, L3 and clasps. 
C-D. Cells in a mature clasp enter L2 in a paired-manner where one cell is a Runx2+ osteoblast and the other is a 
CD31 + endothelial cell. Both cells are of neural crest origin. 
d Dermis 
Scale bar indicates 50\Jm. 
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Figure 2.4: Diagram of parallel vasculature and bone morphology development 
A. In an immature frontal bone vascular cells (red) and osteoblastic cells (green) enter L2 from the generative layers 
L 1 and L3 (grey) in a twinned manner. The close proximity of the cells indicates the cooperative manner of 
establishing the layer morphogenesis and vasculature. 
B. As the bone develop5 the osteoblastic cells (green) surround the bone matrix (light green) while the vasculature 
(red) develops in parallel and surrounds the matrix via de novo tube formation. 
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Figure 2.5: Neural crest contributes to the endothelia of the mature frontal bone 
Sagittal section through the frontal bone at embryonic day E 18 after conception; Wnt1-Cre+/- x Rosa26LacZ-/-
specimen. IHC for J3-Galactosidase showing neural crest cells (green) and vWF (white); nuclear counterstain DAPI 
(blue). Layers 2, and 3 are indicated as L2, and L3, respectively. 
A. Overview of the vasculature of a mature area of the frontal bone near the nasal bone. vWF-positive lining of blood 
vessels are seen running perpendicular (*) and parallel (-) to the section plane. Red box indicates the location of B. 
L 1 is above the plane of the image and L2 and L3 are indicated. 
B. Zoom of the neural crest vasculature in the frontal bone. Orange box indicates the location of C. 
C. Frontal view of the section line along which 0 is oriented. 
D. Plane cut through the axis indicated with section line in C, confirming the double J3-Gal and vWF expression of this 
neural crest-derived endothelia. 
Scale bar indicates 50~m. 
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vWF Figure 2.S: One cell in a rosette is positive for endothelial markers 
Sagittal section through the frontal bone at embryonic day E 18 after 
conception; Wnt1-Cre+l- x Rosa26LacZ-I- specimen. IHC for vWF (red); 
nuclear counterstain DAPI (blue). 
A single cell within the rosette formation (L 1) is positive for the 
endothelial marker vWF; this cell interfaces with endothelial cells 
beneath it at the L 1 : L2 interface. 
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Figure 2.7: Rosettes connect the 
bone to dermis vasculature 
Sagittal sections through the frontal 
bone of a wild-type mouse at post-
natal day 1 (PO). IHC for a-SMA 
conjugated to FITC (green, A) and 
cy3 (red, B); nuclear counterstain 
DAPI (blue). Layers 1, 2, and 3 are 
indicated as L 1, L2, and L3, 
respectively. 
Rosettes connect to external 
(dermis) vasculature late in 
development. A. Mature area of 
the frontal bone where nascent 
blood vessels in the dermis, 
positive for the pericyte marker a-
SMA, connect to a rosette (circled). 
B. Magnification of an area where 
an L 1 rosette ties to a blood vessel 
in the dermis skirting the top of the 
bone. 
Scale bar indicates 50JJm. 
Murine, Wild-Type P2, Frontal Bone Osteostracans, 
Pore Canal System 
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Figure 2.8: Rosettes are similar to the pore-canal system of basal vertebrates 
A. Flat mount of the frontal eminence of a wild-type mouse at postnatal day 3 (P2) . Nuclear counterstain DAPI (blue) 
and reflection imaging to examine bone topography. Three rosettes sit along the walls of craters formed by 
depressions in the bone surface. At the base of the crater a pore connects L 1 to L2. 
B. Diagrammatic surface view of the pore canal system of osteostracans, a clade of fossil, armoured jawless 
vertebrates from the Silurian and Late Devonian eras. The orientation of the system is similar to that of the rosette 
system . Modified from Gross 1956. 
Scale bar indicates 50!Jm. 
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2.3 Conclusion 
The observation that endothelial precursors enter L2 in a concomitant 
manner with osteoblastic cells is in contrast to the traditional model of 
intramembranous ossification whereby the bone forms around pre-existing 
vasculature. The current findings show that there is no pre-patterning of the 
bone by the vasculature, but rather a development of a cancellous bone 
structure by the expansion of sheets of osteoblastic and vascular cells 
intercalating into L2. 
There is no evidence of involution of entire vessels from the dermis, as L 1 
and L3 create a closed system and the only entry points into L2 are through 
rosettes. The early clasp structures are surprisingly heterogeneous: cells of 
both neural crest and mesodermal origin co-participate in individual clasps 
and clasps can simultaneously contain both vascular and osteoblastic cells 
(Figure 2.9). Clasps provide the scaffold for ingression of highly migratory 
osteoblastic cells and endothelia. 
Three-dimensional histological analysis shows that both osteoblasts and 
adjacent endothelial cells generate internal surfaces within Layer 2 that later 
connect up with vasculature on the outside of Layers 1 and 3. This 
observation is not commensurate with traditional angiogenesis modes that 
rely on 'sprouting' from pre-existing vessels as I find no clear-cut evidence 
for a direct physical link between early dermis vasculature and bone 
vasculature. The connection between the bones internal vascular network 
and external vessels is only evident in late stages of maturation, following 
extensive establishment of the internal organisation of L2, indicating that 
bone vasculature development is not predicated on contact with the dermis 
vasculature. 
The late link between bone and dermis vasculature is facilitated by rosettes 
fulfilling the ancient role of the pore canal system in basal vertebrates. 
Interestingly, the expression of OPN within the rosette has additional 
significance in the context of vascularisation as Osteopontin expression is 
attractant for vasculature and plays a role in hematopoietic stem cell niches 
. in bone (also termed osteoblastic niches) (Nilsson et al. 2005; Yin and Li 
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2006); as such the OPN+ cell of the rosette could playa role in attracting the 
endothelia of L 1 to the rosette or mediating the late interface of L 1 and 
external blood vessels. 
Results from both Chapter 1 and 2 support a mode of dermal bone 
development where the generative architecture of the bone is dictated by de 
novo sheet formation within L2. The concomitant development of layer 
morphogenesis and angiogenesis is achieved by the paired entry and 
persistent juxtaposition of osteoblast and endothelial precursors, a spatial 
relationship that ensures mutual benefits to both cell types: osteoblasts are 
supplied with nutrients, while the vasculature can influence the bone 
development to prevent precocious ossification. In this model, co-
development would further support a mechanism of growth that did not 
require re-modelling by osteoclasts to accommodate any additional vascular 
development after the establishment of mineralised matrix, explored further 
in Chapter 3. 
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Figure 2.9: Clasps are formed by diverse cell types 
Sagittal section through the frontal bone at embryonic day E18 after 
conception; Wnt1-Cre+l- x Rosa26LacZ-I- specimen. IHC ~-Galactosidase 
showing neural crest cells (green) and CD31 (red) indicating endothelia; 
nuclear counterstain DAP I (blue). 
A nascent clasp across L2 connects L3 to a rosette in L 1 (the pore in the 
centre of rosette indicated *). This clasp comprises a neural crest cell, 
which is not endothelial, from L 1 connecting to an endothelial cell of 
mesodermal origin (red *). The mesodermal endothelial cell is adjacent 
in Layer 3 to a neural crest-derived endothelial cell (white *). 
Scale bar indicates 50~m 
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2.4 Summary of findings 
- The development of intramembranous layer morphogenesis and de novo 
vasculature are paired; vasculature does not pre-pattern the bone's 
organisation; 
- Vasculature in the frontal bone is of both neural crest and mesodermal 
origins; 
- Both osteoblastic cells and endothelial cells enter the maturing L2 system 
via the rosettes; 
- Rosettes also serve as anchor points for dermal bone vasculature to 
connect to the bone late in frontal bone maturation; 
- Rosettes and the clasp system may be the mammalian counterparts of the 
pore-canal system in basal vertebrates and provide a framework for re-
examining acellular bone in the gnathostome stem group. 
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3. Biomineralisation of dermal bones 
3.1 Introduction 
The establishment of layer morphogenesis and the parallel development of 
the bone vasculature led to a further analysis of another key process to bone 
maturation: matrix deposition and biomineralisation. 
Biomineralisation is the process by which the mineral phase is added to the 
organic matrix leading to the hardened bone tissue (Bala et a/. 2010). In the 
case of vertebrates, the mineral phase of bone, dentine and tooth enamel 
predominantly consists of calcium phosphate (hydroxyapatite) crystal 
formation along a collagen scaffold (George and Veis 2008; Weiner 2008). 
The organic phase (the osteoid) is primarily comprise collagens, but also 
contains proteoglycans and acidic non-collagenous proteins containing 
glycosaminoglycans (Golub 2009) and the process by which the 
hydroxyapatite crystals form in the osteoid in vivo is highly contentious. 
Alternate theories for the initial nucleation have been proposed, with the 
most widely supported being the heterogeneous nucleation theory, favouring 
direct formation of apatite from soluble inorganic ions on organic and 
inorganic precursors (Veis 1981). Irrespective of how nucleation 
commences, it is generally accepted that biomineralisation is essentially the 
process by which the crystals form along the collagen scaffold nucleating on 
the collagens themselves, by entering the collagen pore and growing in 
between collagen fibres or by growing along the fibres as thin platelets 
perpendicular to the longitudinal axis of the fibres (Galieraman et a/. 2007); 
biomineralisation in vertebrates mayor may not involve an early unorganised 
mineral being replaced by a more stable structured mature crystalline phase, 
a mode of growth found in invertebrates that can be induced in mammalian 
tissues (Crane et a/. 2006; Weiner 2006). 
The issue of remodelling the bone matrix is complex: remodelling is a 
constant feature of some endochondral bones, however some species (SUch 
as rodents) display little secondary remodelling (Bala et a/. 2010), in these 
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animals -as in dermal bones- the initial mineral deposition may be highly 
controlled and coordinated if later remodelling is not expected. 
Several genes play a role in directing the process of biomineralisation: 
Osteopontin has the contrasting functions of both promoting mineralisation 
and also capping it in a directional manner: growth of HAP crystals can only 
occur away from the Osteopontin protein core and the polarisation of 
Osteopontin localization has direct implications for the directionality of 
emerging HAP crystals (Boskey et al. 1993; Boskey 1995). Similarly in 
calcified cartilage Fibronectin also acts to mediate the mineralisation process 
(Burton et al. 1996) and Collagen itself is implicated in crystal modulation 
(GaDeraman et al. 2007). Many extracellular matrix proteins are acidic and 
inhibit calcification by binding Ca2+ and there is enough calcium phosphate in 
bone tissue that crystal inhibitors are required to prohibit spontaneous 
mineralisation leading to a hyper-calcification (Marcus et al. 2008; Weiner 
2008; Golub 2009). The roles these genes play in the biomineralisation of 
dermal bone has not been extensively studied in vivo, despite mutants being 
available for many of them (Aubin et al. 1995; Norris et al. 2007; Frazen et al. 
2008; Farrow et al. 2009); indeed the process of biomineralisation is typically 
explored in endochondral bones as dermal bone ossification was perceived 
as a variant of endochondral ossification. Outstanding issues of dermal bone 
biomineralisation include: to what extent the initial mineralisation process is 
controlled by the osteoblasts expressing Runx2, OPN and/or Fibronectin; 
additionally, the pre-eminence of either initial mineral deposition or later 
remodelling remains to be clarified. 
For the purpose of the current study, the aim was to explore how the forming 
bone architecture and gene expression influences mineralisation of dermal 
bones: the newly identified mechanism of continually supplying cells to the 
bone as it grows in thickness would be expected to have implications for the 
process of biomineralisation. To this end, I examined the ontogeny of dermal 
bone biomineralisation, and conducted a study of the process of collagen 
synthesis, cleavage and concomitant matrix production in and ex vivo. 
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3.2 Normal time-course of matrix deposition in dermal bone 
The process of bone mineralisation was examined ex vivo by the histological 
addition of calcein, a fluorescent chelating agent that marks bone 
mineralisation by incorporating into areas where calcium-phosphate 
(hydroxyapatite) has been added to the osteoid (Hale et al. 2000; O'Brien at 
al. 2002; Kihara et al. 2004). During a time-course of development from E 12 
through birth, the presence of mineralised osteoid in dermal bone was 
confirmed at E14. 
Early mineralisation occurred within very immature regions of L2, near the 
coronal suture, in distinct 'clouds' or 'islands' (Figure 3.1). Each calcein+ 
island was separated from its neighbour by the clasps across L2, which 
remained unmineralised, and the extent of the mineralisation did not reach 
L 1 or L3 (Figure 3.1 B). In a more mature region of L2, the mineralised 
islands formed a single plane of mineralisation. As development progressed, 
sheets of mineralised matrix form parallel to the surface of the bone. These 
calcein planes were physically separated by non-mineralised sheets of cells, 
which reached from L 1 to L3, connected to the clasps/rosettes identified 
above (Figure 3.1 C). The calcein planes were, therefore, like tectonic plates 
or plywood that could be moved as the system increased in complexity, 
allowing thickness growth to occur without stunting the lateral and vectorial 
growth of the bone taking place Simultaneously. Curiously, the planes of 
mineralisation were located centrifugally, an unusual feature that counters 
the classical concept of apposition, which would imply the planes should be 
stacked from L3 towards L 1. 
In the clavicle at E18, the blocks of mineralisation are fully surrounded by 
Undulin positive flattened cells, giving the impression that calcein carrying 
areas are packaged by the Undulin+ cells producing the matrix (Figure 3.2). 
These cells are adjacent to small blood vessels observed within the 
spongious matrix, giving the appearance of a contiguous growth surface of 
Undulin+ osteoblasts and endothelial cells within Layer 2. This observation 
would be commensurate with a de novo sheet formation within Layer 2 as 
• 
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again, the points of entry are focal and involution of entire Layers 1 and 3 
was not observed, 
Cells trapped within the mineralised matrix, presumably producing the 
osteoid, were unexpectedly heterogeneous: all cells at the margin of the 
calcein-positive areas were Undulin-positive; conversely Runx2-expression 
was variable and the cells surrounding and within the mineralised areas were 
largely, but not entirely Runx2-positive (Figure 3.3). The expression pattern 
of Osteocalcin (OCN) was equally intermittent: Osteocalin expression 
appeared confined to cells that were not fully embedded in the mineralised 
front. In the immature condition a discernible cleft is evident between the 
margin of OCN and the calcein-positive island (Figure 3.4); in the mature 
bone, cells surrounded by calcein are largely OCN-negative, especially 
toward the internal margins of the bone away from L 1 (Figure 3.4). 
Osteocalcin negativity in mineralised areas was unexpected as Osteocalcin 
is reportedly a marker of late osteoblasts and osteoclasts. 
Taken together, results of the ex vivo study indicate the biomineralising zone 
changes significantly with time (from clouds-like structures, to flat sheets 
within L2, to multi-layered planes interconnected by radial areas of 
mineralisation) suggesting a remodelling process. However, in light of the 
irregular pattern of Runx2 and OCN expression within the biomineralising 
zone, it is impossible from the ex vivo study to determine the identity of the 
cells producing the matrix and, potentially, accomplishing the remodelling. 
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Figure 3.1: Mineralisation begins as islands and becomes planes surrounded by non-mineralised walls 
Sagittal sections of a wild-type frontal bone at embryonic day E16 after conception (positive vaginal plug is taken as 
EO). Histological addition of calcein (green) stains the mineralised matrix; nuclear counterstain DAPI (blue). Layers 1 
and 3 are indicated as L 1 and L3, respectively. 
A. Overview of calcein positive areas along the frontal bone. Mineralisation begins adjacent to the coronal suture (*). 
Matrix mineralises in individual islands (8) surrounded by un-calcified clasps. 
c. In the most mature region two planes of mineralisation form in parallel and sheets of cells still connect 
unmineralised L 1 to unmineralised L3 (arrows). Calcified areas are found toward the centre of L2. 
Dermis 
Scale bar indicates 50~m . Rostral ./ ...-, 
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Figure 3.2: Undulin-positive cells surround and package mineralised islands 
Sagittal sections of a wild-type clavicle at embryonic day E18 after conception. Calcein stain of mineralised matrix 
(green); IHe for Undulin (red); nuclear counterstain DAPI (blue). 
A-C. Calcein was reconstructed in 3D and the nuclei and Undulin from three optical sections was stacked to show the 
Undulin+ projections of cells encompassing the mineralised islands. In A blood vessels are indicated (white 
arrowheads); the top blood vessel is inside the calcified area and the stacks indicate a contiguous growth surface of 
Undulin+ osteoblasts and endothelial cells inside the spongious Layer 2. 
Scale bar indicates 50~m . 
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Figure 3.3: Runx2-positive osteoblasts in the mineralised matrix 
Sagittal sections of a wild-type frontal bone at embryonic day E16.5 after conception (positive vaginal plug is taken as 
EO). Calcein stain of mineralised matrix (green); IHC for Runx2 (red); nuclear counterstain DAPI (blue). Images are 
oriented cranial to the top and ventral to the left. 
A-C. Bird's eye-view of Layer 1:2 interface showing Runx2 expression in relation to matrix mineralisation in the 
immature frontal bone. Cells sitting on top of calcein 'clouds' are Runx2+. Notably, this Runx2 expression is weaker 
than expression within L 1. Part of a rosette (arrowhead) is seen separating the two mineralised clouds. 
O-F. Runx2 expression in the most mature aspect of L2 in the frontal bone of an E16.5 mouse; two planes of 
mineralised matrix are surrounded by Runx2+ cells (with a cleft between the calcein and the generative Layer 1, 
arrow in F). The majority of the cells sitting in calcified matrix are Runx2, with some exceptions (*). 
d Dermis, b Brain 
Scale bar indicates 50lJm. 
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Figure 3.4: Osteocalcin-positive osteoblasts surround the mineralised matrix 
Sagittal sections of a wild-type frontal bone at embryonic day E16.5 after conception. Calcein stain of mineralised 
matrix (green); IHC for Osteocalcin (red); nuclear counterstain DAPI (blue). 
A-C. Osteocalcin expression in relation to matrix mineralisation in the immature frontal bone. Cells along the margin of 
the calcified area (not within it) are Osteopontin positive. There is a cleft (indicated with an arrow in C) between OCN 
expression and the mineralised matrix, visible comparing Band C. 
O-F. Osteocalcin expression in the most mature aspect of the E16.5 frontal. Osteocalcin expression is confined to the 
exterior aspects of the bone. Cells at the internal calcification are negative for OCN expression or only very weakly 
positive (red **). Blood vessels are indicated (white *). 
d Dermis, b Brain 
Scale bar indicates 50~m. 
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3.3 In vivo time-course of matrix labelling 
3.3.1 Introduction 
I designed an in vivo time-course experiment to explore the exact spatial 
extent of the mineralising zone in dermal bones and its changes in time. Two 
alternative cellular models of biomineralisation were feasible in light of the 
results of the ex vivo calcein study (namely the molecular heterogeneity of 
the cells in the mineralising zone and the apparent remodelling of the mineral 
phase) (Figure 3.5): 
A) Apposition: non-mineralised cells could sandwich the mineralised area 
and lay osteoid appositionally. 
8) Nesting: osteoblasts could invade the mineralised matrix and continually 
remodel the bone as it grows from within. 
The former model, A, would require the younger matrix to be deposited on 
top of the previous matrix; the finding that the mineralised areas are always 
located centrifugally would indicate cells enter from Layer 1 and 3 and 
encase previous matrix with new osteoid. Alternatively, model 8 would lead 
to remodelling taking place within (and outside of) previously established 
mineral and new osteoid would be located within a shell of older matrix 
(Figure 3.5). 
For in vivo analyses, fluorescent chelating agents would be injected into 
pregnant dams at concentrations high enough to confer the dye to the 
embryos without producing pharmalogical side effects (ex: high doses of 
tetracyclines can alter osteoblastic metabolic rhythms and impair bone 
formation in vitro (Tam and Anderson 1980; Simmons et a/. 1981». At a later 
time-point a second dye would be injected, and an analysis of the dye 
configuration would yield an insight into the patterns of biomineralisation 
• 
including any remodelling taking place. Injections would be made into the 
peritoneal cavity and the phYSical proximity of the osteoblasts and blOod 
vessels in the bone would ensure dye delivery to the target matrices. The 
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labelling experiments would address the two models of bone mineralisation 
supported by the ex vivo calcein experiments (Figure 3.5) and support the 
model of layer morphogenesis (namely, two generative layers) hypothesized 
in Chapter 1. If the mineralisation occurs purely appositionally and there are 
two generative surfaces (L 1 and L3), the first injected colour is expected to 
be sandwiched by the second colour injected; alternatively if deposition is 
appositional from a single generative surface, the second colour will be 
external to the first. Alternatively, a more unusual alternative would be if cells 
continually invade and nest into the previously established matrix resulting in 
the second colour found inside areas labelled by the first injection. The 
appropriate license for the experiments was procured and the following 
controls conducted prior to commencing the experiments: 
3.3.2 Controls for in vivo labelling experiments: 
3.3.2.1 Histological addition of chelating agents to confirm there Is no 
spectral overlap. The labelling agents chosen for the in vivo analyses had 
previously been used in in vivo studies of endochondral bone repair, where 
they were successfully imaged without overlap (Pautke et a/. 2005). To 
confirm it is possible to image the labelling agents without overlap, previously 
untreated slides from wild-type mice were subjected to histological addition 
of each agent (at in vivo concentrations) and imaged. Despite the previously 
published report, I found a high level of spectral overlap between the 
compounds (Figure 3.6, Technical Appendix 11.1). The slides were deemed 
to be over stained as the actual concentration of dye incorporated into the 
matrix in vivo would be significantly less than the histological preparations 
using the injection concentration. Using confocal microscopy, a wave-length 
spectrum for each labelling agent was established that diminished the 
overlap between the emissions of the various dyes, and this optimal range 
was used in all ensuing experiments. However, to ensure maximal 
confidence in the experiment it was decided that the two dyes most 
frequently used would be calcein and xylenol orange, due to their largely 
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non-overlapping spectra. If a third dye was to be added, it would be 
doxycycline, added in a sequence guaranteeing no time overlap with calcein. 
3.3.2.2 Time-course of dye retention. To confirm the individual labelling 
agents would clear the system prior to the addition of the next compound, a 
single labelling agent was added to a dam between E11-12 and the offspring 
were isolated at two time-points, E18 and P2. Matrix mineralisation first 
occurs at E14, so any labelling agent present still from the E11-12 injection 
that was retained in the system for more than 2 days would incorporate into 
the matrix. The 2 day gap between injection and mineralisation was chosen 
as 2 days was the desired minimum injection period between addition of 
labelling agents in the later experimental phase of the project. Analysis 
revealed the matrix of the animals injected between E11-12 did not contain 
any labelling agents, when examined at E18 and P2 (Figure 3.7). Examining 
the two time-points of sacrifice was done to ensure that any areas that were 
labelled by the E11-12 injections were not missed due to subsequent 
remodelling in vivo (leading to the erroneous conclusion that the dye had not 
been retained through the mineralisation). I conclude from these findings that 
the dye does not circulate within the system for more than 2 days and 
incorporation times closely matched the injection times. 
3.3.2.3 Dye swap. The next control was to ensure that different fluorescent 
dyes would not preferentially label different types of matrix and would not 
differ significantly in their ability to penetrate through tissues. To this end dye 
swap experiments were performed such that each labelling experiment was 
conducted as a pair involving a dye reversal; ie calcein injection at E14 and 
xylenol orange at E 18 has the dye swap control of xylenol orange injection at 
E14 and calcein at E18. Patterns produced by the labelling regime could be 
confirmed in the dye swap to validate they were not a result of -for example-
preferential binding of one labelling agent. 
3.3.3 Results of in vivo labelling experiments 
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The initial labelling experiment (EX1) consisted of a calcein injection at E14, 
followed by xylenol orange injection at E16 and specimens were isolated and 
analysed at postnatal day 3 (P2). Analysis revealed an inside-out 
arrangement with the majority of xylenol orange labelling nested inside 
calcein labelling (Figures 3.8-3.9); the implication that cells dug into the 
calcein-Iabelled matrix is supported by focal areas where xylenol orange 
extended from the inside of the calcein block to its external face, presumably 
indicating the cell's entry point into the previously mineralised area. Notably, 
at high magnification, the areas were largely green or red, and although 
closely nested, they were not yellow, demonstrating the matrix was 
deposited by two separate cells (as a single cell carrying both dyes would 
incorporate the dyes into the matrix at a spatial resolution leading to a yellow 
appearance). Neither L 1 nor L3 was labelled, and the cleft between the 
generative layers and the mineralised matrix suggests osteoid secretion 
occurs only after cells have invaded L2. 
The short interval between the injections, and the resulting nested pattern, 
illustrated the dynamic nature of the L2 mineralising area and the fast pace 
of matrix production and subsequent remodelling. A successive experiment 
(EX2) lengthened the time between injections (calcein injection E14, xylenol 
orange injection E18) and results indicated a pattern where xylenol orange 
encased calcein, which in turn surrounded a xylenol orange core (Figure 
3.10). This xylenol-calcein-xylenol pattern indicates that between E18 and 
birth (the timeframe for xylenol to be present in the system) some cells 
remodel the existing calcified matrix, while others enter the system and start 
depositing new mineralised matrix. The orientation of the calcein toward the 
centre of L2 is reminiscent of the ex vivo experiments, implying that as cells 
enter L2 from L 1 and L3, the generative layers progressively move away 
from each other and new cells enter L2, sheathing the pre-existing L2 
architecture. There was a tendency for unlabelled areas (calcified after both 
dyes had cleared) to be more extensive toward L 1, raising the possibility that 
L 1 is more active than L3 in inserting cells into L2 in the two days following 
birth (Figure 3.10). 
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A specimen from the dye swap of EX2, with the injection regimen E14-
Xylenol Orange;E18-Calcein, matured to P8, was then analysed to examine 
the extent of the remodelling through the first week of murine postnatal 
development. Similarly to the specimen isolated immediately after birth, the 
initial xylenol orange labelling is found toward the centre of L2, furthest from 
L 1 and L3 (Figure 3.11). One cell within L2 can be seen carrying the second 
colour (calcein), which has dug into the area that is otherwise xylenol 
labelled (Figure 3.11). An additional cell is observed traversing the calcein 
front; the radial collagen fibres emanating from this cell are visualised using 
refection imaging, showing this cell carries no label, indicating remodelling is 
actively taking place even in the postnatal condition when the dyes are no 
longer being incorporated by the cells. Indeed, the degree of remodelling is 
evidenced by the extensive area within the mature frontal bone of the P8 
specimen that is unlabelled. 
After the first week of post-natal development there are striking changes 
within L 1 and L3. At the L 1 :L2 border there is a region where cells from L 1 
appear to have deposited a thin layer of unlabelled matrix appositionally onto 
the top of L2 (Figure 3.11), giving this region the appearance of a 
characteristic compacta. Even more dramatically, the condition of L3 at P8 is 
extremely altered from that of a littermate examined at P2. Immediately after 
birth the thin stacks of cells in L3 were unmineralised and tightly packed, 
contrasting this a week later, L3 has mineralised and the cell sheets within 
L3 are widely spaced apart and cell sparse: this arrangement is reminiscent 
of a classical appositional model of matrix deposition whereby cells deposit 
matrix (either polarised toward L2 or in all directions) and become separated 
from one another, trapped in the secretions from themselves and the 
osteoblasts surrounding them. 
Intriguingly, reflection imaging in the late L3 condition displays plywood-like 
crossed bundles of collagen fibres, indicative of what in basal vertebrates is 
termed the isopedine layer (Gross 1956; Donoghue and Sansom 2002). 
3.3.4 Conclusion 
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Results from in vivo labelling experiments indicate a dual mechanism of 
dermal bone biomineralisation; from E14 through birth the mineralising zone 
is a dynamic space with L2 being actively remodelled by cells intercalating 
from L 1 and L3, and after birth there is a later stage of appositional addition 
of matrix from L 1 and L3 (Figure 3.12). The secondary invasion of cells into 
areas already arranged into collagen fibres is similar to the process by which 
scales mineralise in zebrafish (Le Guellec et al. 2004), potentially highlighting 
that remodelling by invading cells is a conserved feature between teleosts 
and mammals. Mineralisation is known to be guided along a collagen 
scaffold (Golub 2009) and our reflection imaging appeared to show the 
collagen within the bone; I next investigated the collagen system and its 
relationship to the biomineralisation pattern observed in vivo. 
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Figure 3.5: In vivo biomineralisation 
experiment designed to assess the 
growth mode of the mineralising zone 
A. Two fluorescent dyes (green and red) will 
be sequentially delivered to the mineralising 
bone of murine embryos via intraperitoneal 
injection to pregnant dams. The resulting 
pattem of the dyes will indicate the mode of 
growth. 
B. Appositional biom ineralisation. 
Osteoblasts from one or two generative 
surfaces will secrete osteoid that becomes 
mineralised; the first mineralised matrix will 
be labelled green and will be sandwiched by 
the second colour (red). 
C. Deposition of osteoid in a nested pattem. 
Cells produce osteoid only once inside L2 
and mineralised matrix can be remodelled 
by subsequent osteoblasts entering the 
system carrying the second dye. The 
second colour is sandwiched inside the first. 
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Figure 3.6: Analysis of spectral overlap of matrix labelling agents 
Sagittal sections of a wild-type bone (endochondral, cranial base) at embryonic day E18 after conception (positive 
vaginal plug is taken as EO). Histological addition of calcein, alizarin red, xylenol orange and doxycycline and 
subsequent spectral analysis. 
The total emission range in which each labelling agent can be detected are displayed, with a box indicating the 
strongest area of expression (from which the images were collected). Calcein was excited off the 488 laser, alizarin 
and xylenol orange off the 543, and doxycycline off the 405. The emission curve of DAPI (nuclear counterstain) is also 
plotted. The emission of each potential labelling agent when excited with each laser (405,488,543 and 647) was also 
analysed and can be found in the technical appendix (11.1). 
Significant overlap between the agents was observed. 
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Figure 3.7: Control experiment: analysis of 
dye clearing 
Sagittal sections of a wild-type frontal bone at 
postnatal day 3 (P2), following injection of a 
single labelling agent at embryonic day E 11 
after conception. Images are oriented cranial to 
the top and ventral to the right. Nuclear 
counterstain DAPI (blue). 
A-C. No calcein is detected in the bone (C), 
therefore the calcein was cleared from the 
system before the matrix mineralised at E 14. 
Reflection image (8) shows mineralised areas. 
O-F. No xylenol orange is detected in the bone 
(F), therefore the XO was cleared from the 
system before the matrix mineralised at E14. 
Reflection image (E) shows mineralised areas. 
In subsequent experiments, areas of labelling 
from compounds injected at E 14 were visible at 
P2, confirming the absence of labelling in the 
control is due to dye clearing not remodell ing of 
the matrix. 
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Figure 3.8: Labelling Experiment 1: A nesting pattern of labelling agents 
Sagittal sections of a wild-type frontal bone at postnatal day 3 (P2), following injections of calcein at E14 and xylenol 
orange at E16 (positive vaginal plug is taken as EO). Nuclear counterstain DAPI (blue). Layer 1, 2 and 3 are indicated 
as L 1, L2 and L3, respectively. 
A-C. Overview of calcein and xylenol orange patterns in an immature frontal bone region; overlay in A and individual 
channels B-C show that xylenol orange labelled matrix (second colour injected) is found nested inside calcein positive 
areas (first colour injected). The section lines of D-G are indicated. 
O-G. The surface of the 3D reconstruction was sectioned through (clipping plane into the plane of the image) to look 
into the cross section of the nested expression. The second colour injected (xylenol orange) is found inside the first 
colour (calcein) indicating the system was remodelled allowing additional osteoid (red) to be laid within the previously 
mineralised area (green). 
Scale bar indicated 50l-lrn. 
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Figure 3.9: Labelling Experiment 1: The biomineralising zone is subject to remodelling 
Sagittal sections of a wild-type frontal bone at postnatal day 3 (P2), following injections of calcein at E14 and xylenol 
orange at E16 (positive vaginal plug is taken as EO). Nuclear counterstain DAPI (blue). Layer 1,2 and 3 are indicated 
as L 1, L2 and L3, respectively. 
A-C. Overview of calcein and xylenol orange patterns in a mature frontal bone region; overlay in A and individual 
channels 8-C show that xylenol orange labelled matrix is found nested inside calcein positive areas. The section lines 
of O-F are indicated. 
O-F. The surface of the 3D reconstruction was sectioned through (clipping plane into the plane of the image) to look 
into the cross section of the nested dyes. The second colour injected (xylenol orange) is found inside the first colour 
(calcein) indicating the system was remodelled. At places the line of xylenol orange expression extends to the external 
face of the calcein island, indicating a potential entry point of the cell delivering the xylenollabelled-mineral. 
Scale bar indicated 50lJm. 
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Figure 3.10: Labelling Experiment 2: Cells remodel previously calcified matrix and secrete new osteoid 
Sagittal sections of a Wild-type frontal bone at postnatal day 3 (P2), following injections of calcein at E14 and xylenol 
orange at E 18 (positive vaginal plug is taken as EO). Nuclear counterstain DAP I (blue). Layer 1, 2 and 3 are indicated 
as L 1, L2 and L3, respectively. 
A-C. Overview of calcein and xylenol orange expression patterns in an immature frontal bone region; overlay in A and 
individual channels B-C show that xylenol orange expression is found nested inside calcein positive areas, as well as 
external to the calcein areas where new cells enter the system and secrete matrix that becomes mineralised. The 
section lines of O-F are indicated. The external boundaries of L 1 and L3 are indicated with white and red dotted lines, 
respectively. 
O-F. The surface of the 3D reconstruction was sectioned through (clipping plane into the plane of the image) to look 
into the cross section of the nested labelling pattern. The second colour injected (xylenol orange) is found nested 
inside the first colour (calcein) indicating the system was remodelled; and xylenol-positive areas outside the calcein-
reactive border indicates that new cells enter from L 1 and L3 and secrete new matrix that subsequently mineralises. 
Scale bar indicated 50\Jm. 
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Figure 3.11: Labelling Experiment 2 Dye Swap, P8: Evidence of osteoblast remodelling and late apposition of 
matrix deposition from L 1 and L3 
Sagittal sections of a wild-type frontal bone at postnatal day 9 (P8), following injections of xylenol orange at E14 and 
calcein at E 18 (positive vaginal plug is taken as EO). Nuclear counterstain DAP I (blue). 
A-C. Overview of a mature frontal bone where only a thin margin of labelling within the bone is noted as the early 
matrix has been remodelled. Xylenol orange has lingered in the vasculature. The location of 8-0 is indicated. 
B. Overlay of the xylenol orange, calcein, DAPI and reflection imaging (birefringence of collagen fibres) from the 
region indicated in A. Zoom indicates the frontal bone that has been remodelled with very IitUe matrix that was 
labelled between E14 - P1 remaining in L2. The L 1-L2 boundary is noted with a white line, and the L2-L3 boundary is 
indicated in red. One cell (filled arrow head, C) still carrying calcein has burrowed into the remaining xylenol-Iabelled 
area. An additional cell (empty arrowhead in C) can be seen that is etching through a green line of matrix labelling, 
carrying no labelling agent; in D the reflection imaging shows the fibres from this cell are radial. 
Reflection imaging highlights that L3 is arranged in parallel sheets of mineralised matrix, indicating a late apposition of 
matrix from L3 cells. 
Scale bar indicated 50\Jm. 
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Figure 3.12: Diagrammatic representation of biomineralisation process as modelled on the current results of 
in vivo labelling experiments 
A. Mineralisation occurs as soon as the diploe architecture of the bone is formed. Initial mineralisation occurs in 
distinct 'clouds' or 'islands' (green), cells on the outside of which encase the mineralised areas in Undulin. The mineral 
phase does extend to the generative layers (L 1 and L3) and each island is separated from its neighbour by 
unmineralised sheets of cells. 
B. As new cells enter the L2 area they dig into previously laid mineral and add new matrix into the internal space. The 
results of this, in in vivo labelling experiments, is the second injected colour being nested inside the first (in B it's red 
inside green). 
c. Remodelling of the mineralised area results into a core of L2 that has amorphous mineral (dark green); at a time-
point after birth L 1 and L3 add matrix to this, laid appositionally, generating the characteristic outer compacta and 
sheets of mineral found in a mature bone (light grey). 
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3.4 Building and remodelling collagen scaffolds 
3.4.1 Introduction 
Results from in vivo matrix mineralisation labelling experiments indicate a 
high level of remodelling takes place in dermal bones; what remains elusive 
is the mechanism by which this can occur in the absence of osteoclasts and 
in the sole presence of osteoblasts (Runx2+ or OPN+) and endothelial 
precursors. 
AFM studies have shown that HAP crystals sit on collagen fibres and the 
organisation of collagens is fundamental to the biomineralisation process 
(George and Veis 2008); as such the building and reorganising of collagen 
scaffolds might be critical for remodelling biominerals within Layer 2. Notably, 
high concentrations of Collagen I can form liquid crystals, i.e. they have a 
self-organising capability whereby they generate crossing stacks of fibres on 
their own (Giraud-Guille et al. 2000; Giraud-Guille et al. 2003; Kikuchi et al. 
2004). As such, high expression of Collagen I in an enclosed space in vivo 
might lead to a crossed-fibre stacking morphology, as observed in Layer 3 
(whose physical location corresponds to the basal layer in fish scales and the 
isopedin of fossil gnathostomes (Le Guellec et al. 2004; Donoghue et al. 
2006». 
In addition, mixtures of different collagens can render fibrous col/agen into an 
amorphous substance and HAP associated proteins (such as OPN) can 
define the directionality of crystal growth (Nishiyama et al. 1994). For this 
reason, the exact position of collagens with regard to the osteoblasts 
populating L2 was examined in vivo. 
My analysis of the collagen system in dermal bones focused on collagens I 
and II. Collagen I is believed to be up-regulated in cells of the osteoblastic 
lineage (preosteoblasts, osteoblasts, and osteocytes) (Huang et al. 1997) 
and constitutes the majority of the scaffold of the bone matrix (Whelan and 
Senger 2003; Abzhanov et al. 2007; Shapiro 2008). Conversely, Collagen II 
was previously associated with cartilaginous development, but has recently 
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been found to be expressed by pre-osteoblasts and an intermediary cell type 
of the osteoblastic lineage, termed chondrocyte-like osteoblasts (CLO cells) 
(Abzhanov et al. 2007; Shapiro 2008). 
3.4.2 Results 
Analysis of the immature frontal bone at E16.5 yielded the surprising result 
that Collagen \I was present in L2 prior to Collagen I (Figure 3.13). Collagen 
\I is identified within L2 at the margin of L 1 as soon as the diploe architecture 
of the layers is established, potentially indicating an early infusion of 
Collagen \I into the L2 area by the cells of L 1 (Figure 3.13). In a short 
developmental timeframe, Collagen \I quickly spreads to fill the entire L2 
space (Figure 3.13). The expression of Collagen \I in the immature frontal 
bone overlapped with Runx2 expression at the L 1 :L2 interface, although 
Runx2+ cells in the external margin of L 1 do not secrete Collagen II. 
Collagen \I expression did not overlap with Collagen 1 (Figure 3.13). As the 
bone matures, the majority of the matrix remains weakly positive for Collagen 
\I (Figure 3.14). 
Initial Collagen \I expression in L2 takes place during a time in which 
Collagen I is synthesized only on the internal margins of L3 (toward, but not 
within, L2), as well as in the dermis (Figure 3.13). As L2 matures, Collagen I 
is noted within this layer but confined to the area of clasps (Figure 3.14); 
based on Collagen I expression mapped in previous studies, expression of 
Collagen I in clasps and L3 could be attributed to either early osteoblasts or 
the endothelial precursors in the generative layers (Whelan and Senger 
2003; Shapiro 2008). To confirm the Collagen I expression pattern was true 
(and not an artefact of using a monoclonal antibody or epitope sensitivity to 
fixation), a polyclonal Collagen I antibody was used, which confirmed the 
previously defined boundaries of Collagen I. 
In the mature areas of an E18 frontal bone, Collagen I expression was wider 
I 
but not ubiquitous (Figure 3.14). This finding contradicts the widespread 
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notion that Collagen I forms the majority of the L2 matrix or may indicate the 
antibody may only be binding to areas that have not crystallised. 
Confirming the expression found in the prenatal frontal bone, in the clavicle 
of a newborn mouse, Collagen I was present in cells of L3, as well as along 
the clasps across L2 and at the connection points of muscle to the bone, 
again confined to un-mineralised areas (Figure 3.140). 
Collagen I and Osteopontin are widely co-expressed throughout the frontal 
bone, most conspicuously along vascular margins of the bone matrix:blood 
vessel interface, as well as along the seams between mineralised regions 
(Figure 3.15). Late in ontogeny some Runx2-positive osteoblasts also co-
express Collagen I (Figure 3.16). The previously noted co-expression of 
Runx2 and Osteopontin (Chapter 1) was mapped in detail and 
Runx2+/0PN+ cells were found in mature regions of the frontal bone, 
focused around the sites of vasculature/bone interfaces, with OPN polarised 
toward the vasculature (Figure 3.17). As OPN acts to cap mineralisation, this 
arrangement presumably prevents mineralisation from impinging on blood 
vessel formation (Kawasaki and Weiss 2008). 
3.4.3 Conclusion 
The larger expression domain of Collagen " compared to Collagen I in the 
immature frontal bone was unexpected. Results presented here indicate the 
initial collagen scaffold of the frontal bone may composed of Collagen ", 
secreted by Runx2+ cells of an osteoblastic lineage; later Collagen I 
secretion is achieved by both Runx2+ and OPN+ cells. The finding that 
Collagen " is closely associated with Runx2 is not surprising, given that 
previous dissociation studies had categorised an intermediary cell type 
(between pre-osteoblasts and fully functional osteoblasts) called 
chondrocyte-like osteoblasts (CLO cells) that co-expressed these markers 
(Abzhanov et al. 2007). In that study, Collagen I expression was co-localised 
with Osteopontin expression in cells believed to be osteoblasts, a cell type 
the authors believed to be developmentally later than CLO cells. What is 
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noteworthy from the current results is that co-expression of Runx2 and 
Collagen \I does not precede osteoid secretion (which was previous thought 
to be accomplished by OPN+ osteoblasts). In fact, the Runx2+/Collagen 1\+ 
cells are contemporaneous with the early OPN+/Collagen 1+ cells and, 
therefore, segregation of cells by their marker profiles is spatial and not 
temporal. Additionally, in late ontogeny, cells that are Collagen I-positive also 
express Runx2. Results presented here highlight the importance of 
examining the marker combinations in vivo and stresses that there may be a 
dynamic relationship between the expression of the markers and the role of 
the cell: i.e. early Runx2+/Coll 1\+ cells may establish the initial matrix, which 
Runx2+/ColIl+ and OPN+/ColIl+ cells remodel. 
The issue of remodelling, first introduced by the in vivo labelling studies, and 
highlighted here by the intriguing pattern of collagen crystals, warrants 
further investigation. Hydroxyapatite crystals grow with collagen fibre 
systems as their guide-posts, given that the shape of the biomineralised 
zone changes significantly with time (from clouds, to sheets, as described 
above), a reorganisation of the collagen system would be needed to provide 
the flexibility requires for elaboration and embellishment of the mineral 
structure independent of the function of osteoclasts. 
Collagen I expressing cells may have a role in remodelling the mineralising 
zone which would necessitate the cleaving and etching of the pre-existing 
fibres by proteases, namely members of the matrix metalloproteinase (MMP) 
family. MMPs would be utilised by cells intercalating into L2 after an initial 
osteoid or mineral phase had been established; MMPs could be used to 
dissolve pre-existing collagen scaffolds, including amorphous HAP (calcein-
positive) mineral deposits. To confirm there is a remodelling of the collagens, 
and explore which cells are capable of remodelling, I investigated the 
expression of MMPs within the forming intramembranous bones. 
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Figure 3.13: The initial osteoid is Collagen II rich and Collagen I poor and laid by Runx2+ cells 
Sagittal sections through the frontal bone at embryonic day E16.5 after conception (positive vaginal plug is taken as 
EO); wild-type specimen. IHC for Collagen II (Green A-F), Runx2 (red, B-C), Collagen I (red, D-F); nuclear 
counterstain (DAPI) in blue. Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. 
A-C. Overlay (A) and individual channels showing Collagen II is widely expressed along the anterior margin of L2 (at 
the L 1: L2 interface) in cells that also express Runx2; on the external side of L 1, Runx2-positive cells do not secrete 
Collagen II. 
Contrasting the pattern of Collagen II, in D-F the expression of Collagen I is confined to the dermis and L3, with little 
to no overlap between the collagens in the immature frontal bone. 
d Dermis, b Brain 
Scale bar indicates 50l-lm. 
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Figure 3.14: Collagens I and II in mature 
dermal bone 
Sagittal sections through wild-type frontal (A-
C) and clavicle (0) bones at embryonic day 
E18 after conception. IHC for Collagen " 
(Green A-B) , and Collagen I (red, C-O); 
nuclear counterstain (DAPI) in blue. Layers 1, 
2, and 3 are indicated as L 1, L2, and L3, 
respectively. Blood vessels are indicated (*) 
Collagen 1\ expression is ubiquitous in the 
matrix of the mature frontal bone (A-B). 
Alternatively, Collagen I expression (C-O) is 
more pronounced but not ubiquitous. Collagen 
I expression appears confined to edges of 
mineralised and unmineralised areas, as well 
as the muscle-bone interface in the clavicle 
(0). 
d Dermis, b Brain 
Scale bar indicates 50l-lm. 
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Figure 3.15: Co-expression of Collagen I and Osteopontin 
Sagittal sections through a wild-type frontal bone at embryonic day E18 after conception. IHC for Collagen I (red), and 
Osteopontin (green); nuclear counterstain (DAPI) in blue. Images are oriented cranial to the top and ventral to the left. 
Layers 1, 2, and 3 are indicated as L 1, L2, and L3, respectively. Blood vessels are indicated (*) 
Collagen \I and Osteopontin are co-expressed in the developing frontal bone. 
A-C. In immature areas Osteopontin is weakly expressed in L3, and co-expression of Osteopontin and Collagen 1 in 
L 1 is focal (potentially mapping to rosettes). Overlay in A and individual channels B-C. 
0-1. Co-expression of Osteopontin and Collagen I in a mature region of the frontal bone. Expression of both markers 
is widespread and overlapping in L2. A magnification of the region indicated by a red box in D shows that OPN and 
Collagen I expression is in the seams of the matrix and around blood vessels. 
Scale bar indicates 50l-1m. 
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Figure 3.16: Co-expression of Collagen I and Runx2 
Sagittal section through a wild-type frontal bone at 
embryonic day E18 after conception (positive vaginal 
plug is taken as EO). IHC for Collagen I (red), and Runx2 
(green); nuclear counterstain (DAPI) in blue. Layers 1, 2, 
and 3 are indicated as L 1, L2, and L3, respectively. 
Blood vessels are indicated (*) 
Runx2 and Collagen 1 have wide areas of co-expression 
(overlay in A, individual channels in 8 and C) in a mature 
region of the frontal bone; however, the majority of the 
bone matrix that is mineralised (indicated by the DAPI 
'sheen') is negative for both markers. 
Scale bar indicates 50jJm . 
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Figure 3.17: Expression of Osteopontin and Runx2 in the frontal bone 
Sagittal sections through the frontal bone at embryonic day E 18 after conception; Wnt1-Cre+l- x Rosa26LacZ-I-
specimen. IHC for Runx2 (red), and Osteopontin (green); nuclear counterstain (DAPI) in blue. Layers 1, 2, and 3 are 
indicated as L 1, L2, and L3, respectively. Blood vessels are indicated (*) 
Runx2 and Osteopontin have focal co-expression in mature L2. A . In an immature condition areas of yellow overlap 
are not noted. But as L2 matures (B-C) areas of co-expression are discernible. In the most developed region of L2 
these co-expressing cells are at boundary of the vasculature-matrix interface. An optical slice (D) of a blood vessel 
shows polarity within the cell , with OPN expression on the external margin toward the blood vessel. 
d Dermis, b Brain. Scale bar indicates 50lJm. 
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3.5 Modulating the collagen scaffold system by MMPs 
3.5.1 Results 
Both Collagens I and II, which are expressed throughout the dermal bone, 
are substrates for MMPs -1, -8 and -13 (Egeblad and Werb 2002). My 
analysis focused on MMP13 as recent evidence indicates MMP13 is 
secreted by osteoblasts and degrades Collagen I and Collagen II as part of 
endochondral bone-remodeling processes (Nakamura et al. 2004). Collagen 
II appears to be the first collagen to generate a scaffold in dermal bone 
formation and MMP13 cleaves Collagen II 40-fold more effectively than 
MMP1 (Golub 2009). Once Collagens I and II are subjected to the initial 
cleavage, they can then be degraded by gelatinases, including MMP9 (Golub 
2009). 
To confirm MMP13 has a role in remodeling the matrix, I explored MMP13 
expression in combination with histological calcein staining. At early stages 
of bone maturation MMP13 is localised within L3 and atfocal points in L 1, as 
well as along the Layer 3/brain interface (Figure 3.18) As L2 elaborates, 
MMP13 was found within all of the calcified areas, inside all of the individual 
calcein+ parcels described earlier (Figure 3.19). This arrangement indicates 
an external shell of mineralisation surrounds a pliable core, enabling mineral 
remodeling and further matrix deposition within each initial calcein parcel. 
Cells entering these calcein-carrying matrix islands would be able to etch into 
the existing matrix and continue to secrete new osteoid, with the calcified 
exterior expanding outwards (Figure 3.12); this mode of action would be in 
line with the results of the in vivo labeling experiments where nested patterns 
of matrix were observed. The co-expression of MMP13 by Runx2+ 
osteoblasts invading the L2 matrix was confirmed (Figure 3.18). Notably, 
widespread areas of MMP13 expression where Runx2 was absent were also 
observed, and may correspond to areas where OPN+ cells from L3 are 
entering L2 (Figure 3.18). 
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Blood vessels were previously found nested inside mineralising areas and 
the theory that the morphology, biomineralisation and vascularisation are 
developing in parallel would necessitate the ability of the vasculature to also 
etch into pre-existing matrix. MMP9 is expressed by pericytes and 
endothelial cells and is critical for vascularisation of endochondral growth 
plates (Vu et a/. 1998; Egeblad and Werb 2002). MMP9 is found to be widely 
expressed in L 1and co-expression of MMP9 and Collagen I in flattened cells 
entering L2 from L 1 and L3 in areas that have the characteristic 'sheen' 
(DAPI channel) indicating osteoid/matrix (Figure 3.20). As it stays confined to 
the clasp regions themselves, this unique localisation would enable 
integration of new cells onto the surfaces of pre-existing mineralized areas. 
MM P9 is a gelatinase that digests Fibronectin, and expression within L 1 may 
make L 1 a more permissive environment to aid cellular invasion into L2 
through the threading in process described in Chapter 1. In the mature bone, 
several areas of overlap between MMP9 and Collagen I were found within 
the bone matrix, and along the edge of blood vessels (Figure 3.20). As 
Undulin is also a substrate for MMP9, MMP9 expression could be involved in 
breaking down the ties around the calcein blocks to aid the remodeling 
(Sigma 2001). 
3.5.2 Conclusion 
Collectively, the results of our exploration of the biomineralisation of dermal 
bones indicate the matrix is not static but is instead a dynamic space that 
serves as a malleable substrate for rapid thickness growth. The development 
of the mineralising areas is dictated by the simultaneous development of the 
bone morphology and vasculature. There was a notable distribution of the 
MMPs whereby MMP9 is superficial and found at the osteoblast:endothelial 
interface within Layer 2, while MMP13 is injected into the core of the 
biomineralised matrix itself. The inference from this is that these MMPs have 
different substrates and the substrates would be distributed in a similar 
manner to their respective MMPs. With regard to Layer 2 elaboration, this 
would mean that MMP9 mediates an increase of the osteoblast:vasculature 
interface, while MMP13 mediates an extension of the biomineralising zone 
by internally cleaving the collagen fibre system. This provides an 
understanding of how the in vivo labeling results can be achieved, with a 
later dye found inside a previously-labeled area. 
The most important implication of the current results is that the Runx2+ 
osteoblasts themselves are the ones that modulate the collagen depositions, 
which they and their predeceasing cells have accomplished - without the 
need of osteoclasts. MMP13 has been shown to be directly regulated by 
Runx2 at the transcriptional level (Jimenez et al. 1999), a notion established 
in tissue cultures whose in vivo relevance may be to enable remodeling by 
Runx2-positive osteoblasts. MMP-mediated bone remodeling, as shown 
here, supports previous work on MMP13 null mice that indicates the 
knockout has abnormalities in the growth plate and delayed ossification 
during endochondral ossification, (Inada et al. 2004). However, dermal bones 
have not been studied in these mutants. 
The unusual finding that osteoblasts themselves remodel the mineralised 
matrix supports recent work by Witten (Witten and Huysseune 2009) on 
osteoblasts/osteoclasts in zebrafish and can shed light on the molecular and 
cellular mechanism of how bone mineral may have changed in fossil fish in 
the gnathostome stem group, which did not possess osteoclasts. 
Placoderms are the earliest evolutionary group displaying classical bone 
remodelling akin to that observed in newborn or adult mice (Donoghue et al. 
2006), which occurs at a significantly later stage of development than that of 
the current study. 
Matrix remodeling is predicated on the invasion of cells from the generative 
layers, a process that was clearly disrupted in the Hand2 mutant strains. To 
establish the effect of the disrupted layer formation on the biomineralisation 
of Hand2-mutant strains, I examined the mineralising zone of Handillft-Wnt1_ 
ere mice ex vivo. 
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Wnt1-Cre x R26Lacz Figure 3.18: Runx2 expressing osteoblasts dig into 
matrix via MMP13 expression 
Sagittal section through the frontal bone at embryonic day 
E 18 after conception (positive vaginal plug is taken as EO); 
Wnt1-Cre+l- x Rosa26LacZ-I- specimen. IHe for MMP 13 
(green) and Runx2 (red); nuclear counterstain (DAPI) in blue. 
A-B. Overview (A) and magnification (B) of MMP13 and 
Runx2 co-expression (yellow) in a semi-mature frontal bone. 
Co-expression of Runx2 and MMP13 in L2 and isolated 
MMP13 expression throughout the L2 matrix and in L3. 
Scale bar indicates SOjJm. 
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Figure 3.19: MMP13 is at the core of mineralised islands 
Sagittal sections through the frontal bone at embryonic day E18 after conception; Wnt1-Cre+l- x Rosa26 LacZ-I-
specimen. IHC for MMP13 (red); calcein stain (green); nuclear counterstain (DAPI) in blue. 
A. MMP13 is found at the core of all mineralised areas (calcein shell around MMP13+ centre). 8-C. Stack of 
additional optical slices in 3D show that this arrangement can be found in all the mineralised areas, which are distinct 
islands of calcein positivity. 
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Figure 3.20: MMP9 expression in the developing frontal bone 
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Sagittal sections through the frontal bone at embryonic day E18 after conception (positive vaginal plug is taken as 
EO); Wnt1-Cre+l- x Rosa26LacZ-I- specimen, IHC for MMP9 (green) and Collagen I (red); nuclear counterstain (DAPI) 
in blue. 
A. Co-expression of Collagen I and MMP9 in a few thin cells within L2 in the immature frontal bone; widespread 
MMP9 expression in L 1. In more mature regions (B-C), MMP9 and Collagen I co-expression is found around the 
vascu lature. 
Scale bar indicates 50~m 
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3.6 Hand2 mutant analysis: biomineralisation 
In the dermal bones of Hand2fllft-Wnt1-Cre mice there is an abrogation of 
clasp structures leading to an unregulated filling of the Layer 2 space by 
Runx2+ osteoblasts. This appositional growth mode results in a lack of any 
internal osteoblastendothelial layer formation. Results presented above 
indicate that mineralisation of dermal bone begins as soon as diploe 
architecture is achieved in the wild-type condition, and the dynamic process 
of mineralising the matrix involves excessive remodelling to expand the bone 
in thickness and complexity and to accommodate the concurrently 
developing vasculature. In the absence of proper layer formation, where an 
appositional mode of growth is favoured, biomineralisation would be 
expected to commence as soon as precocious Runx2+ osteoblasts invaded 
Layer 2, and continue until a single plane of mineralisation is formed, which 
would not be remodelled. 
Indeed, ex vivo histological application of calcein to dermal bones of the 
Hand2ft/ft-Wnt1-Cre mice confirmed aberrant biomineralisation in the absence 
of proper layer morphogenesis. In both the frontal bone and dermal clavicle, 
the mineralised zone comprises a single contiguous block of calcein. In the 
frontal bone, a thin sheet of calcification extends along the dorso-ventral axis 
and the bone does not increase in complexity along its growth plane (Figure 
3.21). In the neural crest components of the mutant clavicle, calcified areas 
were dramatically different in appearance to adjacent unaffected, 
mesodermal areas (Figure 3.22A). The juxtaposition between mineralisation 
in the affected versus non-affected regions is evident on a single section 
where the mesodermal-derived component of the clavicle (at the attachment 
of the pectoralis) has a wide zone of mineralisation surrounding numerous 
trabeculations, contrasting to the single band of calcification along the 
attachment of the SCM (Figure 3.22). 
The appearance of the mineralised zone in dermal bones of Hand2f11ft-Wnt1_ 
Cre mice is similar to a classical hyperossification pathology (Hessle et a/. 
2002; Anderson et al. 2005; Laue et al. 2008), which presumably results in 
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the Hand2-mutants from the combination of Runx2-deregulation and a lack 
of remodelling. 
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Figure 3.21: Biomineralisation in the frontal bone of Hand2fllfl; Wnt1-Cre mice Dermis 
Rostral ~ 
Sagittal sections through the frontal bone at postnatal day 1 (PO) in a Hand2 knockout mouse; Hand2fllf/; Wnt1-
Cre+/- x Rosa26LacZ-/- specimen. Calcein stain (green); nuclear counterstain (DAPI) in blue. 
A. Overview of the single plane of biomineralisation in the frontal bone of Hand2-knockout mice. The coronal suture 
is in the white box, indicating the magnification in B. In B-C the mineralised area is seen as a single sheet at the 
coronal suture (B) and the most mature region of the bone (C). 
d Dermis, b Brain,s Suture 
Scale bar indicates 50~m . 
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Figure 3.22: Biomineralisation in the clavicle of Hand2f1lfl; Wnt1-Cre mice 
Sagittal sections through the clavicle at the SCM attachment at postnatal day 1 (PO) in a Hand2 knockout mouse; 
Hand2f/lf/; Wnt1-Cre+l- x Rosa26LacZ-I- specimen. Calcein stain (green); IHC for F-Actin (red); nuclear counterstain 
(DAPI) in blue. 
A. Overview of the clavicle; at the SCH attachment biomineralisation is a single plane, versus at the pectoralis (PE) 
where Hand2 has not been ablated, the clavicle is trabeculated and the biom ineralised area is expanded. B-C. The 
biomineralised area is a single plane though a cell-sparse L2; a section through the calcein (D) shows it is a solitary, 
dense block. 
Scale bar indicates 50~m . 
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3.7 Summary of findings 
- Early biomineralisation occurs when small 'clouds' or 'islands' of osteoid 
within L2 are calcified; these islands are separated by unmineralised clasps 
of cells, capped by rosettes; 
- As biomineralisation progresses the calcified areas form planes, focused 
toward the centre of L2 and are always surrounded by sheets of non-
mineralised cells that connect to the un-mineralised generative layers (L 1 
and L3) allowing for lateral and vectorial growth of the bone; 
- An in vivo time-course of bone mineralisation indicates areas of calcified 
matrix are remodelled as the bone develops through a mechanism where 
matrix is continually expanded from within; 
- Remodelling of the biomineralising zone continues through the first week of 
murine post-natal development and after birth matrix is added apposition ally 
from the generative layers; 
- Osteoblasts within calcified areas express Runx2 and Undulin and Undulin 
cloaks the individual calcein islands; 
- The initial osteoid is rich in Collagen II, produced apposition ally by Runx2+ 
osteoblasts at L 1/L2 interface; 
- Collagen I does not comprise the majority of the L2 matrix, however, 
Collagen II is widespread in the matrix of mature dermal bones; 
- Collagen I is deposited later than Collagen II by both Runx2 and 
Osteopontin expressing cells; 
- Runx2 and Osteopontin are co-expressed in mature frontal bones, with 
principle co-expression centred around vascular spaces providing a 
boundary between the matrix and the blood vessels; 
- Remodelling the collagen scaffolds is established by MMPs: Calcified areas 
are mineralised shells around cores containing MMP13, which would make 
the centre area permissive for remodelling; 
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- Runx2+ and Runx2- cells express MMP13, presumably as part of matrix 
remodelling; 
- Cells with vascular-like morphology express MMP9, often in conjunction 
with Collagen I, presumably as a part of vascular remodelling of the 
biomineralising zone; 
- Osteoblasts may have the potential to remodel the biomineralised zone in 
the absence of osteoclasts; 
- In Hand2 mutants biomineralisation is confined to a single layer 
calcification, underscoring the importance of the dynamic co-development of 
layer morphogenesis, vasculature and the ensuing biomineralisation. 
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4. Muscle connectivity of dermal bones 
4.1 Introduction 
Bones play a crucial role in mediating movement, a function enabled by 
bone-muscle attachments; toward this end, several dermal bones have 
muscle insertion sites (entheses). Entheses comprise the connective tissue 
of the muscle and the corresponding bony attachment site, each of which 
forms from independent progenitors of the same embryonic origin (Matsuoka 
et al. 2005; Ahlberg and Koentges 2006) (known as the 'connectivity rule' 
whereby neural crest connective tissue inserts into a neural crest derived site 
on the bone, and the same from somitic/mesodermal tissues). 
Entheses are classed into two group describing the mechanics of the 
bone:connective tissue interface; in direct insertion (commonly near joints) 
there is a four zone arrangement of the tendon/ligament, non-calcified 
connective tissue, calcified cartilage, and the bone (Hashimoto et al. 2007); 
alternatively, indirect insertion (usually found in a diaphysis) connects the 
tendon to the periosteal surface of the bone and may also be termed 'fibrous' 
insertion (Hashimoto et a/. 2007). Intriguingly, there does not appear to be a 
link between the form of ossification (intramembranous or endochondral) and 
the character of the enthesis (Hems and Tillmann 2000). Furthermore, while 
skeletal muscle attachment to bone is always mediated by a form of 
connective tissue, there is a large breadth of intermediates ranging from 
tendons to ligaments to indistinct connective tissues (Benjamin et al. 2002). 
To date, little is known about the molecular composition of entheses and the 
majority of the literature focuses on the development of the muscle-bone 
interface in endochondral formations. 
Results from Chapter 1 indicate Layer 1 is a periosteal-like tissue, therefore, 
it may be assumed that entheses of dermal bones are achieved via L 1, an 
assumption underscored by the physical location of L 1 at the external margin 
of the bone, where a musculoskeletal attachment would form. However, the 
abnormal layer formation displayed in the Hand2 mutants (both the Hand2fl1fl _ 
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Wnt1-Cre and Hand2BAenh-l- strains) did not disturb the muscle-bone 
interface of the clavicle, indicating the enthesis may not be established by 
Layer 1. To clarify the role of Layer 1 in forming entheses and to 
contextualise muscle:bone attachment in light of the current findings on the 
diploe architecture of dermal bone development, immunohistochemistry was 
combined with three-dimensional imaging to characterise the attachment 
point of the sternocleidomastoid to the dermal clavicle. 
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4.2 Results 
4.2.1 Musculoskeletal attachment is achieved by a molecularly 
discernible subdivision of Layer 1 
In areas with no muscle attachment (such as the frontal bone) Layer 1 has a 
dual function whereby it houses the rosettes and acts as a generative layer 
providing both osteoblastic and vascular cells to the developing cancellous 
structure (Layer 2) (See Chapters 1-2). In the frontal bone there is no 
physical separation between the rosettes and the surrounding cells, in fact 
the adjacent proximity is what allows the osteoblastic and vascular cells to 
migrate from L 1 into L2. 
At the site of muscle attachments, however, Layer 1 has further subdivided, 
such that a sUbsection of L 1 provides the attachment point of the skeletal 
muscle. This area is physically separated from the remainder of L 1 at the 
most exterior margin (Figure 4.1). This sub-section of L 1, termed here L 1-
attachment (L 1-A), has cortical expression of Periostin (an ancient 
homophilic binding protein (Takeshita et al. 1993» which can be used to 
visualise the unique physical topography of the region: in three-dimensional 
reconstructions the attachment site resembles a tube in cross section 
(Figures 4.1-4.2). This docking area is conspicuous in all regions around the 
circumference of the clavicle where muscles attach, and notably flattened in 
areas lacking any insertion pOints (Figure 4.2). The cells within the L 1-
attachment region have a prominent orientation whereby their nuclei are 
arranged perpendicularly to the rest of L 1, which renders them in a parallel 
orientation with the muscles that are inserting into the layer. 
To confirm the docking region is truly a sub-division of L 1, its molecular 
characteristics were further explored. The region of L 1 that acts a generative 
surface for osteoblasts and endothelial cells widely expresses Undulin and 
has polarised POSTN expression within rosettes (see Chapter 1.3); Runx2 
expression by osteoblasts within the layer is cytoplasmic except within the 
rosettes and cells entering L2, and Hand2-nuclear expression also localises 
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to rosettes (see Chapter 1.3). Compared to this, cells in L 1-attachment 
widely express Periostin, however, there is no expression of Undulin (Figure 
4.3). The majority of cells within L 1-attachment do not express Runx2; the 
notable exception to this are the muscle fibres themselves at the insertion 
point, which terminate with a nucleus that is Runx2- and Hand2-positive 
(Figure 4.4); these Runx2/Hand2-nuclear cells appear to capture muscle 
fibres prior to insertion into L 1, effectively acting as docking points (Figure 
4.4). In some areas, immediately prior to the docking being established, 
expression of Hand2 is not observed, although the muscle fibre connection 
point to L 1-A after the docking is established is Hand2+; this potentially 
indicates a highly confined temporal pattern of Hand2 expression in 
mediating muscle attachment to L 1-A (Figure 4.4). 
The expression profile of L 1-docking, therefore, largely resembles that of 
previously established regions of L 1, with an intriguing protein re-Iocalisation 
in L 1-attachment. 
4.2.2 p..Catenin, a potential lineage-specific marker of attachment 
The canonical Wnt pathway acts to mediate the muscle position relative to 
the bone prior to muscle insertion (Kardon 1998; Kardon et al. 2003); to 
explore this further, I3-Catenin expression was mapped in L 1-attachment. 13-
Catenin is widely expressed in L 1 in non-attachment regions of the frontal 
bone and by some cells within L2 and L3 (see Chapter 1.1). In the murine 
clavicle, the Runx2-expressing cells mediating the muscle-fibre L 1-A 
attachment also express cytoplasmic I3-Catenin (Figure 4.5). ~-Catenin 
expression maps to areas of sternocleidomastoid insertion and the 
omohyoideus, but not to deltoid or pectoralis insertion on the same section 
(Figure 4.6). Moreover, l3-catenin positive neural crest cells also contribute to 
entheses of intercostals muscles (Figure 4.6C). Thus, the I3-Catenin 
expression pattern correlates with the neural crest-derived muscles but is 
notably absent from regions of mesodermal insertions (Matsuoka et al. 
2005). While this was an interesting and unexpected finding, further analyses 
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would be required to see if this pattern holds true for all neural crest-derived 
muscle insertions. 
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Figure 4.1: A sub-section of Layer 1 provides the bone:muscle attachment of the SCM to the clavicle 
Sagittal sections through the clavicle at the SCM attachment at embryonic day E18 after conception (positive vaginal 
plug is taken as EO); Wnt1-Cre+l- x Rosa26lacZ-I- specimen. IHe for Periostin (purple); nuclear counterstain (DAPI) in 
gold. 63x magnifications. 
A. At the SCH attachment, layer 1 comprises a wide physical area and houses rosette formations at the l1:l2 
interface, as well as a sub-partition that forms the enthesis. At the muscle:l1 interface, here termed l1-Attachment 
(l1-A), POSTN expression is cortical. The boundary of l1-A is indicated with a yellow dashed line. 
B. An oblique section showing the 3D topography of the clavicle at the SCM enthesis. The bone is a raised plateau, 
lined by l1 and l3. l1-A has a unique architecture and appears like a tube in cross section. Three individual muscle 
fibres (*) are connected to l1-A. 
63x magnification + zoom 
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Figure 4.2: The topography of the SCM enthesis 
Sagittal sections through the clavicle at the SCM attachment at embryonic day E18 after conception (positive vaginal 
plug is taken as EO); Wnt1-Cre+l- x Rosa26LacZ-I- specimen. IHC for Periostin (white) and Runx2 (green) ; nuclear 
counterstain (DAPI) in blue. 
A. At the SCH attachment, L 1-A is a subsection of L 1 that formed the enthesis. The clipping plane in B shows the 
location through which the oblique 3D cross section of C is taken. The boundary of L1-A:L1 is indicated (yellow 
dashed line). 
D. A diagrammatic representation of the clavicle at the SCM enthesis. L 1-A (**), into which individual muscle fibres 
connect, is in teal and is physically raised from the remainder of L 1 (blue, *), which houses rosettes, osteoblasts and 
endothelial cells. The bone proper (including the L 1:L2 interface, L2, and the L2:L3 interface) is a raised plateau e'). 
The cartilaginous core of the clavicle is represented in dark grey. 
40x magnifications. 
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Figure 4.3: Undulin is not expressed by the cells of l1-A 
Sagittal sections through the clavicle at regions of muscle:bone attachment at embryonic day E18 after conception 
(positive vaginal plug is taken as EO); Wnt1-Cre+/- x Rosa26LacZ-I- specimen. IHC for Periostin (green) and Undulin 
(red); nuclear counterstain (DAPI) in blue. 
A. Diagrammatic representation of the clavicle showing the positions of B-F. 
B. At the omohyoideus L 1-A is discernible by the cortical expression of POSTN; without the POSTN channel (C) the 
exclusion of Undulin in the attachment region is notable. Cells of the wide intermediary area between l1-A and l1 
closest to the l2 interface are also largely Undulin-negative . 
D. A cross section through l1-A (region of cross section indicated in B) shows the cortical expression of POSTN 
encompasses the entire attachment region. 
E-F. At the attachment of the SCM Undulin expression in l1 again excludes the attachment region, l1-A There is a 
visible line of Undulin expression at the margin of l1-A and l1. 
63x magnifications 
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Figure 4.4: Runx2-positive, Hand2-positive cells mediate the attachment of muscle fibres to L 1-A 
Sagittal sections through the davicJe at the SCM and omohyoideus attachments at embryonic day E18 after 
conception (positive vaginal plug is taken as EO); Wnt1-Cre+l- x Rosa26lacZ-I- specimen. IHC for Runx2 (teal, A,C) 
and Hand2 (green B); nuclear counterstain (DAPI) in blue. 
locations from which A-C are taken is indicated on the schematic of the clavicle, far right. 
A. High resolution image (100x) of three individual muscle fibres connecting to l1-A Cells expressing Runx2 appear 
to mediate the interface of the enthesis. Two of the fibres (far left and far right) have already connected and are 
Runx2-negative; this contrasts to the central fibre, which terminates in two Runx2-positive nuclei. 
B. Hand2 expression in the same region as A; unlike Runx2' the two muscle fibres docked into l1-A are positive for 
Hand2, as is the single nucleus external to muscle fibres. 
C. At the interface of the omohyoideus and the clavicle, several Runx2-positive nuclei are visible mediating the 
muscle:l1-A interface. Runx2-expression is abundant at the end of each muscle fibre before it connects to l1-A, an 
example is highlighted (*). 
D. Schematic representation of individual muscle fibres connecting to l1-A. At areas where a muscle fibre is in the 
process of connecting, it terminates in a Runx2+ nucleus (indicated in blue); post-docking the muscle fibre is fully 
embedded in l1-A (*) and the connection point is positive for Hand2. 
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Figure 4.5: f3-Catenin expressing cells mediate the attachment of muscle fibres to L 1-A 
Sagittal sections through the clavicle at the SCM attachment at embryonic day E 18 after conception (positive vaginal 
plug is taken as EO); Wild-type specimen. IHG for Runx2 (teal , A) and I3-Catenin (red, B); nuclear counterstain (DAPI) 
in blue. 100x magnification + zoom . 
The Runx2-positive cells that mediate the muscle fibre attachment to L 1 (A) also express I3-Catenin (B). 
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Figure 4.6: I3-Catenin expressing cells are confined to entheses of neural-crest derived muscles 
Sagittal sections through the clavicle at the SCM attachment at embryonic day E 18 after conception (positive vaginal 
plug is taken as EO); Wnt1-Cre+l - x Rosa26LacZ-I- speciman. IHC for j3-Galactosidase (green) indicating neural crest 
cell and j3-Catenin (red); nuclear counterstain (DAPI) in blue. A. 63x magnification; B-C 20x magnification + zoom . 
In the clavicle , j3-Catenin is expressed by cells at the entheses of neural crest-derived muscles, such as the SCM (A-
B) and omohyoideus (OM), but not the pectoralis (PE) or deltoid (DE) (B); this is also true for the intercostal muscles 
(/C) (C) between ribs. 
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4.3 Conclusion 
Results presented here suggest that the establishment and maintenance of 
skeleto-muscular patterning is a separate process from that of Layer 2 
elaboration. Thus dermal bones and muscle attachments could evolve 
separately. The finding that L 1 has a discrete, molecularly distinct, sub-
structure to facilitate the muscle:bone interface resolves previous findings by 
other groups where expression of ethesis markers did not penetrate into the 
bone proper (Benjamin et al. 2002). The organisation of L 1, separating L 1-
attachment into its own autonomous sub-structure, explains how muscle 
attachments are maintained through ontogeny while the cancellous bone 
structure (L2) is formed, another hitherto unexplained complication of the 
traditional appositional bone growth model. 
As ~-Catenin is a molecular sensor for mechanical stress (Armstrong et al. 
2007; Case et al. 2008), its expression was expected along all tendino-
periosteal interfaces; however, it was confined in the clavicle to attachment 
regions that are neural crest-derived and may, therefore, constitute the first 
lineage specific attachment marker (if future work supports the current 
findings). 
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4.4 Summary of findings 
- The entheses of the clavicle are formed by a sub-section of L 1 (L 1-
attachment) that is physically separated from the remainder of L 1 housing 
rosettes and the generative cells of L2; 
- Partitioning of L 1 enables muscle attachments to be established early in 
ontogeny and maintained even as the architecture of the cancellous structure 
of the bone increases in complexity through development; 
- L 1-attachment is characterised by cortical expression of Periostin; Undulin 
expression is excluded from attachment regions; 
- At the point of muscle insertion, the muscle fibre docking into L 1-
attachment is mediated by a neural crest cell with nuclear Runx2 and nuclear 
Hand2 expression, 
- In entheses of the clavicle, expression of I3-Catenin, a component of 
canonical Wnt signalling that senses mechanical stress, appears confined to 
areas where neural crest-derived muscles attach to the clavicle and excluded 
from mesodermal insertion sites. 
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5. Discussion & concluding remarks on dermal bone formation 
I chose to focus my investigations of intramembranous ossification on the 
murine frontal bone and dermal component of the clavicle as their structure, 
development and homologies are accepted as characteristic of membranous 
bones. The vectorial growth of the frontal bone permits simultaneous 
observation of different stages of maturation in an unbroken temporal and 
spatial continuity at a given time; while in the clavicle, the parallel 
development of the dermal and endochondral components allows the easy 
juxtaposition of the different mechanisms of growth between the two forms of 
ossification. I analysed bone maturation during a time-course of ontogeny 
from E13 through post-natal day 8, using molecular markers traditionally 
associated with long-bone development and progression through the 
osteoblastic lineage (from pre-osteoblast through mature osteoblast and 
osteocyte) . 
I explored the hypotheSiS that dermal bones expand in thickness via 
appositional deposition of cells and matrix in an area pre-patterned by the 
existing vasculature; in contrast to this, findings presented here suggest an 
alternative model of dermal bone formation in which the external envelope, 
comprising l1 and l3, is established before these layers act as generative 
surfaces contributing cells to the embellishment and radial growth of in 
intervening space, l2, housing the mineralised matrix and cancellous core of 
the bone. 
The establishment of the two generative layers in the frontal bone (l1 and 
l3) by embryonic day E13 indicates a molecular heterogeneity of the 
morphologically homogenous mesenchymal condensations and an early pre-
patterning of the frontal bone primordium. The expression pattern and 
morphology of the two generative layers continues through bone 
development and birth (notably, cell layer definitions were based on majority 
expression as the generative layers were heterogenous due to their mosaic 
nature whereby they comprise both osteoblastic and vascular cells). The 
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integrity of the molecularly defined Layers 1 and 3 is not broken at any stage 
of development, essentially creating a closed system. Thus, involution or 
wrapping of these layers around pre-existing dermal blood vessels could not 
be found as one would expect to find at least grooves of partially engulfed 
dermal vasculature, which were never observed. Neither was uncontrolled 
entry of cells from the generative layers observed, as would be predicted by 
the appositional model of bone development; instead the entry points of cells 
in L2 were highly constrained to areas where cells in L 1 are organised into 
rosette structures, reminiscent of stem cell populations in the both 
mammalian CNS and teleost fish (Mirzadeh et a/. 2008; Hava et a/. 2009). 
These newly discovered rosette formations may act as a dermal bone stem 
cell niche, although such an assertion cannot be definitively made without 
further examination of the molecular characteristics and cell division 
dynamics within rosettes. Cells within Layer 1 of both osteoblastic and 
vascular lineages use the rosette as the entry point into Layer 2. Rosettes 
are the only entry point for cells into L2 and we show in a single embryonic 
time slice and across ontogeny that L2 grows in thickness as additional 
cellular material is added to it from generative layers L 1 and L3. In the most 
immature stage of frontal bone development where diploe architecture (L 1-
L2-L3) is evident, L2 is a cell sparse region; as maturation progresses 
increasing numbers of cells invade L2 in pairs of Runx2-positve osteoblasts 
and C031/vWF-positive endothelial cells. This twinning can serve as a 
mechanism to ensure that although these osteoblasts later secret matrix in a 
polarized fashion, osteoblasts are always supported by vasculature that 
forms in direct juxtaposition. This proximity is also the precondition for labels 
(such as calcein etc.) to reach the osteoblasts and the matrix they secrete. 
The ability of the generative layers to give rise to cells that bee-line into L2 
and there form a sheet-like architecture resembles convergence-extension 
like behaviour dependent on both the PCP pathway and the transcription 
factor Hand2, as evidenced by the disrupted formation of dermal bones in 
the Hand2-mutant strains of mice. Hand2 joins the group of other interactors 
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of Runx2 that can block and modulate its function by direct binding. Here I 
find evidence of a tethering mechanism that ensures that although Runx2 is 
expressed in the developing bone, it cannot act as it is prevented from 
entering the nucleus in the entirety of L 1, except the few 1-2 cells within 
rosettes and cells entering L2. Upon Hand2 removal we see significant 
deregulation of this process and re-Iocalisation of Runx2 to the nuclei of cells 
within L 1 and L2; the bone becomes a permissive environment with 
uncontrolled cell entry into L2 and subsequent inability of cells within L2 to 
form sheets, a key hallmark for the growth of L2 in wild types. 
We posit that acquisition of a Hand2-dependent molecular programme by the 
neural crest was a key preadaptation for the elaboration of dermal bone (L2) 
beyond that of single radial cancellar walls. The level of disruption of bone 
formation in the Hand2-mutants was surprising, including effects observed in 
very medial areas of the clavicle that have contradictorily been described as 
forming via dermal or endochondral ossification (Huang et al. 1997). These 
results could alternatively suggest a dermal method of ossification of this 
area, or a role of Hand2 in the endochondral development of the outer layers 
of the clavicle. 
In the wild-type condition, the L2 system is highly dynamic, with the layer 
morphology, vascularisation and biomineralisation developing in parallel, with 
evidence of continual remodelling within the bone through foetal 
development and the first week of birth. 
Remodelling of the bone is an important feature of the new model proposed 
herein for dermal bone formation. A time course of in vivo matrix production 
revealed the surprising result that osteoblasts are the key agents not only of 
initial matrix secretion but also in remodelling the matrix that they (or 
preceding osteoblasts) have laid down. Results suggest the first collagen 
scaffold in the bone is formed by Collagen II, secreted appositionally by cells 
at the L 1 margin of L2. I then observe a remarkable mechanism of L2 
invasion and immediate matrix deposition in 'cloud' or 'bag' like 
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arrangements, followed by a bidirectional invasion of cells into the mineral 
phase of L2 and subsequent internal remodelling of the calcified areas. This 
counters classical models of mineral accretion on a pre-existing scaffold as, 
in contrast, the collagen scaffold is continually being remodelled. Osteoblasts 
dissolve the existing mineral with MMP13 (rendering the calcified matrix 
flexible), which is initially on the outside of L2 and becomes injected radially 
into the mineral cores by virtue of invading osteoblasts. MMP13 is a direct 
target of Runx2, allowing cells to switch easily between osteoid/matrix 
dissolution and production (Nakamura et a/. 2004). Vascular cells also 
remodel the previously established osteoblast-endothelial sheets inside L2 
by secreting MMP9 which stays confined to these sheet-like inner surfaces. 
We posit that this is used to expand the number of cells taking part in sheet 
formation. Interestingly, MMP9 is able to cleave Osteopontin (Nilsson et a/. 
2005), indicating the MMP9 carrying vasculature could invade the OPN+ 
vasculature-matrix boundary as part of the remodelling. 
Introduction of MMPs to the L2 system, as well as mixtures of different 
collagens within L2 (such as Collagen I, Collagen II and Collagen XIV 
(Undulin» changes the mixtures of fibrous versus amorphous collagens, 
which has previously been speculated to be a key mechanism by which 
woven bone could come into being. PMT imaging of a P8 murine frontal 
bone displays the biomineralised zone contains an amorphous core of 
mineralised islands surrounded by a late appositional matrix. The 
appearance of appositional matrix surrounding amorphous inner matrix is a 
feature retained throughout evolution from the earliest examples of fossilised 
biomineralised tissues in Anaspids (Figure 5.1). Halstead and others 
previously discussed whether these centres of cancellar walls are cellular or 
not (Halstead and Sarjeant 1995). The osteoblast-endothelial interface, 
which we find can be derived from the same ancestral cell population and 
emerges as the result of a convergence-extension motion into and out of the 
rosette system, could provide a cellular framework in which biomineralization 
occurs in fossil fish (Jordan, Koentges and Donoghue, unpublished). Here I 
have described a model of mineralisation and its remodelling that entirely 
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rests on the protean ability of this osteoblast-endothelial surface and that 
may have been conserved through over 420 million years of evolution 
(Figure 5.1). 
The establishment of the bone morphogenesis, vascularisation and 
mineralisation precedes the introduction of osteoclasts to the system. I base 
this supposition on several factors: the majority of the frontal bone is of 
neural crest origin (including the vasculature) and I have found no evidence 
indicating monocytes and megakaryocytes (the precursors to osteoclasts 
(Geissmann et al. 2010)} derive from the neural crest. Osteoclasts are 
introduced to the bone via the vasculature, which we have shown here 
develops in parallel with the morphology and biomineralisation; ergo, the only 
way osteoclasts would be introduced during the time-course of our analysis 
would be if the mesodermal cells found within the early bone differentiate into 
osteoclasts. Additionally, I do not observe cells within the bones at this stage 
of maturation that display the classic morphological indicators of osteoclasts, 
namely mutli-nucleation, characteristic F-Actin rings, or nuclei containing a 
high proportion of vesicles (Nijweidi et al. 1986; Vaananen et al. 2000; 
Buccione et al. 2004). 
In addition to bone layer morphogenesis, vascularisation and 
biomineralisation, the establishment of the skeletal muscle:bone interface 
was also examined. The structure of L 1 mediates the enthesis, whereby it is 
sub-compartmentalised into an area where Runx2/Hand2-nuclear expressing 
cells dock the skeletal muscle fibres into a periosteum-like tissue. This 
arrangement allows an early connection to an area of L 1 that is physically 
connected to the bone proper, but does not insert muscle fibres into an area 
that will be remodelled; in this arrangement, bone development can progress 
without being impinged upon by mechanical strain and bone thickness 
growth is not stunted. 
The major differences between the traditional and new models of bone 
development are described in Table 5.1 and Figures 5.2-5.6. 
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The success of the current study was predicated on the type of analysis 
conducted: a time-course of immunohistochemsitry combined with high 
resolution imaging and three-dimensional analysis of bone development. The 
extensive cohort of markers examined at single-cell resolution was an 
attempt to interlink all the crucial aspects of bone development, including 
layer morphogenesis, vascularisation, biomineralisation and muscle:bone 
connectivity. Although the majority of these markers have been well-
characterised in endochondral formation, they have not been used for 
analyses of direct ossification. 
Crucially, I observe the expression pattern of bone-related markers is 
determined by their position rather than temporally by stage in development. 
For example, the establishment of periost/perichondrium-like tissues (L 1 and 
L3) is prior to the generation of an embellished L2; and the osteoblasts did 
not progress through stages of development marked by alternating Runx2 
and Osteopontin expression. Remarkably, co-expression of several markers 
and post-translational modifications appear to be critical for dermal bone 
formation. 
The discrepancy between current findings and previous studies is 
attributable to three features: firstly, the use of immunohistochemistry, rather 
than in situ hybridisation; secondly the analysis of these markers in 
undisturbed conditions (avoiding the use of dissociation or explant 
techniques); and thirdly the extensive time-points analysed as single time-
point studies could not map the continuity of Layers 1 and 3, nor explore the 
mechanism of L2 expansion. Immunohistochemistry was favoured over in 
situ due to the many post-translational modifications and protein localisation 
events that effect the function of some of the genes that were to be analysed 
(ex: Runx2 (Harada et al. 1999; Westendorf 2006; Jonason et al. 2009). By 
exploring the protein localisation of the markers in question in a time-course 
of development under in vivo conditions at single-cell resolution, we were 
able to discern the fine detail of the bone development. For example, this 
technique enabled me to identify previously repudiated co-expression of 
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Runx2 and OPN, which appears to define the matrix-vasculature interface 
and may have been overlooked in previous studies due to the minority of 
cells exhibiting co-expression. 
I have, therefore, classified the cell types analysed in the current study by 
their unique molecular properties and the functions they appear to play in 
intramembranous ossification. This classification includes: rosettes, motile 
osteoblasts, osteoblasts with remodelling potential and those at the boundary 
of biomineralised areas and the mineral:vasculature interface; additionally, I 
differentiate between generic vasculature and the endothelia capable of 
remodelling. Molecular maps of marker co-expression, and corresponding 
diagrams of the model of intramembranous ossification based on current 
results, are found in Figures 5.7-5.13. 
The mechanism of generating the architecture of dermal bone described 
herein would have existed before endochondral ossification, a feature that is 
phylogentically more recent than intramembranous ossification (Donoghue 
and Sansom 2002). The model of dermal bone formation based on the 
current study is predicated on the continual intercalation of both neural crest 
and mesodermal cells into the developing bone, revealing the highly dynamic 
nature of intramembranous ossification. Interestingly, because of the 
evolutionary precedence of dermal over endochondral bone, one can 
consider that certain aspects of indirect ossification follow similar generative 
rules to those observed in the current study; for example, the invasion of 
vasculature to the cartilaginous template of endochondral bones. As such, a 
reanalysis of the process of bone remodelling during endochondral 
ossification may be warranted, as this process is often studied in adult 
animals in the context of bone injury, which may be very different from the 
early development of endochondral structures (Lieberman and Friedlaender 
2005). By examining the various features of dermal bone formation, this 
study aimed to put the ontogenetic features of bone development in the 
correct phylogenetic order, based on the assumption that it is endochondral 
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bone formation that co-opts its mechanism of growth from the older form of 
dermal ossification. 
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Figure 5.2: The traditional model of dermal bone development contrasted to the alternative model supported 
by the current data: Initialising bone development 
Contrasting models of dennal bone development. 
A. The traditional model of dermal bone development favours an appositional mode of growth. The early 
mesenchymal condensation features pre-osteoblasts (turquoise) in the vascularised dennis (early condensed 
mesenchyme/dermis in yellow). Pre-osteoblasts differentiate into osteoblasts (white) and secret matrix (grey) which 
mineralises (green). Modified from Bruder & Scaduto in Bone Regeneration and Repair, 2005, Human Press Inc. 
Lieberman & Friedlaender, eds. 
B. The model supported by the current findings: in the earliest stages (E13) the mesenchymal condensation (grey 
cells) is already a bi-Iayer comprising osteoblastic and vascular cells (grey), that sits beneath the dermis (yellow) and 
above the brain (blue). 
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Figure 5.1: The phylogenetic development of bone including amorphous versus apPositional matrix 
deposition 
A. A phylogenetic tree (modified from Janvier 2008, Figure 1) indicating the first instances of a mineralised matrix, a 
tri-partite (diploe) dermal bone architecture and finally endochondral bone formation. 
B-C. Examples of amphorphous mineralisation surrounded by compact sheets of mineralisation in the fossil fish 
Loricopteraspis (8) and Ang/aspis (C) (images kindly donated by P. Donoghue). This arrangement is also observed 
during the current study in the development of the murine frontal bone. 
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Table 5.1: Contrasting the major features of the traditional model of dermal bone growth (via apposition) 
and the new model of dermal bone growth (via invasion). 
Traditional Model New Model 
Single generative layer Two generative layers 
Discontinuity of developing trabacles Contigous l1 and L3 encasing l2 which matures in time and is in constant communication 
Morphogenesis with L hnd L3 
Osteogenic -fronr moving through dermis Osteogenesis occurs in controDed and coordinated manner by increasing the complexity of 
l2 
Pre-patteming from vasculature Vasculature develops cCH:ommitantly with layer morphogenesis and biomineralisation 
Vascularisation Vasculature is in place before bone, or introduced via Vasculature is introduced via rosette formations, in conjunction with osteoblastic cells 
remodeUing 
Some vasculature introduced by periosteum Bone vasculature contigous with L 1 and l3 vasculature 
! Bone architecture is defined by mineralised layers Bone architecture can be remodelled even after mineratisation, accomodating tangential I 
-growth 
Mineralisation in distinct layers or trabacles IMinerafisation first in cloudsflSlandS, then horizontal sheets and later radial connection; this 
Biomineralisation No defined constraints on minerarlSation 
laBows bone to grow radiaDy 
'Mineralising areas are encased by non-minerafising cens with distinct molecular signature 
Osteoblasts secrete ostoid; bone resorption by osteoclasts Osteoblasts both secrete and remodel the osteid matrix 
Cels Introduced Via Appositional growth i Growth via intercalation of cells from l1 and L3 mediated by rosettes Periosteum is a cambial growth surface iNa evidence of columns of ceAs across layers deposited in a cambial fashion 
CeDular Differentiation Cels progress through distinct stages of differentiation ICeDs maintain tt:e ~uIar signature of the~ layer of origin .. 
-
IProposed ~rogression of molecular marker exE!:ession iMarker eX2!:esslOl1lS strong~ related to s~atial. not temporal. ceRular identity 
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Figure 5.3: The traditional model of dermal bone development contrasted to the alternative model supported 
by the current data: Early mineralisation 
A. In the trad itional model of intramembranous ossification, the osteoblast front grows and cells that were pre-
osteoblasts (turquois) in Figure 5.2 differentiate into osteoblasts, around the pre-existing vasculature. Osteoblasts 
secrete and are trapped in the osteoid (grey), which becomes mineralised (green). Modified from Bruder & Scaduto in 
Bone Regeneration and Repair, 2005, Human Press Inc. Lieberman & Friedlaender, eds. 
B. The alternative model of dermal bone development features cell invasion from two generative layers as the mode 
of growth. An early bi-Iayered mesenchyme matures when cells of the bi-Iayers flatten and move apart with the 
intervening space carrying the matrix (green). The two generative layers comprise osteoblastic (dark green) and 
vascular (red) cells and carry periost markers from an early stage. Cells from these layers enter into the space 
between them at points dictated by the presence of rosette formations. Mineralisation is seen in distinct islands from 
E16 (green), cells producing the matrix are of osteoblastic origin (Runx2 or OPN expressing cells) (white). 
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Figure 5.4: The traditional model of dermal bone development contrasted to the alternative model supported 
by the current data: Expanding bone thickness 
A. In the traditional model of bone development, the mineralisation occurs as a single front that continues to progress 
through the mesenchymal condensation. Osteoblasts trapped in osteoid further differentiate into osteocytes. Modified 
from Bruder & Scaduto in Bone Regeneration and Repair, 2005, Human Press Inc. Lieberman & Friedlaender, eds. 
B. The new model of dermal bone formation in which the biomineralisation occurs in parallel sheets that form 
concomitantly and are separated by unmineralised sheets of cells (grey indicating a mixed population of osteoblasts 
and vascular cells) maintaining contact with the generative layers. The unmineralised sheets experience horizontal 
elaboration within the cancellous bone and supply both osteoblastic and vascular cells to the growing system. The 
mineralised areas can be moved and remodelled during their formation, without the presence of osteoclasts. 
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Figure 5.5: The traditional model of dermal bone development contrasted to the alternative model supported 
by the current data: Further maturing the bone 
A. The bone continues to mature as additional sheets of mineralisation are added in an appositional manner. At a final 
stage of development the periost surrounds the bone and the spongious core of the bone is surrounded on either side 
by compact bone (not shown on this diagram). Modified from Bruder & Scaduto in Bone Regeneration and Repair, 
2005, Human Press Inc. Lieberman & Friedlaender, eds. 
B. In the invasive model of dermal bone development, the layer morphogenesis, vasculature and biomineralised 
areas develop in parallel and are subject to remodelling. The biomineralised areas are expanded from cells burrowing 
in (example of a cell leaving from the sheet of unmineralised cells and approaching the mineralised area to burrow in 
indicated with *) and increasing the mineralised area from within; simultaneously, the vasculature invades the growing 
bone. The cells invading from the generative layers (grey) continue to provide material for bone expansion. The 
mature bone structure features a spongious layer surrounded by late appositionally added compact bone (late 
apposition from L 1 and L3 not shown on this diagram), 
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Figure 5.6: Molecular profile of cells participating in dermal bone development according to traditional 
models of intramembranous ossification 
Molecular map of all the markers assayed in the current study (Chapters 1-5) and the expected expression domains 
as defined by published analyses of bone development (for details and references, see text). 
Markers cluster into 4 distinct subgroup: those associated with osteoblastic lineages, the neural crest marker (LacZ; 
synonymous here with GFP), enzymes associated with remodelling (matrixmetalloproteinases -9 and -13) and 
vascular markers (endothelia express CD31 and vWF, while SMA is a pericyte marker). 
The markers associated with osteoblastic cells are further subdivided by the stage of cell maturation (pre-osteoblast 
vs osteoblast), an association with a certain pathway (ex: PCP, planar cell polarity), a notable feature (ex: motility), 
and/or a stage of overall bone maturation (ex: markers of the periosteum). 
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Figure 5.7: Molecular profile of E13 frontal e 
bone anlage 
Schematic diagram (A) of the condensed 
mesenchyme stage of dermal bone 
development and the accompanying 
molecular map (8) detailing the single cell 
molecular marker co-expression profiles 
found in the study. Markers active in L 1 
indicated in purple, L3 in green and both L 1 
and L3 in red. Exclusive co-expression is 
indicated by a solid line between two markers 
and a lack of co-expression (from a 
double/triple immune-labelling experiment) is 
indicated with a yellow dashed line. 
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Figure 5.8: Molecular profile of rosettes s 
Schematic diagram (A) of an early stage of 
dermal bone development including rosettes 
in L 1, and the accompanying molecular map 
(8) detailing the single cell molecular marker 
co-expression profiles found in the study. 
Markers active in the cell at the apex of 
rosettes are highlighted in blue and co-
expression is indicated by a solid line between 
two markers. 
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Figure 5.9: Molecular profile of motile and 
stationary osteoblasts 6 
Schematic diagram (A) of a semi-mature stage 
of dermal bone development including motile 
(gold box) and stationary (heather box) 
osteoblasts. The accompanying molecular map 
(8) details the single cell molecular marker co-
expression profiles. Exclusive co-expression is 
indicated by a solid line between two markers 
and non-exclusive co-expression, some but not 
all cells co-express the markers in a 
double/triple immuno-Iabelling experiment, is 
indicated with a dashed line. 
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Figure 5.10: Additional images of motile osteoblast cells Dennis 
Rostral ~<---+--
A-F. IHC for molecular markers found to be expressed by motile osteoblasts, combinations described in Figure 5.9, 
above. All 63x magnifications from E18 Wnt1-Cre+l- x Rosa26lacZ-I- transgenic mice. All have nuclear counterstain 
DAPI (blue). 
A. Within L 1 and at some points in l2, neural crest cells (indicated by J3-Galactosidase reactivity, green) express 
Fibronectin (red), a cell-adhesion molecule. Notably, in this region, l2 has an unusually high population of 
mesodennal cells. 
B. CRABP1 (red); calcein stain of mineralised area (green); nuclear counterstain DAPI (blue). Motile cells in L 1 and 
those in L2 that are remodelling the mineralised area are CRABP1 positive (*), while those that secrete the matrix and 
are embedded within it do not express CRABP1 ("). 
C. The dennal component of the clavicle, where it meets the SCM. POSTN (red) is found at the muscle-bone 
interface and within l1, l2 and l3. Some POSTN expressing cells also express Collagen I (green) although, notably, 
osteoblasts of clasps of cells traversing across l2 are the most reactive for Collagen I. 
D. The dermal component of the clavicle where there is a wide expression of Runx2 (green) within L 1 and l2; some 
cells within l2 are also co-expressing Hand2 (red). 
E-F. In the frontal bone near the coronal suture (E), all of l1 and L3 cells express F-Actin (red, rhodamine phalloidin 
stain), while at the most mature end of the frontal bone (F), a chain of cells can be extending from L3 into l2 (* at L3 
base of chain). 
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Figure 5.11: Molecular profile of osteoblasts found at the centre of re-modelled mineralised areas 
Schematic diagram (A) of a semi-mature stage of dermal bone development including osteoblasts in the centre of 
mineralised matrix that has been remodelled from within the previously calcified areas (dark green box). The 
accompanying molecular map (8) details the single cell molecular marker profiles of cells at the centre of these 
remodelled areas (from a double/triple immuno-Iabell ing experiment). Exclusive co-expression is indicated by a solid 
line between two markers and non-exclusive co-expression, some but not all cells co-express the markers in a 
double/triple immuno-Iabell ing experiment, is indicated with a dashed line. Notably, any osteoblast that is capable of 
motility may also be capable of remodelling, however the specific osteoblastic markers indicated were assayed in 
combination with the MMPs. 
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Figure 5.12 continued on the next page 
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Figure 5.12: Molecular profile of cells at the vasculature-mineralisation boundary 
Schematic diagram (A) of the vascular bone interface; the accompanying molecular map (8) details the single cell molecular marker profiles 
of cells at this border. Exclusive co-expression is indicated by a solid line between two markers and a lack of co-expression (from a 
doubleltriple immuno-Iabelling experiment) is indicated with a yellow dashed line. 
C-O. IHC for Undulin (red) and WVF on a section with histological addition of calcein; in an immature part of the frontal bone Undulin 
expression is found at the margins of all areas that are mineralised but not in the developing vascular cells; in a semi-mature clavicle (D), 
Undulin is notably absent from the lining of vascular space (8V indicated with *) 
E. At the blood vessel (*) :bone interface, the endothelia is von Willibrand Factor positive (blue) and there is a border of Osteopontin 
expression between the calcein carrying mineralised area and the vasculature. OPN caps mineralisation and is always found at the bone-
vasculature interface. 
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Figure 5.13: Molecular profile of generic and motile/digging vasculature 
Schematic diagram (A) of a semi-mature stage of dermal bone development and the accompanying molecular map 
(8) detailing the single cell molecular marker co-expression profiles of vasculature found in the study. Markers active 
in generic vasculature are highlighted in pink; vasculature capable of remodell ing also expressed MMP9 (gold). 
Exclusive co-€xpression is indicated by a sol id line between two markers and non-€xclusive co-expression, some but 
not all cells co-express the markers in a double/triple immuno-Iabelling experiment, is indicated with a dashed line. A 
lack of co-€xpression (from a double/triple immuno-Iabelling experiment) is indicated with a yellow dashed line. 
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PART II: 
EXPLORING THE CHIARI MALFORMATION 
AS A NEUROCRISTOPATHY 
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6. Chiarl and the neural crest 
6.1 Introduction: Chiarl malformations and the neural crest 
Work undertaken in our laboratory in 2005 used genetic lineage analysis 
(Cre-recombinase-mediated transgenesis) to map the neural crest and 
mesodermal contributions to the head and neck, leading to the discovery of 
the 'connectivity' rule in mammals (also known as the 'scaffold model', 
previously illustrated in lower vertebrate species (Huang et al. 2000; Olsson 
et al. 2001» and the contribution of neural crest cells to territory previously 
believed to arise from mesodermal progenitors (Matsuoka et al. 2005). This 
finding held clinical significance for a number of human syndromes as areas 
primarily affected in several conditions were now shown to derive from a 
specific sub-population of cells, the post-otic neural crest (PONC). The 
implication that one syndrome, the Chiari malformation, is a neurocristopathy 
was further investigated in the current study. 
The Chiari syndromes are characterized as malformations of the base of the 
skull and neck regions where the cerebellum herniates through the foramen 
magnum by at least 3-5mm, pushing this component of the hindbrain 
downwards into the spinal cord, often accompanied by the development of a 
syrinx (Figure 6.182) (Milhorat et al. 1999). The syndrome was first 
described by Hans Chiari in the 1890s and the prevalence of the disorder is 
estimated to be up to 1 in 1000 people (Loukas et al. 2008; Labuda 2010). 
Chiari is broken into 4 subtypes, related to the severity of the deformation, 
with types I and II being predominant; in Chiari 1/11 the cerebellum herniation 
is often symptomatic and can be debilitating but is not associated with 
lethality (versus types III and IV where the malformation leads to mortality, 
often before or immediately after birth). The genetic basis for Chiari is 
unknown, although it is purported to be heritable and is suspected to be 
congenital (Speer et al. 2000). Chiari is diagnosed via MRI, usually in the 
third decade of life, following years of unattributed symptoms (personal 
communication, Conquer Chiari Annual Research Conference 2008) 
(Milhorat et al. 1999». Symptoms of Chiari range from mild to severe 
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(described in detail, below) (Milhorat et al. 1999; Mueller and Oro 2004) and 
Chiari patients present with diverse phenotypes, complicating the prognostic 
and diagnostic criteria. 
The Chiari malformations can be attributed to cell-differentiation defects. 
Chiari is hallmarked by improper ossification as a result of erroneous cell-fate 
decisions. The misappropriation of cells into certain fates is confined to 
specific areas, indicating an issue of regulation exclusive to subpopulations 
of cells forming the head and neck. Neural crest cells form connective tissue 
of all muscles innervated by cranial nerves (N. V, VII, IX, X, XI), the skeletal 
regions to which these muscle attach, the branchial skeleton, areas of the 
cranial base, the spinous processes of cervical vertebrae, and attachments 
of the pharyngeal constructors (Matsuoka et al. 2005). Cranial neural crest 
cells can differentiate into cartilage, endochondral bone, dermal bone, 
connective tissues, neurons and glia (Couly et al. 1993; Le Douarin et al. 
1993; Kontges and Lumsden 1996; Le Douarin and Kalcheim 1999; Knecht 
and Bronner-Fraser 2002). Chiari phenotypes involve a range of the 
structures derived from the neural crest and, as such, Chiari is a candidate to 
be a neurocristopathy. Of note, many of these structures had previously 
been attributed to mesodermal origins and Chiari has previously been 
labelled a mesodermal or segmental defect (Mesiwala et al. 2001; Koyanagi 
and Houkin 2010). The aim of the current study was to further explore the 
contributions the neural crest to the areas affected in Chiari, which would 
support the classification of the disease as a neurocristopathy. 
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6.2 Results Chiari as a neurocristopathy, correlation studies 
6.2.1 PONC expression in regions affected in Chiari 1111 
Prior to undertaking new experimentation, it was necessary to conduct a 
detailed examination of the initial evidence supporting the role of the neural 
crest in generating the areas affected in Chiari 1/11. Chiari is an extremely 
complex syndrome involving a multitude of seemingly incongruent 
symptoms. According to personal communications at the Conquer Chiari 
Annual Research Conference in November 2008, more than half of Chiari 1/11 
patients are referred for psychological examination prior to their Chiari 
diagnosis as their differential diagnoses indicate a psychosomatic and not 
physiological issue (Milhorat et a/. 1999). In light of the syndromic diversity 
among the patients, a comprehensive list of what phenotypic characteristics 
should be used as indicators for the malformation has been impossible to 
generate. One potential unifying component of the variegated symptoms is 
the embryological tissue of origin of the pathognomic deficiency resulting in 
the symptom. As such, initial analysis in the current study focused on 
compiling a list of the symptoms of Chiari 1/11 and the pathognomic deficiency 
that could be the aetiological cause, which was correlated with the results of 
previous lineage analyses to ascertain in how far the pathognomic 
deficiencies arise in neural crest-derived structures. Lineage analysis was 
undertaken using the Wnt1-Cre+l- strain of mice, in which a Cre-recombinase 
is combined with the Wnt1 dorsal neural tube enhancer, such that the 
transgene is expressed in the neural crest precursor population and their 
resulting progeny (barring NC of rhombomere 1) (Jiang et a/. 2000; Ferguson 
and Graham 2004; Matsuoka et al. 2005). Wnt1-Cre+l- founder mice are then 
combined with a Cre-reporter strain with transgenic f10xed resistance-pA 
cassettes; the reporter strains in the current analyses included 
ROSA26LacZ-I- mice in which LacZ is under the control of the Rosa26 locus 
(Soriano 1999); and XZ-DR-I- mice with GFP under the control of the human 
Ubiquitin C minimal promoter (hUbC) (Zhang and Koentges, unpublished) 
(Schorpp et a/. 1996; Lois et a/. 2002). 
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The symptoms of Chiai 1111 were compiled from primary literature on Chiari, 
medical resources and patient support websites (ChiariOne ; Milhorat et al. 
1999; Speer et al. 2000; Mueller and Oro 2004; NINOS 2011) and included 
all symptoms involving the cranio-facial region. Symptoms were grouped into 
6 categories: headaches (A), craniofacial anomalies (8), musculo-skeletal 
anomalies (C), pharyngeal/vocal impairments (excluding dysphagia) (0), 
dysphagia (E) and neurological abnormalities (F). 
Symptoms of Category A include the characteristic Chiari 1111 headaches 
which are often described as heavy, severe, suboccipital or posterior; the 
neural crest-derived components of the clivus, foramen magnum, cranial 
nerves and smooth muscles of cranial blood vessels may be contributing 
factors in these headaches (Table 6.1, Figure 6.1). 
Category 8 includes the craniofacial anomalies leading to calvarial defects, 
foramen magnum malformations, Wormian bones, hypoplasia, and lambdoid 
sutures; neural crest was found to contribute in this category to the clivus, 
pharyngobasilar membrane attachments, occipital protuberance and nuchal 
ligament (Table 6.2, Figure 6.2). 
The musculoskeletal anomalies described in Category C include cervical 
spina bifida occulta, ectopic ossification/cervical hypo mobility and shoulder 
pain. These symptoms may arise due to malformations of neural crest-
derived cervical spinous processes, the pre-vertebral ligaments, bones along 
the calvaria midline/tentorium and the connective tissue of the trapezius 
muscle (Table 6.3, Figure 6.3). 
Category D includes symptoms related to pharyngeal/vocal impairments, 
including symptoms related to deficits in the extrinsic and intrinsic tongue 
musculature and connective tissue, all of neural crest origin, such as: 
displaced/deficient attachments, vocal impairments and laryngomalacia. The 
vocal impairments, mechanical dysphagia, laryngomalacia and additionally 
hoarseness can also be attributed to the PONC-derived larynx and pharynx 
muscles and attachments, and basihyoid and attachments (Table 6.4, Figure 
6.4). 
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Dysphagia, described in Category E, is attributable to the neural crest 
derived pre-vertebral ligament (Table 6.5, Figure 6.5), as well as structures in 
Category D. 
Finally, deficits of the cranial nerves may lead to several neurological 
problems (category F) in Chiari 1111, including impaired gag reflex, tremors, 
dysmetria, facial sensory loss, phototypic and visual sensory issues, and 
vocal cord paralysis (Table 6.6, Figure 6.6). 
To date this is the first study that correlates the variegated multitude of 
symptoms associated with Chiari with the cellular origins of the effected 
structures leading to the phenotype, and supports a neurocristopathic origin 
of Chiari 1111. 
6.2.2 Mutant analysis: Replicating the Chiari phenotype 
The 2005 study reported in Matsuoka et al. revealed that some aspects of 
the Chiari phenotype were replicated in previously characterised mutant mice 
lacking genes involved in the ossification process (Matsuoka et al. 2005); 
most prominently, when the master bone-regulator, Runx2, is ablated, mice 
have deficiencies in the clivus, pharyngobasilar membrane attachment, 
bones along the calvarial midline, occipital protuberance, and nuchal 
ligament. Analysis of mutant strains provides powerful ad hoc evidence of 
the role of a relevant pathway in generating a phenotype. Our laboratory was 
interested in the potential role of the sonic hedgehog (SHH) signalling 
pathway in patterning the neural crest cells and obtained a smoothened 
mutant lacking the SHH ligand, Smo, specifically in neural crest cells 
(transgenic generated in laboratory of T. McMahon), which prohibited the 
activation of the SHH pathway in a lineage-confined manner. For the current 
study the effect of losing Smo was analysed with specific regard to 
replicating the Chiari phenotype. 
The smoothened mutant lacks the attachment region of the pre-vertebral 
ligament in the cervical area, a phenotype shared by both Chiari and Klippel-
Feil patients (Figure 6.7). However, the mutants did not display other 
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abnormalities associated with Chiari and exploring each individual pathway 
by generating a mutant strain was decided to be too laborious and unbiased 
for future work. 
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Table 6.1: Neural crest contributions to anatomical regions generating symptoms of category A 
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Figure 6.1: Category A 
The symptoms of category A 
are a result of pathognomic 
deficiencies as outlined in the 
table above. Several of these 
structures have a neural crest 
component (A1) that leads to 
the physical deficiency in the 
Chiari malformation (A2) 
A 1-A2 after Matsuoka ef. al.2005 
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Table 6.2: Neural crest contributions to anatomical regions generating symptoms of category B 
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B2. ANATOMY 
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NEURAL CRE ST-DERIVED ELEMENT 
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Figure 6.2: Category B 
The symptoms of category Bare 
a result of pathognomic 
deficiencies as outlined in the 
table above. The neural crest 
component of these structures 
and the mature anatomy in a non-
affected condition are shown in 
81 and 82, respectively. 
81 after Matsuoka et. al.2005 
82 © 2003 Primal Pictures Ltd 
Table 6.3: Neural crest contributions to anatomical regions generating symptoms of category C 
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Figure 6.3: Category C 
The symptoms of category B are a 
result of pathognomic deficiencies 
as outlined in the table above. The 
neural crest component of these 
structures and the mature 
anatomy in a non-affected 
condition are shown in C1 and C2, 
respectively. 
C1 after Matsuoka et. al.2005 
C2 © 2003 Primal Pictures Ltd 
Table 6.4: Neural crest contributions to anatomical regions generating symptoms of category 0 
CATEGORY PATHOGNOMIC DEFICIENCY 
-~ 
« 
w 
~~ Z« 
>-0 
0::0 
«> 
I 
0... 
o 
A 
B 
C 
0 
E 
F 
Chvus, sIze of the foramen magnum, 
lell(Jth of era m a I ba se 
Cramofaclal anomahes 
Musculo-skeletal anomahes 
PharyngeaWocallmpalrments 
Dvspahgla 
Neurological 
01. Wnt1-CrexROSALacZ 
NEURAL CREST 
RESUL TlNG SYMPTOM OF CHIARI un 
Headaches heavy, severe, suboccIpItal, postenor 
Calvanal defects, dysplastic extended/constncted 
foramen magnum, platybasla, Wormlan bones, 
hypoplaSia, lambdoid suture/foramen 
Cervtcal spina blfida occutta, ectopIc 
osslflcatloniceMcal hypomobillty, shoulder pain 
Displaced/deficient attachments, vocal Impairments, 
larvll(JomalaCia . QaQ reHex 
Swallowmgdlfficuttles 
Faoal palnlnumbness, syncope, aspiration sensory 
loss, apnea, Impaired gag renex, sensallon defects 
02. ANATOMY 
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NEURAL CREST-DERIVED ELEMENT 
Cllvus,cramal nerves, smooth muscles of cranIal blood 
vessels 
Clivus, pharyngobasllar membrane attachments, 
occIpital protuberance, nuchal hgament 
Cervtcal SpinOUS processes, pre-vertebral cervtcal 
ligament bones along cali/alia mldlme - tentonum 
trapeZIus CT 
Larynx & pharynx musdes, attachments, basihyoid 
and attachments 
Prevertebral hqament 
Cramal nerves, DRGs 
Figure 6.4: Category 0 
The symptoms of category B are a 
result of pathognomic deficiencies 
as outl ined in the table above. The 
neural crest component of these 
structures and the mature 
anatomy in a non-affected 
condition are shown in 01 and 02, 
respectively. 
01 after Matsuoka et. al.2005 
02 © 2003 Pictures Ltd 
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Table 6.5: Neural crest contributions to anatomical regions generating symptoms of category 0 
CATEGORY PATHOGNOMIC DEFICIENCY 
« 
(j 
« 
I 
0... (f) 
>-o 
w 
I 
A 
B 
C 
D 
E 
F 
Clivus, sIze of the foramen magnum. 
length of cralllal base 
Cramofaclal anomalies 
Musculo-skeletal anomakes 
PharyngealNocallmpalrments 
Dyspahqla 
NeurologIcal 
-----
E 1. Wnt1-CrexROSALacZ 
NEURAL CREST 
f ct . 
.~ 
p)..: ............. , It!;- Uga.mlnt 
1 I .-
. ,. 
.; 
, I 
ventraJ 
~ 
dorsi l 
RESUL TING SYMPTOM OF CHIARI UII 
Headaches. heavy, severe, subocapnal, postenor 
Calvanal defects, dysplastic extended'constncted 
foramen magnum, platybasla, Wormlan bones. 
IhvPoplasla lambdoId suture-foramen 
CelVlcal spIna blfida occulta ectopIc 
osslficatJon/celVlcal hypomoblhty, shoulder pam 
DlsplaCed'defiaent attachments vocallmpamnenls, 
larynqomalaaa QaQ reJlex 
Swanowlng difficultIes 
FaCial pain/numbness syncope aspiratIOn sensory 
loss, apnea. Impaired gag reflex. sensatJOn defects 
E2. ANATOMY 
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------.' - ----._-- -- -
NEURAL CREST-DERIVED ELEMENT 
Cllvus,cranlal nerves, smooth muscles of cralllal blood 
vessels 
Clivus, pharyngobaslfar membrane attachments, 
ocapltal pro1uberance, nuchal bgament 
Cervical spmous processes pre-vertebral celVlcal 
ligament, bones along catvana midline - tentorium, 
trapezius CT 
Larynx & pharynx muscles, attachments, basIhyoid 
and attachments 
PrevertebraJ liqament 
Cranial nerves, DRGs 
Figure 6.5: Category E 
The symptoms of category B are a 
result of pathognom ic deficiencies 
as outlined in the table above. The 
neural crest component of these 
structures and the mature 
anatomy in a non-affected 
condition are shown in E1 and E2, 
respectively . 
E1 after Matsuoka et. a/.2005 
E2 © 2003 Primal Pictures Ltd 
, ------~-----
Table 6.6: Neural crest contributions to anatomical regions generating symptoms of category F 
CATEGORY PA TI-lOGNOMIC DEFICIENCY 
....J 
« () 
(9 
o 
....J 
o 
~ 
=> 
W 
Z 
W 
A 
B 
C 
0 
E 
F 
Clivus, size of Ihe foramen magnum, 
lenqth of cranial base 
CraniofaCial anomalies 
Musculo-skeletal anomalies 
PharyngeaVVocallmpalrments 
Dyspahqla 
Neurological 
F1 . Wnt1-CrexROSALacZ, 
"E D Lor F~ 
RESUL TlNG SYMPTOM OF CHIARI VII 
Headaches: heavy, severe, suboccIpital, posterior 
Catvanal defeds dysplastic extended./constncled 
foramen magnum, platybasla Wormlan bones, 
hypoplasia lambdoid suturelforamen 
CelVlcal sprna blfida occulta, ectopIc 
osslficahon/ceMcal hypomoblhty, shoulder pam 
Displaced/deficient attachments, vocal Impairments, 
larvnqomalaCJa. qaq reflex 
SwallovlIllQ difficulties 
Faaal parnfnumbness, syncope, aspirabon sensory 
loss apnea ImpaIred qag reflex. sensa bon defeds 
F2. ANATOMY 
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NEURAL CREST-DERIVED ELEMENT 
Clivus. cranial nerves, smooth musdes of cranial blood 
vessels 
Clivus, pharyngobasllar membrane altachments, 
occIpital protuberance, nuchal ligament 
CelVlcal sprnous processes, pre-vertebral celVlcal 
ligament, bones along catvana mrdlrne - lenlOflum 
trapeZIus CT 
Larynx & pharynx muscles, attachments, basihyoid 
and attachments 
Prevertebral hqament I 
Cranial nerves, DRGs 
Figure 6.6: Category F 
The symptoms of category B are a 
result of pathognomic deficiencies as 
outlined in the table above. The 
neural crest component of these 
structures and the mature anatomy 
in a non-affected condition are 
shown in F1 and F2, respectively. 
F1 Ryll & Koentges , unpublished 
F2 © 2003 Primal Pictures Ltd 
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Figure 6.7: Pathognomic deficiency of the SMO..f-; Wnt1-Cre+/- mice 
SMO-/-xWnt1-Cre -
S __ S .-_ 
Coronal view of whole mount alcian blue (blue), alizarin red (red) stained wild-type (A) and smoothened (SMO) ligand 
knockout transgenic mice at postnatal day 0 (8). 
A. Wild-type animal in which the cartilage precursor to the cervical attachment of the prevertebral ligament is evident 
(above white arrowhead). This contrasts with B in which activation of the sonic hedgehog (SHH) pathway has been 
ablated in the neural crest cells of the transgenic animal lacking the SMO ligand. The attachment point of the pre-
vertebral ligament is notably absent and ossification of the cranial base is slightly retarded. The SMO-knockout 
replicates the phenotype of Chiari and Klippel-Feil patients and indicates that the SHH pathway may playa role in 
generating the Chiari malformations. 
* Transgenic knockout and histological preparation conducted by members of T. McMahon group; analysis by K. 
Jordan. 
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6.3 Conclusion 
The accumulated evidence that symptoms of Chiari arise in neural crest 
derived structures, and ablation of certain pathways in the neural crest can 
replicate the Chiari phenotype, supports the hypothesis that Chiari is a 
neurocristopathy. In order to further explore the neural crest contribution to 
the Chiari phenotype, it was next necessary to more precisely elucidate the 
role of the neural crest in generating the structures of the cranial base 
associated with Chiari 1/11. 
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6.4 Summary of Findings 
- The diverse and seemingly incongruent symptoms of Chiari arise due to 
pathognomic defects affecting structures that are largely of neural crest 
origin; 
- Neural crest being the common precursor to tissues affected in Chiari 1111 is, 
to my knowledge, the first uniting feature to be identified among the majority 
of symptoms suffered by Chiari patients; 
- The strong correlation between the symptoms and their structural origin 
supports Chiari as a neurocristopathy; 
- Ablating the smoothened ligand in post-otic neural crest cells replicates the 
phenotype of Chiari and Klippel-Feil patients, who lack the attachment pOint 
of the pre-vertebral ligament; this indicates the sonic hedgehog pathway 
could playa role in developing the Chiari phenotype. 
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7. Homing into the anatomical defects of Chiari Ini 
7.1 Introduction 
Results of lineage labelling studies have mapped the cryptic boundaries of 
the neural crest in the neurocranium and cranio-cervical regions; many 
structures hitherto attributed to paraxial mesoderm have shown a dual origin 
(Figure 7.1), and neural crest forms the attachment regions connecting the 
head and shoulder girdle/neck vertebrae even in structures largely formed 
from somatic mesoderm (Figure 7.1). To refine the study of Chiari as a 
neurocristopathy, it was necessary to home into the anatomical location of 
the principle structural defect. 
While many of the neural crest-derived structures associated with the 
symptoms of Chiari may be malformed in the given condition, the lack of 
congruence among them indicates no one is individually causative of the 
complaint. Additionally, the elusive nature of Chiari is such that diagnosis 
most commonly occurs in the third decade of life, indicating it as a late 
developmental defect reported to become symptomatic in the first decade of 
life in 37% of patients (Milhorat et al. 1999). 
In his seminal work describing Chiari, Milhorat ascribed the chief anatomical 
defect of the Chiari syndrome to be a malformation of the posterior cranial 
fossa (PC F), the cup-like area in which the cerebellum sits, bounded by the 
tentorium, basiocciput, supraocciput and petrous ridges (Figure 7.2). While 
the brain of Chiari patients was found to be an average size, the PCF had a 
volumetric reduction (40%, on average) and cerebrospinal fluid volume was 
also diminished in 100% of the 364 patients assessed (Milhorat et al. 1999). 
Further morphometric studies attributed the small PCF to the length of the 
supraocciput and clivus (Koyanagi and Houkin 2010) and baSioccipital 
hypoplasia (Noudel et al. 2009). 
The ontogeny of the cranial base involves a significant amount of postnatal 
craniofacial growth in the structures contributing to cranial base angulation 
and the resulting morphology of the posterior cranial fossa (Coben 1998; 
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Jeffery and Spoor 2004; Jeffery and Spoor 2004). Detailed morphometric 
studies in humans and other primates have shown the clivus, which borders 
the PCF ventrally and whose angulation/retroflexion determines the size of 
the peF overall, is a patchwork of three anlagen (the pre-, basisphenoid and 
basioccipital), separated from each other through synchondroses early in 
development. These synchondroses act as hinge-points during development 
that lead to a successive retroflexion of this bony base. Along the dorso-
ventral axis, the closure of the growth plates of the sphenoid bone occurs at 
distinct developmental time-points (Figure 7.3). The spheno-ethmoid 
synchondrosis, between the ethmoid and presphenoid bones, undergoes 
juvenile closure; the mid-sphenoidal synchondrosis, separating the 
presphenoid and basisphenoid bones, has postnatal closure in the first 
decade of life; and finally the spheno-occipital synchondrosis, partitioning the 
basisphenoid and basioccipital bones, does not close until early adulthood. 
Any eccentric ossification in these areas would alter the length of the bone 
and the resulting posterior cranial fossa volume. Of particular significance for 
the overall size of the peF is the spheno-occipital synchondrosis (50S) 
ventrally and the supraoccipital/interparietal region dorsally (Jeffery and 
Spoor 2004; Jeffery and Spoor 2004). Premature closure (stenosis) of the 
50S would block the necessary retroflexion and lengthening of the clivus 
and lead to platybasic (a flat skull base) condition characteristic of Chiari I 
(Noudel et a/. 2009). 
Given the age of onset of the symptoms and the time of diagnoses in Chiari 
patients, I re-examined the endochondral ossification process and the neural 
crest contribution at the cranial base around the spheno-occipital 
synchondrosis and the supra-occiput late in ontogeny, as the majority of fate 
maps utilised in the previous study (Chapter 6) were generated early in 
development before endochondral ossification is complete or utilising more 
imprecise methods, such as retroviral injections, that do not allow clean 
separation of label between neural crest and mesoderm (Couly et al. 1993; 
Le Douarin et a/. 1993; Huang et a/. 2000; Evans and Noden 2006). 
An additional examination was conducted on a potential role of the neural 
crest in generating the suboccipital headaches, experienced by 81-98% of 
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Chiari patients (Milhorat et a/. 1999; Mueller and Oro 2004). Headaches 
emerge when nociceptive neurons, located in the trigeminal and vagus 
ganglion that innervate the meninges (dura and arachnoids), sense 
increased vasodilation and intracranial pressure above a given threshold. 
Work by Strassman, Burstein and Levy, Goadsby and others have outlined 
the physiological basis of this pain system (the so-called trigeminocervical 
complex) and have defined the various fibre types involved (Strassman et a/. 
1996; Storer et a/. 2001; Storer et a/. 2003; Olesen 2006). These fibres are 
embedded inside the collagen matrix of the dura and arachnoids. Any 
physiological or genetic changes that affect the biomechanical properties of 
the system would mediate the stretching of the nociceptor terminals and 
could lead to headaches; these changes could include congenital increased 
intracranial pressure, different tissue composition and resulting compliance 
of venous drainage systems, or differences in the collagen composition (and 
associated proteins) of the meninges themselves. 
The localized headaches in Chiari "" could result from architectural 
differences among blood vessels of the brain that can skew fluid dynamics. 
Differences in blood vessel architecture may be attributed to the 
developmental origins of the cells providing the vasculature. Previous studies 
have shown that the vasculature of the brain is a complex patchwork of 
mesoderm and neural crest-derived cells that are discretely spatially 
organized, i.e. the meninges (and meningeal blood vessels) around 
particular brain regions are not mixed in origin (Etchevers et a/. 2001); there 
is a spatial segregation in those meninges that are crest and those that 
derive from the mesoderm. The mechanisms of cellular development (Le. 
how the vasculature forms the connective tissue walls of these blood 
vessels) has significant effects on vessel size and blood flow dynamics and 
may be determinants of suboccipital headaches. Mechanical properties of 
head vasculature are studied by others in the Chiari researcher community, 
using engineering and imaging tools (personal communication, Conquer 
Chiari Research Conference 2008), however no group, to date, has explored 
the implication that lineage differences relate to headaches in Chiari. 
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Figure 7.1: Neural crest contributions to the cranial base 
A. Diagrammatic representation of the ossification centres of the cranial base (modified from Nemzek et a/. 2000) . 
Areas that are derived from the neural crest, as found in our fate-mapping studies, are indicated in blue. Notably, 
areas contributing to the Chiari phenotype arise from neural crest cells, including portions of the basioccipital and 
occipital bones, as well as components of the clivus. 
B. Schematic illustration mapping the neural crest components of the cranial base and cervical regions (blue) to the 
areas previously mapped to be somitic mesoderm. The segmentation of the neurocranium aligns to the consecutive 
contributions of the somites, numbered from cranial to caudal 1-7. Modified from Huang et al. 2000. 
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Figure 7.2: MRI of the Chiari malformations 
The Chiai malformations are described clinically as any herniation of the cerebellum ~ 3 mm below the foramen 
magnum, forcing that component of the brain into the spinal cord. Chiari is diagnosed by a sagittal T1-weighted MRI 
(Modified from Matsuoka et a/. 2005) . 
A. Example MRI of a normal, healthy adult; this contrasts to B, where a dysmorphic clivus is visible and indicated with 
a wh ite arrow. 
In B the cerebellar herniation (often described as "peg-like") is visible (red circle) . In a paediatric example of Chiari II 
(C) the clivus is almost totally absent (white arrow) and there is cerebellar retardation and pegs (black arrow). 
The Chiari malformations often result in the development of a syrinx in the spinal cord, exemplified in D, where the left 
panel shows a moderate syrinx (white arrow), which enlarges with time (right panel, white arrow). 
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Figure 7.3: Homing into the primary anatomical defects of the Chiari malformations 
A. The primary anatomical defect of Chiari 1111 is a diminished volume of the posterior cranial fossa (PCF), leading to 
an overcrowding forcing the cerebellum to herniate through the foramen magnum. Measurements of the posterior 
cranial fossa (PCF) using T1-weighted sagittal MRI scans of a 44-year-old female patient with Chiari I. The PCF is the 
cup-like area housing the cerebellum, indicated with a white dotted line. The PCF is measured by examining the 
length of the clivus (0, dorsum sella, to 8, basion), the distance across the foramen magnum (8 to 0, opisthion), the 
length of the supraocciput (from 0 to I, internal occipital protuberance) , and the slope of the tentorium (T) (as 
calculated by measuring the angle (a) formed by the tentorium and the supraocciput). Cerebellar herniation is evident, 
indicated with a white arrowhead. This patient had a short supracocciput, increased slope of the tentorium, hypoplasia 
of the clivus, and descent of the cerebellar tonsils 1.6 em below the foramen magnum; all characteristic of Chiari 1111. 
Modified from Milhorat et al. 1999. 
B. The volume of the PCF is partially determined by the angulation/retroflection of the clivus. The clivus is a 
patchwork of three anlagen (the pre and basisphenoids and the basioccipital), outlined in red. The anlagen are 
separated from each other through synchondroses acting as hinge-points during development that lead to a 
successive retroflexion and growth of this bony base. The spheno-ethmoid synchondrosis (gold box) undergoes 
juvenile closure; the mid-sphenoidal synchondrosis (green box) has postnatal closure in the first decade of life; and 
finally the spehno-occipital synchondrosis (blue box) does not close until adulthood. Any eccentric ossification in these 
areas would alter the length of the bone and the resulting posterior cranial fossa volume. Modified from Lieberman & 
McCarthy, 1998. 
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7.2 Results: Neural crest invasion late in ontogeny 
7.2.1 Late neural crest invasion into the cranial base 
The current study utilised a newly developed transgenic reporter mouse 
strain (Xl-DR-I-) which, when combined with Wnt1-Cre+l- mice confers 
labelling to all neural crest cells with GFP under the control of the hUbC 
minimal promoter, with the exception of neural crest from rhombomere 1 
(which do not express the Wnt1 transgene); the GFP expression is strong 
enough to visualise de novo or in conjunction with an anti-GFP antibody. 
This study revealed a late re-invasion of neural crest into mesodermal areas, 
including a previously uncharacterised contribution to the vasculature of 
endochondral bones. 
The clivus is a structure with dual neural crest and mesodermal origin; at 
E18.5 in the spheno-occipital synchondrosis anlage there is a large 
contribution of neural crest cells (Figure 7.4). The basisphenoid is of neural 
crest origin, while the basioccipital is somitic mesoderm. A late contribution 
of the neural crest was also observed in the occipital protuberance, supra-
occiput, and the atlas (Figures 7.4-7.6). 
A close examination revealed that at a time-point immediately preceding birth 
in murine development (E18.5), a considerable portion of the vascular 
endothelia inside the endochondral clivus is of neural crest origin (Figure 
7.6). Neural crest also contributed to the endothelia of the atlas and the 
vasculature surrounding the cartilaginous tissues (Figure 7.6). This neural 
crest invasion is notably anatomically confined as the exoccipital condyle 
from the same section contains no neural crest contribution (Figure 7.7). 
7.2.2 Neural crest contribution to cranial vasculature 
Results of the study on the neural crest-derived vasculature of the cranial 
region (utilising the Wnt1-Cre+l- x XZ-DR-I- strain of mice) indicate the 
meninges of the cortex are neural crest in origin, while the meninx of the 
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cerebellum are unlabelled, presumably because the cerebellum derived from 
cells of rhombomere 1 (Figure 7.9). These results are in line with previous 
grafting studies showing the neural crest origins of forebrain meninges, while 
mesodermal cells comprise the midbrain and hindbrain meninx (Le Douarin 
and Kalcheim 1999). I observe that there are neural crest derived vessels in 
the cortex where both the pericyte and endothelia are of crest origins, as are 
the arachnoids (Figure 7.10). Arachnoids of the spinal cord were also found 
to be neural crest in work conducted on Wnt1-Cre+l- x ROSA26LacZ-l- mice, 
indicating a possible contribution of the neural crest to meninges of 
hindbrain. 
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Figure 7.4: The dual neural crest and mesodermal origin of the mammalian clivus at E18.5 
Sagittal section through the cl ivus immediately prior to birth at E18.5 after conception (positive vaginal plug is taken 
as EO); Wnt1-Cre+l- XZ-DR-I- mouse. A. IHC for GFP indicating the neural crest cells (green), CD31 (purple) and 
Rhodamine Phalloidin (red). B. de novo GFP expression under fluorescence on the Arcturus PixCell " LCM. Nuclear 
counterstain DAPI (blue, A-B). 
A-B. The spheno-occipital synchondrosis anlage (50S) contains a large contribution of neural crest cells; the 
basisphenoid (85) is neural crest while the basioccipital (BO) is mesodermal. 
Scale bar indicates 50~m . 
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Figure 7.5: The dual neural crest and 
mesodermal origin of the mammalian cranial 
base at E18.5 
Sagittal section through the cranial base 
immediately prior to birth at E18.5 after 
conception (positive vaginal plug is taken as EO); 
Wnt1-Cre+l - XZ-DR-/- mouse. de novo GFP 
expression under fluorescence on the PixCell II 
LCM. Nuclear counterstain DAPI (blue). 
A late contribution of the neural crest is observed 
in the occi~ital protuberance, supra-occiput, and 
interparietal. The trapezius muscle is also neural 
crest in origin. 
IP interparietal, OP occipital protuberance, T 
trapezius muscle, SO supraocciput 
Acquired at 10x magnification. 
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Figure 7.S: The dual neural crest and mesodermal origin of the cranial base vasculature at E18.5 
Sagittal section through the clivus and atlas immediately prior to birth at E18.5 after conception (positive vaginal plug 
is taken as EO); Wnt1-Cre+l- XZ-DR-I- mouse. A. IHC for GFP indicating the neural crest cells (green), and CD31 + 
vasculature (red). Nucelar counterstain DAPI (blue, A-B). 
A. Some vasculature of the endochondral component of the clivus derives from the neural crest; as does the 
vasculature surrounding the forming bone and the pharyngeal constrictor muscles. 
B-C. The atlas also contains neural crest-derived vasculature at the stage of murine development immediately prior to 
birth, at both it's ventral (8) and dorsal (C) margins. 
C clivus, Ph_C pharyngeal constrictor muscles, A atlas 
Scale bar indicates 50~m. 
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Figure 7.7: At E18.5 the murine exoccipital condyle is 
purely mesodermal 
Sagittal section through the exoccipital condyle immediately 
prior to birth at E18.5 after conception (positive vaginal plug 
is taken as EO); Wnt1-Cre+l- XZ-OR-I- mouse. A. IHC· for 
GFP indicating the neural crest cells (green), Rhodamin 
Phalloidin (red) and CD31 + vasculature (purple). Nucelar 
counterstain OAPI (blue). 
The vasculature of the exoccipital condyle, unlike other 
components of the cranial base from the same histological 
section, is purely mesodermal in origin. No neural crest cells 
are detected. 
EX exoccipital condyle 
Scale bar indicates 50l-'m. 
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Wnt1-Cre x XZ-DR Figure 7.8: Neural crest contribution to the meninges 
Transverse section through the murine cranium immediately 
prior to birth at E18.5 after conception (positive vaginal plug is 
taken as EO); Wnt1-Cre+l- XZ-DR-I- mouse. IHC for GFP 
indicating the neural crest cells (green); nuclear counterstain 
DAPI (blue, B-C). 
A. Overview of the contribution of the neural crest to the 
murine cranium. 
B. The meninges of the cerebellum are not labelled by the 
transgene, indicating either they are mesodermal or derive 
from the crest population of rhombomere 1, which does not 
express wnt1. Conversely, the arachnoids of the cortex are 
labelled (C). 
Scale bar indicates 50~m. 
* Stain and confocal by Dr X. Zhang, analysis by K. Jordan. 
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Figure 7.9: Neural crest form the arachnoids and both the endothelia and pericytes of the cortex. 
Sagittal section through the murine cortex immediately prior to birth at E18.5 after conception (positive vaginal plug is 
taken as EO); Wnt1-Cre+l- XZ-DR-I- mouse. IHC for GFP indicating the neural crest cells (green), CD31 (red, A,C) and 
vWF (red, D,F); nucelar counterstain DAPI (blue). 
A-C. CD31/PECAM and GFP expression showing the meninx of the cortex are neural crest as is the vasculature 
within the cortex. 
D-F. A second endothelial marker, von Willibrand factor, confirms the finding of neural crest-derived vasculature in the 
cortex and evidences both the endothelia (vWF+) and pericyte (vWF-, arrowhead) derive from the neural crest. 
Scale bar indicates 50~m. 
* Stain and analysis by K. Jordan, confocal by Dr X. Zhang. 
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Figure 7.10 Endochondral ossification is dependent on 
vascular invasion of the cartilage template 
Diagrammatic representation of endochondral bone 
development whereby a hyaline cartilage precursor is laid 
under a-vascular conditions (green). External to the cartilage 
the vascularised periosteum forms, contain osteoprogenitor 
cells and osteoblasts laying appositional matrix to stabilise 
the outside of the forming bone. At the centre of the bone 
(the primary ossification centre), chondrocytes grow and 
become hypertrophic and secrete vascular endothelial 
growth factor (VEGF) before they undergo apoptosis. The 
VEGF secretions recruit blood vessels from the periost, 
which grow into the spaces left by the apoptotic 
chondrocytes. The vasculature brings haemopoietic and 
osteoprogenitor cells to the bone cavity. Osteoblasts 
differentiate from the osteoprogenitors and osteoclasts from 
the bone marrow: these cells form the bone-proper. 
Bone maturation is, therefore, contingent on chondrocyte 
hypertrophy and the ensuing vascularisation of the cartilage 
template. 
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7.3 Conclusion 
Given the fundamental importance of vascularisation on endochondral 
development (Figure 7.8), the late invasion of neural crest vasculature to the 
cranial base is likely to be a key component of the bone maturation process. 
A deficiency in the late neural crest invasion could account for aberrant 
ossification and may link to the Chiari phenotype by affecting the height of 
the supraocciputloccipital protuberance (thus the tentorial angle), as well as 
the atlas/axis, accounting for the retroflexed odontoid process in Chiari I 
patients. 
The contribution of the neural crest, mapped to the arachnoids, pericytes and 
endothelia of the cortex and medulla (Figure 7.11) could indicate that 
differences of compliance between these areas and the mesodermally-
derived midbrain vasculature was a result of connective tissue defects 
among the neural crest vasculature. 
The next phase of analysis focused on isolating single-cell precursors to the 
neural crest anlagen to the cranial skeleton and vasculature for whole 
transcriptome analysis. 
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Figure 7.11: The neural crest and mesodermal contributions to the meninges and arachnoids of the human 
brain 
Diagrammatic representation of the meninges that are neural crest (Wnt1 expressing) (green) and those that do not 
express the Wnt1 transgene (red) in the immature (A) and mature (8) conditions, as mapped to the areas 
corresponding to the results of the current study in murine brains. Neural crest forms the meninges of the cortex, 
medulla and spinal cord, while the cerebellar meninx derive from rhombomere 1 (which does not express Wnt1) . The 
border of the tentorium is indicated in B. 
CO cortex, CE cerebellum, TN tentorium, M medulla, SC spinal cord 
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7.4 Summary of findings 
- The invasive neural crest makes a contribution to the occipital 
protuberance, supraocciput, atlas and clivus at late stages of murine prenatal 
development; 
- The contribution of the neural crest to these structures implicates the neural 
crest in the maturation of the posterior cranial fossa, which is aberrantly 
formed in Chiari patients; 
- At late stages of murine prenatal development, the vasculature of the 
endochondral bones of the cranial base comprises both neural crest and 
mesodermal cells; 
- The neural crest contribution to cranial vasculature includes the arachnoids, 
pericytes and endothelia of forebrain (cortex) and some hindbrain structures 
(medu"a), excluding the cerebellum. 
267 
8. Single-cell analysis of neural crest cells 
8.1 Introduction 
Gene expression profiling (via microarray analysis) of the early embryo 
during foetal development is a successful technique to interrogate the 
transcriptional networks underlying differentiation processes (Livesey et a/. 
2000). Interrogating the transcriptome of individual cells is a form of 
molecular analysis that probes the heterogeneity of developing tissues and 
can be used to explore regional differences among populations of cells 
(Tietjen et a/. 2003). The current study aims to use single cell transcriptome 
analysis to explore the regulatory networks responsible for the differentiation 
of neural crest cells in the anlagen to structures affected in Chiari. The 
similarities and differences among the sub-populations of neural crest cells 
that give rise to various structures of the cranial base affected in Chiari 1/11 
will be explored. Further analyses will be conducted on the transciptome of 
the neural crest-derived vasculature that may play a role in compliance 
issues in the Chiari malformations that result in the predominant symptom 
(sub-occipital headaches). 
Laser capture microdissection (LCM) was used to isolate individual neural 
crest cells. The neural crest is genetically labeled and traced throughout the 
resulting anatomical structures derived from it using Wnt1-Cre+l- transgenic 
mice, in combination with two reporter strains (ROSA26LacZ-I- and XZ-DR-I-) 
(Matsuoka et a/. 2005). In Wnt1-Cre x ROSA26LacZlXZ-DR mice, neural 
crest-derived cells can be identified via J3-Galatosidase staining 
(ROSA26LacZ) on adjacent sections to those used for LCM and lineage 
identity of captured cells is confirmed using PCR for the transgene. In Wnt1-
Cre+l- x XZ-DR/- mice, neural crest cells can be visualised under fluorescent 
light during the isolation process on a PixCell II Laser Capture Dissection 
Microscope (Arcturus), allowing neural crest cells to be picked for analysis 
without contamination from mesodermal tissues. Notably, the technique 
allows the isolation of individual cells, however, in very dense cellular areas 
more than one cell may be picked at a time. Every attempt was made to be 
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diligent in assessing this and it was always noted when more than one cell 
was captured, although for the ease of nomenclature all samples were 
termed "single cell" samples. 
I expression profiled single genetically-labeled neural crest cells from key 
regions affected in Chiari at crucial developmental time-points, namely at E9-
10 after the cells have migrated into the branchial arches (to rule out genes 
associated with migration), at E13 when fate decisions are being made, and 
at E 18.5 after the late invasion of neural crest cells identified in Chapter 7. 
Lineage labelled transgenic mice can also be utilised to isolate vasculature 
from the mesoderm in the cranio-facial region and to validate previous 
assertions that the vasculature is of a defined lineage-patchwork; expression 
profiles can also be generated for areas that are of NC (ex: internal carotid 
artery) versus mesodermal (ex: basilar artery) origin at embryonic stage 
E18.5. Previous studies have suggested that gene expression is more 
closely correlated with cell fate rather than lineage (Liu et al. 2009) and 
whole transcriptome analysis can be used to ascertain if this holds true for 
the vasculature of the cranial base. Furthermore, the transcriptome of the 
NC-derived meninges was investigated at E18. Unfortunately, the clean 
isolation of the neural crest-derived endothelia of endochondral bones 
(identified in Chapter 7) was beyond the limitations of the technique and the 
transcriptome of these cells could not be investigated during the current 
study. 
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8.2 Results: Single cell analysis of neural crest contributions to areas 
affected in Chiar/ Inl 
The single-cell laser capture technique used for the study was pioneered by 
Koentges et a/. and conditions for tissue preparation, single-cell collection, 
cDNA amplification, cDNA labelling and microarray hybridisation were 
optimised for this particular study (Technical Appendix 11.2). 
8.2.1 Laser Capture Microdissection 
The current study was designed to analyse the neural crest contributions to 
the structures affected in Chiari 1/11 that arise from both the early neural crest 
population and the late invading neural crest cells identified in our previous 
studies. 
In early ontogeny I examine the genes being expressed at the time of cell-
fate decisions (approximately E13) when erroneous expression could lead to 
the hypo or hyper-ossification experienced in Chiari 1111. The neural crest 
components of anlagen to structures that are affected in the majority of 
Chiari patients were isolated for analysis. Single cells were captured at E13 
from the condensed mesenchyme anlagen to the neural crest clivus 
(basisphenoid and basiocciput) and pharyngeal constrictors (n=18) 
(annotated Cli/Ph or CIi_Ph), the pre-foramen magnum occipital region 
(n=21) (annotated FM), and the posterior cranial fossa (n = 26) (annotated 
PCF) (Figures 8.1-8.2 & Table 8.1). A total of 25 cells were also captured 
from branchial arches III & IV (annotated BA) at E9-10 to generate a list of 
genes expressed during and immediately after migration of post-otic neural 
crest cells into the branchial arches (Figure 8.3, Table 8.1). Seven controls 
from non-PONC cells were also captured at various time points (Table 8.1) 
(annotated control). 
In late ontogeny, to further explore the transcriptome of neural crest-derived 
meninx, single cells from the neural crest derived meninges at E18.5 were 
also isolated (n = 8) (Figure, Table) (annotated meninges) (Figure 8.4, Table 
8.1). 
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Previously reported regional differences in the lineage origins of cranio-facial 
vasculature were analysed in the current study at E18.5 and we find mosaic 
neural crest contribution to vasculature at the cranial base. At the axial level 
of the cochlea, neural crest and mesodermal vasculature developed in close 
spatial proximity and blood vessels were observed that appeared to have 
contributions from both (Figure 8.4). Single cells from the neural crest and 
mesodermal vasculature were subsequently isolated; neural crest n = 17 
(annotated NC Vasc) and mesodermal n = 15 (annotated Meso Vasc) (Table 
8.1). 
8.2.2 Sample preparation prior to hybridisation to microarrays 
For this pilot study, the experimental cohort was designed to include a 
minimum of three single cell samples from each experimental region, 
determined to be the minimum required for statistically significant analysis of 
gene expression between regions, Single cells from the regions of interest 
were captured in excess of this as in a previously published study only 10% 
of laser captured cells successfully passed quality controls and were 
hybridised to microarrays (Tietjen et al. 2003), The workflow was optimised 
(see Technical Appendix 11.2) and samples were subjected to rigorous 
quality controls prior to microarray analysis, including: confirmation of cDNA 
generation from total cellular RNA, analysis of successful re-amplificaiton of 
cDNA (including length of the product), confirmation of transgene and/or 
housekeeping gene expression via PCR or Southern hybridisation, and 
analysis of cDNA quality via Bioanalyzer and quantitative PCR (Figures 8.5-
8.6). At various stages of quality controls the cohort of samples was 
narrowed down resulting in a total of 34 samples with sufficient quality to 
progress to microarrays, of which 26 were hybridised to arrays: E13 
clivus/pharyngeal constrictors n = 2, E13 pre-foramen magnum occipital 
region n = 4, E13 pre-PCF n = 6 (of which loose mesenchyme outside the 
main condensation n = 3, annotated Loose PCF Mes), E9-10 branchial arch 
controls n = 3, E18.5 NC-meninges n = 4, E18.5 NC vasculature of cranial 
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base n = 3, and E18.5 mesodermal vasculature of cranial base n = 4. The 
microarrays were run in four rounds on three separate occasions. 
8.2.3 Results from microarray analysis: Principle component analysis 
Following hybridisation to microarrays (Affymetrix GeneChip Mouse 4302.0), 
AffyBatch quality controls were performed (see Technical Appendix 11.2, 
Materials and Methods); the first cohort of samples (n = 12) all passed quality 
controls and were subjected to whole transcriptome principle component 
analysis (PCA). PCA is a statistical clustering technique that analyses the 
overall variance within the samples (in this case, differential gene 
expression) and subsequently groups those samples whose transcriptomes 
are more similar. Each principle component is a linear representation of the 
combination of overall gene expression patterns and each principle 
component represents variance among the expression pattern of the 
microarray, with the first two components accounting for the majority of the 
variance. When the first two principle components are plotted against one 
another, the whole transciptome clustering of the samples can be visualised. 
Using PCA reveals that within the first cohort of samples, two discern able 
clusters are evident, one including the vasculature (meninges, NC-
vasculature and mesodermal vasculature) and the other the non-vascular 
samples (Figure 8.7). The neural crest vasculature and meninges were more 
similar to the mesodermal-derived vasculature than they were to the neural 
crest precursors to the bones of the skull base, supporting the idea that cell 
fate more strongly correlates with gene expression than lineage. However; 
the two clusters also neatly divided the two time-points isolated (E13 versus 
E18.5), therefore, it cannot be ruled out that the clustering is due to two 
stages of terminal differentiation or developmental progression. Along the X-
axis (representing principle component 1), the 3 sub-populations of neural 
crest cells from the E13 embryos (namely, the anlagen to the PCF, 
clivus/pharyngeal constrictors and foramen magnum) were more similar to 
each other than to the other sub-populations, potentially representing 
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regional variations in gene transcription in the developing cranial base. 
However, there were not enough replicates to confirm this with statistical 
significance. Among the vasculature samples, neither principle components 
1 (X-axis) nor 2 (Y-axis) clustered the sub-populations of vasculature 
(namely meninges, NC vasculature and mesodermal vasculature). 
The subsequent cohorts of samples included the final 14 microarrays. Post-
hybridisation quality control analysis revealed 9 samples had a notably 
diminished overall intensity level (BA n = 3, meninges n = 2, NC-vasc n = 2, 
meso-vasc n = 2) as well as a borderline result from the Bioanalzer. The 
results from all of the cohorts were subjected to principle component 
analysis, which yielded absolutely no biologically meaningful clustering 
(Figure B.8). When the 9 samples with poor intensity and Bioanlyzer quality 
were removed, the clusters were recapitulated with only one sample (#87, 
pre-foramen magnum) behaving as an outlier and clustering more closely to 
vasculature than the bone anlagen (Figure B.9). 
Within the PCA plot we noticed 4 samples were heavily clustered along the X 
and Y axes, including samples from 3 sub-populations of neural crest cells at 
E13 (sample 14 from the pre-foramen magnum, samples 31 and 33 from the 
loose PCF mesenchyme and sample 74 from the clivus/pharyngeal 
constrictors) (Figure 8.9). Sample 84 (also foramen magnum) was also 
closely aligned to this cluster. These samples had the commonality that they 
had the lowest percentages of genes which were positive for expression on 
the microarray, all under 4%. The reported array coverage in published 
studies of laser captured single cells has wide variation (Kamme et al. 2003; 
Seshi et al. 2003; Tietjen et al. 2003); within the literature, studies that are 
most analogous to our own in both the isolation method (namely, LCM from 
cryo-sectioned rodent tissues) and array platform (Affy GeneChip 430 2.0) 
report % present between 5.6%-13.9% (Kamme et al. 2003). These figures 
also match previous, unpublished, data from our own laboratory. During the 
optimisation stage of the current study (see Technical Appendix 11.2), it was 
noted that the array hybridised with a "blank" cell (a sample that had no 
cellular material added to the original cDNA generation step, and was 
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subsequently re-amplified) had 1 % array coverage, while samples (n =4) that 
had failed pre-microarray quality controls (but were run for comparison), had 
an average coverage of 1.9% and samples that had passed pre-array 
controls but failed the control for array intensity (n = 9) had an average 
coverage of 3.7%. It was, therefore, decided to use 4% present as the 
threshold to include samples in gene expression analyses (Cii/Ph n = 1, PCF 
n = 3, PCF loose mes n = 1, FM n = 2, meninges n = 2, NC vasc n = 1, meso 
vasc n = 2). 
Due to the diminished experimental cohort, after the exhaustive quality 
controls, differential gene expression analyses among the sub-populations of 
cells would not be statistically valid. Gene expression analyses of the single 
cells instead focused on elucidating the major pathways activated in the 
samples, especially those that discriminate between the vasculature and 
non-vasculature samples and/or may have relevance in generating the Chiari 
phenotype. 
8.2.4 Results from microarrays: Single cell gene expression analyses 
The axial origin of the cells was mapped by gene expression profiling of the 
Hox genes. The Hox signatures of the single cells analysed in the current 
study indicate the samples all arise from post-otic or cervical locations (Table 
8.2). This is an important finding as past studies by J.L. Rinn et al. had 
demonstrated that even fibroblastic cells retain the HOX gene Signature of 
their axial origin throughout development into the adult stage (Rinn et al. 
2006; Rinn et al. 2008). As the cells in the current study express posterior 
signatures, it indicates they may have migrated from posterior locations into 
the cranial base. 
Within the single cells analysed, genes in the latent transforming growth 
factor (TGF)-~ (LTBP) family were found to be active in 80% of vascular 
samples as well as in the loose mesenchyme surrounding the pre-foramen 
magnum area (Table 8.3). LTBP genes were not expressed in any of the pre-
skull base samples. The L TBP pathway is of interest as transgenic L TBP-3 
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knockout mice undergo premature stenosis of the basoccipital-basisphenoid 
synchrondroses (Figure 8.10). This phenotype is attributed to a precocious 
maturation of the tissue indicated by an over-extensive zone of hypertrophic 
chondrocytes, with vascularisation being the key committing step in 
chondrocyte hypertrophy (Dabovic et al. 2002; Dabovic et al. 2002). 
Interestingly, this indicates that the vascular invasion of the clivus (which was 
found to comprise both neural crest and mesodermal cells) could playa key 
role in the timing of the ossification of the synchondroses, leading to the 
angulation/retroflexion which determines the size of the PCF. If this is the 
case, the L TBP genes could be Chiari disease candidates, which could be 
screened for. Furthermore, it is intriguing to consider classifying Chiari as a 
vasculogenic disorder; although the bony structures of the cranial base are 
malformed in Chiari, this may be a result of aberrant vascular development 
hastening or delaying endochondral ossification. 
Chiari has been postulated to be a connective tissue disorder as a link 
between inherited connective tissue diseases (namely, Ehlers-Danlos and 
related hereditary disorders of connective tissue) and Chiari was previously 
established (Milhorat et al. 2007); in a prospective study of 2,813 Chiari 
patients, 12.7% met the diagnostic criteria for hereditary connective tissue 
disorders (Milhorat et al. 2007). Examining connective-tissue related gene 
expression in the current study reveals extensive expression and an 
enrichment for collagens in the samples from both the vasculature and skull 
base anlagen (Table 8.4). As connective tissue related genes were 
expressed in all of the areas profiles, which are affected in Chiari 1/11, the 
current data support Chiari as being a connective tissue disorder. 
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Figure 8.1: Laser capture microdissection maps for the single neural crest cells isolated at E13 from the 
anlagen to the clivus/pharyngeal constrictors and the foramen magnum 
A. Human foetus** at 10 weeks of gestation; the areas analogous to those isolated for analysis in an E13 Wnt1-Cre+/' 
x ROSA26Lacz'/' mouse are highlighted in red boxes, comprising the condensed anlagen to the clivus/pharyngeal 
constrictor muscles and the neural crest components of the occipital region surrounding the foramen magnum. 
B-C. Illustrative maps from laser capture microdissection* showing the exact locations of the single cell samples 
isolated for whole transcriptome analysis, as well as a 10X magnification image of the nuclear counterstain in the area 
of interest. Section orientation is indicated. The clivus/pharyngeal constrictor region is shown in B, while the future 
occipital area around the foramen magnum is shown in C. 
**modified from M.A. Hill 2004; * Conditions for sample preparation, laser capture microdissection and subsequent whole 
transcriptome analysis are found in Materials and Methods. 
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Figure 8.2: Laser capture microdissection maps for the single neural crest cells isolated at E13 from the 
anlagen to the posterior cranial fossa/tentorium 
A. Human foetus- at 10 weeks of gestation; the area analogous to the one isolated for analysis in an E13 Wnt1-Cre+ l-
x ROSA26Lacz-l- mouse is highlighted (red box), comprising the future posterior cranial fossa (PCF)/tentorium. 
B-C. Illustrative maps from laser capture microdissection· of the PCF/tentorium showing the exact locations of the 
single cell samples isolated for whole transcriptome analysis, as well as a 10X magnification image of the nuclear 
counterstain in the area of interest. Section orientation is indicated. 
- Modified from M.A. Hill 2004; • Conditions for sample preparation, laser capture microdissection and subsequent 
whole transcriptome analysis are found in Materials and Methods. 
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Figure 8.3: Laser capture 
microdissection maps for the 
single cells isolated at E9-10 
from branchial arches ""IV 
and the post-branchial 
lumina 
A-C. Illustrative maps from 
laser capture microdissection of 
branchial arches III & IV and 
the post-branchial lumina 
showing the exact locations of 
the single cell samples isolated 
for whole transcriptome 
analysis. Section orientation is 
indicated . 
* Conditions for sample 
preparation, laser capture 
microdissection and 
subsequent whole 
transcriptome analysis are 
found in Materials and Methods. 
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Figure 8.4: Areas isolated for single cell transcriptome analysis of neural crest and mesodermal vasculature 
in the cranial base/meninges/arachnoids. 
Sagittal sections of the neurocranium immediately prior to birth at E18.5 after conception (positive vaginal plug is 
taken as EO); Wnt1-Cre+l- XZ-DR-I- mouse. Images acquired with fluorescence on an Arcturus PixCell II LCM; GFP 
expression (de novo) indicating neural crest cells (green, 8, 0, F) and nuclear counterstain DAPI (blue, A, C, 0). 
A-B. Neural crest derived meninges/arachnoids at the tentorium are neural crest in origin; 
in A each number indicates the locations of the corresponding single cell sample. 
C-O. Neural crest-derived vasculature at the axial level of the cochlea; in 8 each number 
indicates the locations of the corresponding single cell sample. 
E-F. Heterogeneity of the origins of the vasculature of the cranial base; whereby samples 
were captured (white numbers in E) from both neural crest (green) and non-neural crest 
vasculature. 
Dermis 
Rostral ~ 
It 
~ 
-I/) I/) 
o 
0:: 
* Conditions for sample preparation, laser capture microdissection and subsequent whole transcriptome analysis are 
found in Materials and Methods. 
280 . _______________ _ 
----- ----,,---
Table 8.1: Details of strain, stage, and region of single cells captured for transcriptome analyses. 
STRAIN STAGE REGION SINGLE CELLS CAPTURED 
Wnt1-CrexROSA28LacZ E13 Cliws_Phayngeal Constrictors 18 
Wnt1-CrexROSA28LacZ E13 Foramen magnum 21 
Wnt1-CrexROSA28LacZ E13 Posterior cranial fossa 26 
Wild-Type E9-10 Branchial arches IllIIV 25 
Wnt1 -CrexROSA28LacZ E 13 Control non-PONC cells 7 
Wnt1-CrexXl-DR E18.5 NC-derived meninges 8 
Wnt1 -CrexXl-DR E 18.5 NC-derived vasculature 17 
Wnt1 -CrexXl-DR E 18.5 Mesoderm-derived vasculature 15 
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TRANSGENIC SPECIMEN BREEDINGIISOLATION 
• Genotype to confirm samples are Wnt1-cre +1- x 
Rosa26LacZ +1- or -1- ; Xl-DR -I-
t 
SINGLE CELL LASER CAPTURE MICRODISSECTION 
• Confirm lineage origins during capture 
t 
eDNA AMPLIFICATION FROM TOTAL RNA 
• Confirm amplification on agarose gel 
t 
eDNA REAMPLIFICATION 
• Confirm reamplification on agarose gel 
• Confirm gene expression (transgene/housekeeping 
gene) with PCRI Southern hybridisation 
• Confirm quality with qPCR 
t 
eDNA FRAGMENTATION & BIOTIN LABELLING 
• Confirm quality and concentration of neat cDNA 
(Bioanalyzer) 
• Confirm successful fragmentation (Bioanalyzer) 
t 
• 
HYBRIDISATION TO MICROARRAYS 
Background correction 
• AffyBatch controls 
MULTIVARIATE 
CLUSTER ANALYSIS 
• Exclude samples that 
do not cluster 
GENE EXPRESSION 
PROFILING 
• Exclude samples that 
do not meet 0/0 
present threshold 
Figure 8.5: Optimised workflow for single cell transcriptome analysis 
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Figure 8.6: Optimised workflow for single cell transcriptome 
analysis studies 
A. Example of samples isolated via laser capture microdissection. 
Left panel shows a blood vessel at 10X immediately post-capture, 
with the black rind indicating the region of capture. To the right are 
examples of single captured cells visualised on the isolation 
membrane (cap). Top left is a neural crest cell, lineage identify 
confirmed at the time of capture as it is a GFP+ cell from a Wnt1-
Cre+/- XZ-DR-/- mouse. Top right, a cell with only a hematoxylin 
and eosin histological preparation, in which the nucleus and cell 
boundaries are hard to distinguish. Bottom set of two images each 
show a single DAPI+ nuclei but dramatically differing cell shapes 
as the right-hand cell is vascular. 
B. Examples of cDNA smears on a 1.5% agarose gel after the 
initial reverse transcription step from total cellular RNA. A variety 
among the length and concentration of cDNA is evident. 
c. Diagrammatic representation of the re-amplification step (left) 
accomplished via PCR and cDNA smears on 1.5% agarose gels 
resulting from re-amplification. The length (ideally 500 -1000+ bp) 
and concentration of some samples is adequate, while others 
failed this quality contro\. 
D. Quality Controls post re-amplification: detecting a gene of 
interest. The LacZ transgene from single cells of Wnt1-Cre x 
R26LacZ mice, or a housekeeping gene such as GAPDH in any 
strain of mouse, can be confirmed using PCR (left) or Southern 
hybridisation (middle and right) using primers that anneal to the 3' 
end of the gene. 
E. Quantitative PCR for the housekeeping gene GAPHD can be 
used to discern between samples with high or low abundance 
GAPDH, used as a proxy for cDNA quality. This plot shows the 
results of several samples that had passed previous PCR-based 
quality controls. 
F. Agilent Bioanalyzer is the final quality control prior to cDNA 
hybridisation to microarrays: the concentration and characteristic 
curve of neat cDNA is analysed, as is the result of the DNAse 
fragmentation step. Neat cDNA should have a curve longer than 
500 and fragmented cDNA should not have dramatically 
diminished intensity and should be 25-500bp. 
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Figure 8.7: Principle component analysis 
plot of the transcriptomes of the first cohort 
of 12 single cell samples hybridised to 
microarrays 
Following all pre- and post-hybridisation quality 
controls, the transcriptomes of the first cohort of 
12 samples were subjected to clustering 
analysis. A plot of principle components 1 and 2 
(accounting for 99% of the variability within the 
samples) clearly divides the samples into two 
sets along the X and Y axes. To the left are the 
vascular samples from the E18.5 mice; versus 
all the non-vasculature samples from the E13 
m ice are to the right. Interestingly, the 
transcriptomes of mesodermal versus neural 
crest derived vasculature do not segregate the 
lineage origins. Among the E13 samples, 
principle component 1 clusters the three sub-
regions of neural crest cells, which may reflect 
region variation in the transcriptomes. 
* Sample preparation, hybridisation conditions 
and descriptions of statistical analyses can be 
found in Materials and Methods. 
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Figure 8.8: Principle component analysis plot of the transcriptomes of the total single cell cohort and results 
of AffyBatch quafity control for intensity 
A. The principle component plot of 21 samples from the total sample cohort which shows no discernible relevant 
clustering. 
B. The results of one quality control from the AffyBatch post-hybridisation report: overall array intensity. The first 
cohort of 12 samples (boxed in red) show an overall higher intensity compared to the subsequent 14 samples 
analysed (boxed in blue). Lowest intensity among the first twelve samples indicated in red line, and is higher than the 
blue counterpart. Notably, 4 samples within the blue cohort had acceptable intensity (red *) and were included in 
further analyses. 
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Figure 8.9: Principle component analysis plot of the 
transcriptomes of the first cohort of 12 single cell 
samples and 4 additional samples with acceptable 
intensity 
Following all pre- and post-hybridisation quality controls, the 
four samples with acceptable overall intensity were added to 
the first cohort of 12 samples and the transcriptomes of the 
16 samples were subjected to clustering analysis. A plot of 
principle components 1 and 2 (accounting for 99% of the 
variability within the samples) clearly divides the samples 
into two sets along the X and Y axes, with only sample 87 as 
an outl ier (yellow box in left cluster). To the left are the 
vascular samples from the E18.5 mice; versus all the non-
vasculature samples (bar #87) from the E13 mice are to the 
right. Notably, the samples to the bottom right most comer, 
comprising samples from 3 sub-regions of neural crest cells, 
have the lowest overall array coverage and this clustering 
may be due to that fact. For further analysis, only 12 
sampled that successfully pass all QC and have %present > 
4% were included in the analysis. 
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Table 8.2: Expression of Hox genes in single cell samples from the whole transcriptome analysis study. Hox 
expression from microarray indicates a post-otic or cervical origin of the samples. 
Hoxbl Hoxdl Hoxa2 Ho){a3 Hoxa4 Hoxb4 Hoxd4 Hoxc6 Hoxb6 Hoxb7 Hoxe8 Hoxd8 Hoxb9 Hoxc13 
4_Mesodermal Vasculature 
11 Mesodermal Vasculature 
£18.5 131=NC Vasculature 
19_Meninges 
87 _Pre-Foramen Magnum 
18_Pre-Foramen Magnum 
80 _Clivus_Pharyngeal Constrictors I x x 
E13 139_PCF 
45]CF 
48_PCF 
x 
x 
x x 
'2aB 
x 
x 
x 
x x 
x 
x 
x 
x 
x 
~---... --- - ---... - ,.,-.. 
Table 8.3: Expression of genes in the LTBP pathways in single cell samples from the whole transcriptome analysis 
study. The LTBP pathway is active in 4/5 of the vasculature samples and one sample from the loose condensation 
surrounding the posterior cranial fossa, which may later differentiate into vasculature. P, present; A, absent. 
E18.5 Wnl t .ere x Xl-DR E13 Wnt1.ere x ROSA26LacZ 
4_Meso 1 1_~.1eso 3UIC 19J1eninges 27 _Meninges 24_Loose 39_PCF 45_PCF 48_PCF 87 _ForMag 18_ForMag 80 Vase Vase Vase PCF Mes Cli/Ph 
-
Gene 
Probe Set ID Symbol 
1438312_s_31 Ltbp3 P P P IA P P l A A A A A A 
1418049_al ltbp3 A lP J A A P A A A A A A A 
1418061_::It ltbp2 A A A A P A A A A A A A 
1436665_3_31 ltbp4 A A A A A A A A A A A A 
1448870 at Llbp1 A A A A A A A A A A A A 
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Figure 8.10: The effect of the LTBP pathway on the basoccipital-
basisphenoid synchrondroses 
Alcian blue (cartilage) and alizarin red (bone) histological preparations 
of wild-type (A,C) and LTBP-3 null mice (B,O). In A-B the left image is 
the cranial base of animals 3 weeks after birth, where LTBP-knockout 
mice show premature fusion of the synchondroses indicated in the 
wildtype between the occipital (oc), sphenoid (sp) and pre-sphenoid 
(ps) bones. The right images in A-B show sagittal sections through the 
clivus at 3 days after birth; the L TBP-3 knockout mutant (B) has 
abnormal ossification in the skull base, precocious ossification is 
indicated by an advanced zone of vascularised (hypertrophic) 
chondrocytes, and an abnormal, narrow synchondrosis. 
C-D. Differences in the ossification of the wild-type and LTBP-3 
o mutant are evident at 1.5 days after birth. C & D top to bottom: 
~ hematoxylin, Safranin 0 and Fast green stain, immuno stain for 
'? Collagen X, immuno stain for Collagen II, and masson's trichrome 
~ staining for bone. The mutant has advanced bone fronts compared to 
I- the control , as well as a wider zone of hypertrophic chondrocytes . 
.....J Arrows indicate fronts of basioccipital and basosphenoid bones. h, 
hypertrophic chondrocyte zone; f , resting chondrocyte zone; p, 
proliferating chondrocyte zone; ph, prehypertrophic chondrocyte zone. 
Modified from Oabovich et a/. 2002 . 
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Table 8.4: Expression of collagens in the 
single cell samples from the transcriptome 
analysis study. All samples, regardless of 
lineage origin or fate are enriched for collagen 
expression. Present calls indicated with green 
box, absent in white. 
8.3 Summary of findings 
- Single cell laser capture microdissection followed by microarray analysis 
can be used to successfully probe cellular transcriptomes with the newly 
optimised protocol; 
- Cell fate may correlate more significantly with gene expression than 
lineage; 
- Whole transcriptome analyses cannot differentiate between neural crest 
and mesodermal-derived vasculature in the cranial base; 
- Among the anlagen to the bone structures in the cranial base, whole 
transcriptome analyses may indicate there are regional differences among 
sub-populations of neural crest cells; 
- The L TBP pathway is active in the vasculature of the cranial base and may 
play a role in defining the angulation/retroflection of the clivus and 
subsequently the overall size of the PCF, which is reduced in 100% of Chiari 
1/11 patients; 
- The link between vascular development and pre-mature ossification may 
indicate Chiari is a vasculogenic disorder; 
- Expression of connective tissue-related genes is enriched in both the late 
and early neural crest populations contributing to cranial base formation and 
vascularisation, supporting previous work that links Chiari to connective 
tissue disorders. 
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9. Discussion & concluding remarks on Chiari as a neurocristopathv 
9.1 Establishing Chiarl as a neurocristopathy 
Correlating the symptoms of Chiari with the pathognomic structure giving rise 
to them, and establishing if these structures are of neural crest origin was our 
first proxy for linking Chiari as a neurocristopathy. The symptoms included in 
the analysis were those associated with the pathognomic deficiencies most 
widely reported in Chiari, not based on actual symptom prevalence as 
absolute prevalence is hard to determine (given symptoms are self-reported 
by patients, the majority of Chiari patients are not included in large scale 
studies, and differences among the studies' methods may make 
comparisons among them difficult). As a result, the symptoms that fall within 
the current analysis include some of the most common (ex: headaches, 
category A) and least common (ex: facial sensory loss, group F) reported to 
effect Chiari 1/11 patients (Milhorat et al. 1999; Speer et al. 2000; Mueller and 
Oro 2004). The current correlation study is the first to find commonality 
among the vast majority of the symptoms of Chiari 1/11, with that commonality 
being the neural crest origins of the affected structures. The correlation study 
relied on previously published fate maps and experimental evidence from 
work undertaken in our laboratory in 2005; as such, the mesodermal 
contributions to some of the areas affected in Chiari (including, but not 
limited to, the lateral components of the posterior fossa, the dorso-Iateral 
components of the foramen magnum, C1 and C2 defects including 
retroflexed odontoid process and cranial venous defects) were not explored. 
Furthermore, based on correlation studies it is impossible to postulate in how 
far the lineage origins contribute to generating the phenotype as cell-cell 
interactions and other environmental or developmental factors may be 
causative of the complaint. In addition, even if cells of a certain lineage are 
primarily responsible for generating the Chiari malformations, the erroneous 
cell-fate decisions, gene expression and malfunctioning signalling pathways 
are not explored by mapping the symptoms to the pathognomic deficiencies. 
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One pathway that has developmental significance and may be involved in 
generating the Chiari phenotype was explored: the sonic hedgehog (SHH) 
pathway. A transgenic strain of mouse was obtained by our laboratory (gift of 
T. McMahon) in which the smoothened (SMO) receptor was ablated in a 
lineage-specific manner in neural crest cells. This transgenic mouse 
replicated one aspect of the Chiari phenotype, namely the loss of the 
attachment point of the pre-vertebral ligament. The fact that the other 
pathological features of Chiari were not recapitulated in the mutant indicates 
a variety of signalling pathways are likely to play a role in the Chiari 1111 
malformations. This complexity is reflected in the fact that no single gene has 
been linked to Chiari, which contrasts with several other cranio-facial 
anomalies that share some symptoms of Chiari, which can be mapped to 
mutations in a single gene, such as Apert's syndrome (FGFR2 mutations 
(Wilkie et al. 1995; Lomri et al. 1998», Cleidocranial dysphagia (Runx2 
mutations (Mundlos et al. 1997; Baumert et al. 2005», Craniosynostosis 
(MSX2 mutations (Jabs et al. 1993», Saethre-Chotzen syndrome (TWIST1 
mutations (el Ghouzzi et al. 1997; Howard et al. 1997», and Pfeiffer 
syndrome (FGFR1 or FGFR2 mutations (Muenke et al. 1994; Tartaglia et al. 
1997». Accepting that Chiari is likely to be a syndrome of compounding 
factors, further analyses focused on defining the precise anatomical defects 
of the malformations. 
9.2 Homing In on the anatomical defects of Chia,i VII 
To refine the current study of Chiari 1111 and establish if it is, indeed, a 
neurocristopathy candidate, I examined the neural crest contribution to the 
precise anatomical defects primarily responsible for the characteristic 
cerebellar herniation in the syndrome. Previous studies have confirmed that 
the size of the brain is not accountable for the over-crowding resulting in the 
herniation, but rather this is the fault of a reduced overall volume (on average 
40%) of the posterior cranial fossa (PCF) housing the cerebellum (Milhorat et 
al. 1999). Diminished PCF volume is attributed to length of the supraocciput 
and clivus (Koyanagi and Houkin 2010) and basioccipital hypoplasia (Noudel 
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et al. 2009). Therefore, the shortened cranial base and its reduced 
retroflection is likely caused by premature stenosis of the spheno-occipital 
synchondrosis, which usually closes after the first decade of life (from 9 
years old onwards) and may explain the late onset of Chiari "". A key factor 
in establishing the timing and mechanics of endochondral ossification is the 
vasculogenesis of the anlagen. To our surprise, a late contribution of the 
neural crest to the vasculature of the endochondral areas of the cranial base 
affected in Chiari "" has been observed. The neural crest derived 
vasculature was found in elements of the clivus, and also in the supraocciput 
(whose height is reduced in Chiari I and affects tentorial angle), the occipital 
protuberance, and the atlas/axis (which is responsible for the retroflexed 
odontoid process in Chiari I). Intriguingly, there was no neural crest 
contribution to the vasculature of the exoccipital condyle at the stage 
currently examined (E18.5). Our results may indicate that the primary 
anatomical defects of Chiari are caused by a hyper-ossification whereby the 
invasive neural crest contributes to precocious vascularisation of the 
endochondral bone resulting in early maturation of the bone leading to the 
phenotypical malformations. Alternatively, if vascular invasion is stunted a 
hypo-ossification phenotype would result. Because only a single time-point 
was sampled, it cannot be discerned if the neural crest vasculature arises 
from adjacent structures (which are of mixed neural crest and mesodermal 
origins) and develops concurrently with the mesodermal vasculature or are a 
late migrating population, although the lack of a neural crest contribution to 
the vasculature of these structures in previously published studies of earlier 
developmental stages indicates the latter possibility. 
This finding is intriguing as it shows there is a striking similarity between the 
blood vessel supply in dermal bones (See Part I) and that of endochondral 
vasculature in the cranial base. As endochondral bone is phylogenetically 
younger than dermal bone, it is possible that programmes of vasculogenesis 
involving neural crest cells were co-opted in evolution into this new 
ossification process. Moreover, it acts as a cautionary tale regarding the time 
window of fate maps as it is likely that many more human diseases that have 
previously been characterized as mesodermal in origin might actually be 
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neurocristopathies due to the invasive nature of these populations. Notably 
neural crest cells appear to preferentially invade at points where they also 
act as attachment regions of musculature, i.e. at regions of pharyngeal 
constrictors (of the clivus region) and dorsally in the interparietal region 
surrounding the occipital protuberance that acts as attachment region of the 
trapezius (Matsuoka et al. 2005). 
In addition to a reduced PCF volume, Chiari 1111 is characterised by a 
reduction in volume and flow of cerebrospinal fluid. Results of our lineage 
analysis have revealed that neural crest-derived cells comprise the meninges 
of the cortex and medulla, as well as the arachnoids of these regions and the 
spinal cord. Conversely, the cerebellar meninx are mesodermal in origin. The 
finding that meninges of the cerebellum are not neural crest, but meninx of 
forebrain and hindbrain are, is at odds with previous findings of Etchevers 
and Couly. This warrants additional exploration into previously established 
fate maps, formulated in chick, which may not accurately reflect the lineage 
contributions to mammalian vasculature. 
Neural crest cells are also found to contribute to the vasculature of the 
cortex, supplying both the endothelia and the pericytes of some vessels. The 
current study also confirmed that the vasculature of the cranial base is a 
mosaic of both neural crest and mesodermal origins. The neural crest 
meninges and vasculature, if aberrant in any way (ex: compliance, fluid 
skew, etc.) could be responsible for the sub-occipital headaches reportedly 
experienced by up to 98% of Chiari 1111 patients (Mueller and Oro 2004). 
Conceptually, increased intracranial pressure (ICP) due to PCF over-
crowding could also be a contributing factor to the headaches; however 
mechanical relief (via decompression surgery) does not always ameliorate 
the condition (personal communication, Conquer Chiari Research 
Conference 2008 & 2010). There is a highly variable response to 
decompression surgery, and continual headaches after surgery could result 
from an overabundance of pain receptors within the meninges involved in 
pain sensation and/or the mechanical composition and architecture of the 
meninges and cranial vasculature. 
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The discovery of the contribution of the neural crest to the vasculature of the 
cranial base further indicates Chiari "" could be a neurocristopathy and may 
even be a vasculogenic disorder. However, these studies do not shed light 
on the exact gene expression and pathways involved in generating the 
cranial base and to explore this, the transcriptomes of the anlagen to the 
structures affected in Chiari "" were probed. 
9.3 Single-cell transcriptome analysis 
Single-cell transcriptome analyses were conducted on the neural crest cells 
in areas affected in the Chiari "" malformations at the time of cell-fate 
decisions (E13 in the mouse) including: anlagen to the clivus/pharyngeal 
constrictors, the mesenchymal condensation precursors to the posterior 
cranial fossa and the foramen magnum. Additional transcriptome analyses 
included the E18.5 neural crest meninges and the mature vasculature in the 
cranial base to determine if there are differences in the transcriptomes of 
neural crest versus mesodermal vasculature. 
The protocol used was generated in a 2003 study by Tietjen et al. and 
required extensive optimisation for use in the current analyses (see 
Technical Appendix 11.2). While I am confident the optimised protocol is 
now sufficient for studies of this nature (and produces similar array coverage 
to previously published studies (Kamme et al. 2003; Tietjen et al. 2003», 
following the optimisation and inclusion of new quality controls there were not 
enough samples in each experimental group to generate statistically 
significant differential gene expression profiles. The data generated in the 
current study was, instead, used to explore crucial pathways expressed in 
the majority of samples that may be linked to Chiari. Differential analysis 
confirmed the cells from E18.5 were all vascular in nature and some cells 
from the PCF anlagen and one sample from the Clivus_Pharyngeal 
Constrictor region may also have been vascular precursors (see Technical 
Appendix 11.2). Clustering analYSis indicated that the transcriptomes of the 
vasculature samples are more similar to one another than they are to the 
cells from the mesenchymal condensations; although this may also reflect 
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the cells from E 13 being less terminally differentiated than the vasculature 
samples. The clustering analysis was not biased by array coverage or 
hybridisation efficiency as the final quality controls removed samples that 
may have had low array intensity biases, low gene expression or poor array 
coverage (under 4% present hits) (see Technical Appendix 11.2). The 
principle component clustering in the final 12 samples, therefore, likely 
reflects genuine differences in the transcriptomes of the single cells profiled. 
The majority of the E18.5 vasculature (4/5 samples) expressed genes in the 
L TBP pathway; this was true for samples from the meninges, neural crest 
vasculature and mesodermal vasculature. The L TBP pathway was also 
active in a cell captured in the loose mesenchyme surrounding the 
cerebellum at E13, which could indicate this cell had a vascular fate. The 
L TBP pathway was not active in the bone-precursor cells from E13, which is 
unsurprising as the L TBP pathway plays a role in endochondral bone 
maturation mediated by vascular invasion and chondrocyte hypertrophy. 
Interestingly, all the cells profiled (from all regions and time-points) were 
enriched for expression of a multitude of collagens. This correlates with 
previous assertions that Chiari links to connective tissue disorders (Milhorat 
et al. 2007). Given the importance of collagens in providing structural support 
and scaffolding for bone development, it is likely that connective tissue 
defects could playa role in the hyper and hypo-ossification in Chiari 1111, as 
well as in compliance issues of the vasculature. 
Future studies that introduce additional samples into the experimental cohort 
would lead to the ability to generate statistically significant gene expression 
profiles of the regions of interest. Notably, in light of the concurrent study on 
dermal bone development, described in Part I, it would be prudent in the 
future to further refine the regions from which cells are isolated as 
mesenchymal condensations and bone formation may be more complex than 
previously anticipated. 
9.4 Conclusion and future perspective 
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Results presented here support classifying Chiari as a neurocristopathy and 
confirm the areas involved, both skeletal and vasculature, are neural crest in 
origin. Several anatomical regions previously thought to be void of neural 
crest have been shown to be of mixed neural crest and mesodermal origins 
and many include a late invasion of neural crest vasculature. The defects 
giving rise to Chiari 1111 are likely to occur in only subsets of cell populations, 
given that the vast majority of the neural crest derived tissues (and the 
adjacent mesoderm) are unaffected. In fact, a unifying component of the 
Chiari malformation is it seems to primarily involve tissues of mixed origins 
and/or those whose lineage is still being elucidated. At this stage it is 
impossible for us to postulate which is more important: the initial cell fate 
decisions of the neural crest cells in the regions affected, or the contributions 
of the newly-identified late invasion of the neural crest. The invasive neural 
crest may be responsible for the maturation of the bones at the cranial base, 
but in order to elucidate how this process occurs a further time-course 
analysis of cranial base vascularisation is warranted. Additionally, single-ce" 
analysis of the neural crest vasculature in the endochondral bones of the 
cranial base is feasible if cell isolation is accomplished via dissociation rather 
than laser capture. Dissociation of tissues to isolate cells may also be less 
disruptive to RNA than the laser capture process. 
Finally, while there are no mouse models of Chiari 1111, Marin-Padilla and 
colleagues demonstrated that retisnoic acid (RA) shock (via injecion of high 
doses of vitamin A) at day EB in hamster gestation resulted in offspring with 
Chiari-like phenotypes, including: cerebellar herniation, a flattened cranial 
base, a shortened basioccipital, problems with the odontoid process and 
what today would be called tethered cord syndrome (Marin-Padilla and 
Marin-Padilla 19B1). Further studies in mice have revealed that RA shock to 
EB.5-9.5 mice will result in the same syndromic features (Kessel 1992). 
Retinoic acid Signalling is, therefore, likely to play a part in developing the 
Chiari phenotype and RA shock and the resulting retention of Froriep's 
ganglion (with their high volume of nociceptive neurons) may be responsible 
for the hypersensitivity and chronic headaches of Chiari patients (Goldstein 
et al. 1996; Fanarraga et al. 1997). A cursory examination of the single cell 
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samples from our transcriptome analysis reveals that 11/12 of the final 
samples in the experimental cohort express genes associated with retinoic 
acid signalling (Table 9.1). Future work correlating the teratogenic action of 
RA with the development of the Chiari phenotype in mice (via RA shock at 
defined developmental time-points and a time-course analysis of the 
malformation development) could elucidate the roll of retinoic acid signalling 
in the Chiari malformations and may also clarify if early cell fate decisions or 
late NC invasion is more important to developing the phenotype. 
300 
Table 9.1: Expression of genes associated with retinoic acid signalling in the single cell transcriptome analysis study. 
P, present; A, absent. 
E18.5 Wnt1 .cre x XZ-DR En Wnl1 -cre x ROSA26Lacl 
4 Meso 11 Meso 31 fK 19 Meni 27 Meni 39 PCF 45 PCF 48 PCF 24_Loose 87 _ForM 18_ForM 80 Vase Vase Vase nges nges - - - PCF Mes ag ag Cli/Ph 
Gene 10 
Rbpl P P P P P A A A \p P IA P 
Aldh2 A A A A A A A A A A A A 
Crabpl A A A A A A A A O A A A Rxra A A A A A A A A P A A 1M 
'-. [[: IA Rxrb P A A A A A A A A A 
Rarres2 A P A A Ip A A A A A A A 
Parpl A A P A A A A A ~ IA A A 
Parp2 A A P A A A Ip jA A A A A 
Parp3 P P A A A A A A ip IA A A 
Parp4 A A A A A P l A A A A A A 
Parp9 A A A A A A A A A A rp A 
Parp14 A A A A A A A A A A A P 
'--
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10. Materials & Methods 
10.1 General Molecular Biology 
10.1.1 Genomic DNA Preparation: Genomic DNA (gDNA) for polymerase 
chain reactions (PCR) was purified from cells (-5 x 106 cells) and tissues 
(maximum 25 mg) using a DNeasy Blood & Tissue Kit (Qiagen) according to 
the manufacturer's instructions with no modifications. gDNA was eluted in 
30-50 ~L under low salt conditions and sample concentrations were 
measured using a NanoDrop ND-1000 Spectrophotometer, operated by ND-
1000 V3.6.0 software. 
10.1.2 Standard peR (template <2 kb): All probes and amplifications of 
target DNA/cDNA described herein were amplified via gradient PCR in a 
Mastercycler Gradient PCR machine (Eppendorf) using a final volume of 20 
I-IL, comprising 25 ng/I-IL genomic DNA or 1 0 pg/~L plasmid DNA combined 
with a master mix of: 0.125 U/~L AmpliTaq® DNA Polymerase, 1x PCR 
Buffer II, 2.5 mM MgCI2 (Applied Biosystems), 0.5 mM dNTP (Roche), 0.5 
~M primers. Reactions containing gDNA were supplemented with 10% 
DMSO (Sigma). Thin-walled 0.2 mL tube trips (Helena Biosciences) were 
used for all PCR reactions. 
Standard PCR protocol was as follows: initial denaturing at 94°C for 2 min, 
followed by 30 cycles of [30 sec denaturation at 94°C, 30 sec of annealing at 
60°C +/- 10-15°C, 1 min per kb extension at 72°C] and a final extension of 10 
min at 72°C, followed by a 4°C hold until analysis. 
Note: Annealing temperatures were modified if the optimal primer annealing 
temperature, as defined by Primer-Blast, is beyond the 59-61°C range. 
10.1.3 Visualising DNA, RNA and eDNA: All PCR products, plasmid 
digests and DNA smears were visualised on 0.8-2% agarose gels (Helena 
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Biosciences or SeaKem) in 1 xTAE supplemented with 6% Ethidiumbromide 
(Sigma) via the addition of 1xDNA loading dye. Gels were run at 80-100V in 
a horizontal gel electrophoresis system (VWR International). 
Fragments requiring purification were run on 0.8-1.5% high quality agarose 
(Seakam) gels, also in 1 xT AE and 6% Ethidiumbromide, run at 80V until 
proper separation was achieved. 
10.1.4 Gel Extraction: DNA fragments were isolated from high quality 
SeaKem GTG Agarose gels using a scalpel under UV Light on a High 
Performance UV Transilluminator. The fragment was purified using a 
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer's 
instructions with no modifications. 
10.1.5 Ladder Marker: Sizing of nucleotide fragments was based on a 
ladder marker with the final concentration 0.2 mg/mL AHindlll DNA 
(Fermentas) and q>174BsuR1 DNA (Fermentas) as illustrated below: 
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10.1.6 Sequence Alignment, Visualisation and Annotation: Comparative 
sequence alignments were performed using MegAlign from the Lasergene® 
software package (DNAstar). Sequence visualisation and annotation were 
performed using Seq Builder (DNAstar). 
10.1.7 Primer Design: Primers were designed using Primer-BLAST software 
(NCBI), with mus musculus as the reference species. Input sequences were 
entered as FASTA files, optimal product size was chosen, and melting 
temperatures were set (minimum 57°C, optimal 60°C. maximum 63°C). The 
program automatically generates the most common binding from BLAST 
results and primers were selected such that they were exclusive to the target 
of interest and would not yield ulterior products (especially when being used 
with genomic DNA). 
10.1.8 Plasmid Propagation 
10.1.8a Plasmid Propagation: Re-growth of plasm ids was achieved in 
chemically competent One Shot ® TOP10 E.Coli cells (Invitrogen C4040-1 0). 
Tranformations were performed with the following protocol: cells were 
thawed from -80°C on ice for 20 min then 2-3 ~L of plasmid DNA was added, 
cells were returned to ice for a further 20 min then heat shocked at 42°C for 
30 sec, 200 ~L SOC was added and cells were immediately returned to ice 
for a minimum of 5 min. Cells were shaken horizontally for 1 hour and plated 
on LB/Amp selective plates. Colonies formed overnight at 37°C in a bacterial 
incubator (Sanyo). 
Single colonies were isolated and grown in 4-6 mL of LB selective media , 
incubated at 3rC overnight with shaking. Plasm ids were purified with 
Qiagen Miniprep kits (Qiagen. 27106) according to the manufacturer's 
protocol and the concentration of the isolated plasmid was determined on a 
NanoDrop ND-1000 Spectrophotometer operating ND-1000 V3. 6.0 software. 
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10.1.8b Modifications for TOPO Plasm ids were as follows: the cloning 
reaction consisted of 2 J,JL PCR fragment (50-100 ng DNA), 1 J,JL TOPO 
vector, 1 J,JL salt solution (1.2M NaCI, 0.06M MgCL2), and 2 J,JL dH20; this 
was mixed gently and incubated for 5-15 min (depending on the length of the 
insert) at 37°C. The transformed cells were plated onto LB-AMP plates 
augmented with 100 J,JL of 20 mg/mL X-gal (plated 30 min prior to the 
addition of cells). Successful TOPO transformations resulted in white 
colonies used for further analysis. 
10.1.9 Sequencing Plasmids: Sequencing was performed at Warwick 
University by the Molecular Biology Service of the School of Life Sciences. 
Typically 200 - 500 ng of DNA was combined with 5.5 pmol of a single 
sequencing primer (see below) and brought to a total volume of 10 J,JL using 
dH20. Samples were run on a 3130x Genetic Analyser (Applied Biosystems) 
operating BigDye Terminator Version 3.1. 
Sequencing Primers, Name 5'-3' 
M13Fwd: tgtaaaacgacggccagt 
M13Rev: caggaaacagctatgacc 
10.1.10 Restriction Digests: Restriction enzyme mediated plasmid 
digestions were achieved using enzymes purchased from New England 
Biolabs. Standard digests consisted of: 3 J,Jg DNA plasmid, 3 J,JI restriction 
buffer (as recommended by manufacturer), 1.5 J,JL restriction enzyme, dH20 
to a total volume of 30 J,JL. Reactions were incubated in a bacterial incubator 
overnight at 37Co. The digestion (complete and not over-fragmented) was 
confirmed using gel electrophoresis (section 10.1.3). Linearised plasm ids 
were then column purified (QIAquick PCR Purification Kit). 
10.2. Animal Work 
10.2.1 Supply & Husbandry: Transgenic (Wnt1-Cre, ROSAEYFP, 
ROSALacZ, Hand2, Xl-DR) and wild-type (SV129/B6 background) mice 
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were housed/maintained by the BSU facilities at Warwick University. 
Transgenic and wild type mice were obtained from projects with authority to 
breed animals of that type and to provide them for use on other projects in 
accordance with current legislation in the UK (Animals Scientific Procedures 
Act 1986). Embryos isolated for analysis at the stages indicated were 
collected after timed matings in which the date of a positive plug was taken 
as EO. Genetically modified strains are established lines; no transgenic lines 
were generated as part of this study. Transgenic alleles are designated with 
a "-"; conversely. wildtype alleles are designated by "+". 
10.2.2 Generation of Transgenic Animals 
10.2.2.1 Generation of transegenic animals, Wnt1-Cre x ROSA26LacZ: 
Neural crest cells were permanently labelled utilising the well-characterised 
Wnt-1 dorsal neural tube enhancer region (Rowitch 1998). The Wnt-1 
enhancer confers transgene expression on the entire dorsal neural tube 
neural crest precursor population. and their subsequent progeny (with the 
exception of NC-cells from rhombomere I. McMahon & Koentges. 
unpublished). Wnt1-Cre mice were crossed with Cre-reporter mice carrying 
transgenic floxed resistance-pA cassettes in front of LacZ under the control 
of ROSA26; this combination yields offspring in which the floxed cassettes 
are subject to Cre-mediated excision. The neural crest cells of these Wnt1-
Cre x R26-LacZ offspring can be visualised with either X-gal staining (LacZ). 
or labelled with an antH3GallLacZ antibody. Wnt1-Cre mice were obtained 
from the Jackson Laboratory (USA) and crossed with the ROSA26 reporter 
mice also obtained from Jackson Laboratory (USA). 
10.2.2.2 Generation of transgenic animals, Hand2-Cre x ROSA26LacZ: 
Hand2-Cre mice express Cre-recombinase under the control of a 7kb 
upstream region of Hand2 (Ruest et al. 2003). Specimen and live mice were 
provided by D. Clouthier. Hand2-Cre mice were crossed with ROSALacz 
mice to generate the Hand2-Cre x ROSA26LacZ line. Cells in which Cre-
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mediated excision has taken place can be labelled with an anti-J3-Gal 
antibody for visualisation. 
. 
10.2.2.3 Generation of conditional knockout, Handt'lfl x Wnt1-Cre-
R26Lacz, bred and maintained by H. Yanigasawa at the University of Texas 
(Dallas): Hand2 was specifically deleted in neural crest cells using the 
following method: briefly, 10xP sites were inserted into the Hand2 allele 
flanking exon 1 in the 5' UTR (Hendershot et al. 2007). Handt"fl mice display 
a normal phenotype and have normal Hand2 expression, validated by qRT-
PCR (Hendershot et al. 2008). Excision of Hand2 and visualisation of the 
cells in which the excision has taken place, is achieved by crossing the 
Hancf111f1 mice with hemizygous Wnt1-Cre and homozygous ROSA26LacZ 
mice. Specimen (torso) and slides (cranio-facial) of Hand2fl1f1 x Wnt1-Cre+l- x 
R26Lacz+l- mice were provided by H. Yanigasawa and D. Clouthier. 
10.2.2.4 Generation of targeted deletion of Hand2 BA enhancer, bred 
and maintained by O. Clouthier at the University of Colorado: Hand2 
expression in the branchial arches requires the Endothelin-1 (ET -1) 
enhancer. This 208 bp enhancer was" deleted using homologous 
recombination (Yanigasawa et al. 2003). The enhancer lies within a 754 bp 
XHOI-BamHI fragment, which was replaced with a 10xP-f1anked neo 
cassette. Cre-mediated excision results in BAenh-l- mice. Specimens 
provided by 0, Clouthier. 
10.2.2.5 Generation of XZ-DR, bred and maintained by X. Zhang, University 
of Warwick. The XZ-OR transgenic is a Cre-reporter strain of mice generated 
by Dr Xintao Zhang. XZ-OR mice carry transgenic f10xed resistance-pA 
cassettes in front of GFP under the control of the Ubiquitin C promoter. 
Wnt1-Cre mice were crossed with the XZ-OR-reporter yielding offspring in 
which the f10xed cassettes are subject to Cre-mediated excision. The neural 
crest cells of these Wnt1-Cre x XZ-OR offspring are permanently labelled 
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and can be directly visualised under fluorescence or by labelling with an anti-
GFP antibody. Specimen that had been isolated, and embedded fresh (no 
fixation treatment) were provided by X. Zhang. 
10.2.3 Genotyping: Genotyping of transgenic animals was performed using 
PCR on tissue isolated via genomic DNA isolation (see 10.1.1 above) of 
embryonic limbs and/or tails, or via HotSHOT genomic DNA extraction (see 
10.2.3.1 below) from ear punches or embryonic materials. PCRs were 
performed using specific primers and protocols, as described below. 
10.2.3.1a HotSHOT Genomic DNA Extraction: Genomic DNA was isolated 
from single ear punches as follows (Truett et a/. 2000): 75 ~L of alkaline 
HotSHOTreagent (25 mM NaOH, 0.2 mM Disodium EDTA, pH12) is added 
directly to the tissue and incubated at 95°C for 10-60 min with occasional 
vortexing, until the tissue is dissociated; 75 ~L of Neutralising reagent (40 
mM Tris-HCL (Sigma), pH 5) is added directly to the sample and temperature 
is reduced to 4°C for 1 hour. This preparation was then stored at -20°C until 
it was used directly for PCR reactions (1-5 ~L per 20 ~L reaction). 
10.2.3.1b HotSHOT Genomic DNA Extraction From Embryonic 
Materials: Genomic DNA isolated from embryonic materials (including limbs 
and tails of embryonic mice from stages E10-E18) were performed as above 
with the following modifications: 75-200 ~L of HotSHOT reagent is added to 
the tissue (as appropriate for the tissue volume); tissue is boiled or heated at 
95°C for >1 hour until the majority of the tissue has dissolved; 1 volume of 
neutralising reagent is added and the solution is chilled at 4°C for 1 hour. 
DNA is precipitated from the solution as follows: 1/10 volume 5 M NaCI was 
added to equalize ionic concentrations; 2 x 100% EtOH (chilled to -20°C) 
was added and the solution was mixed thoroughly; the mixture was 
incubated at -20°C for at least one hour then centrifuged at 13,200 rpm for 
15-20 min; the supernatant was discarded and the pellet was washed with 
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200 ~L 70% EtOH at -20°C then centrifuged for a further 5 min; the 
supernatant was discarded and the pellet was air dried in an extraction hood 
until the pellet was dry and clear; the pellet was resuspended in the desired 
volume (up to 50 ~L) of dH20 (Ultrapure TM/GIBCO). 
10.2.3.2 peR for Genotyping: PCR reactions for genotyping were set up as 
follows in 20 ~L total volume: 3-5 ~L gDNA isolated using HotSHOT or 250-
500 ng gDNA isolated from 1.1; 0.5 mM dNTP (Roche), 0.5 ~M Primers; 2.5 
mM MgCL2; 1 x PCR Buffer II; 0.125 U/L Amplitaq®; 10% DMSO (Sigma); 
brought to 20 ~L volume using DNAse/RNAse free distilled water 
(Ultrapure TM/GIBCO). Protocol for PCR was as follows: initial denaturation 20 
sec at 94°C, N cycles of [denaturation 30 sec at 94°C, annealing 30 sec at 
XOC [see table below], extension 30 sec at 72°C], followed by a final 
extension of 10 min at 72°C and a 4°C hold until peR products are analysed 
on a 0.8-2% Agarose + 6% Ethidiumbromide gel. All primers for individual 
genotyping reactions, N number of cycles and annealing temperature X are 
listed below: 
Transgenic 
Allele Primer (Name: 5'-3') X Annealing 
Temperature 
IMR0015: CAAA TGTTGCTTGTCTGGTG 
IMR0016: GTCAGTCGAGTGCACAGTTT 
Wnt1-Cre 61°C 
IMR1398: CCTCTATCGAACAAGCATGCG 
IMR 1399: GCCAA TCTATCTGTGACGGC 
Sor1: AAAGTCGCTCTGAGTTGTTAT 
Rosa26LacZ SoQ:GCGAAGAGTTTGTCCTCAACC 61°C 
Sor3: GGAGCGGGAGAAA TGGA TATG 
Sor1: AAAGTCGCTCTGAGTTGTTAT 
Rosa26EYFP Sor3: GGAGCGGGAGAAA TGGA TATG 68°C 
IMR4982: AAGACCGCGAAGAGTTTGTC 
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Hand2-Cre 
TWCre1: GCTGGTIAGCACCGCAGGTGTAGAG 
TWCre3:CGCCATCTICCAGCAGGCGCACC 
Expected Fragment Sizes 
Strain Transgene Wild type Allele 
Wnt1-Cre 322 bp 200bp 
Rosa26LacZ -300 bp (Sor1,Sor2) 603 bp (Sor1,Sor3) 
Rosa26EYFP 320 bp (Sor1,IMR4981) 603 bp (Sor1,Sor3) 
Hand2-Cre 500 bp 
Reference 
Jackson Labs 
Soriano 1999 
Jackson Labs 
D. Clouthier 
10.2.4 Project licence, Analysis of the kinetics of dermal bone 
mineralisation: Experiments for labelling mineralised bone matrix were 
undertaken under a new project licence (Home Office reference 
PPL7017118) held by K. Jordan. The licence contains one protocol, "Injection 
of labelling agents,· see Section 10.2.4.1 below for details. 
10.2.4.1 Injection of Labelling Agents: Animals obtained by continued use 
were used to map a time-course of bone mineralisation and to track newly 
synthesised cells within the bone. Concentrations of labelling agents were 
chosen such that the labelling was expected to be conferred to the dam and 
her offspring, without any pharmacological side effects (see below). 
10.2.4.1a Route: Labelling agents were administered via intraparitoneal 
injection to mouse dams. Dosages were sufficient to confer the agents to the 
foetuses to achieve embryonic labelling. 
310 
Labelling Agent 
Calcein 
Doxycycline 
Xylenol orange 
Dosage 
10 mg/kh 
50 mg/kg 
90 mg/kg 
Reference 
Sun et a/. 1992 
Pautke et a/. 2005 
Sun et a/. 1992 
10.2.4.1 b Labelling Agents and Dosages: Mineralised bone was 
permanently labelled at 2-3 time-points between E11 and PO with non-
harmful fluorescent dyes including fluorochromes and tetracyclines. Labelling 
agents were chosen that could be visualised without any treatment to 
enhance signal in emission areas with non-overlapping spectra such that 
they could be concomitantly analysed. Dosages were established from 
literature values, as below, and were prepared in Phosphate Buffered Saline 
(PBS, 137 mM NaCl, 2.7 mM KCI, 8 mM Na2HP04, 1.4 mM KH2P04,pH 7.4) 
and sterilised prior to administration. 
10.2.4.1c Collection of Specimen and Subsequent Analysis: Specimen 
subjected to the protocol were terminated via an appropriate Schedule 1 
method and the tissues were harvested (no sooner than 3 days after the last 
injection). Samples were fixed in fresh 4% PFA overnight, embedded in OCT 
(Optimal Cutting Temperature) media (TissueTek, VWR) and stored at -BO°C 
until cryostectioning. Cryosectioning was performed on OTF 5000 Cyrostat 
(Bright, UK) at a thickness of 15-17 !-1M. Samples were counterstained with 
1: 1000 DAPI (Invitrogen) and 1: 100 Rhodamine-Phalloidin-555 (Invitrogen) 
and Image Acquisition and Analysis were conducted as per details below 
(see Sections 10.4.4 & 10.4.5). 
** 4% PFA Preparation: 500 mL of 4% PFA stock was prepared as follows: 
20 g of PFA was diluted in dH20, 3-4 drops of 10 N NaOH was added and 
the solution was heated to 65°C. PBS (tablet form, Sigma) was added to 
obtain a 1 x PBS solution and the solution was chilled on ice. The pH was 
confirmed (-7.5) and the solution was aliquoted and maintained at -20°C. 
Prior to use aliquots were thawed at a temperature not exceeding 37°C. 
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10.3. Single-Cell Laser Capture Microscopy 
10.3.1 Sample Preparation: Embryos from wildtype (SV129/B6), Wnt1-Cre 
+1- x Rosa26LacZ -1- and Wnt1-Cre +1- x XZ-DR -1- crosses were isolated at 
the following time-points after timed-matings: E9.5-10 (SV129/B6), E13 
(Wnt1-Cre x LacZ), and E18-19 (Wnt1-Cre x XZ-DR). Pregnant dams were 
terminated via Schedule 1 (cervical dislocation) and embryos were dissected 
from the uterus and placed in ice-cold PBS, their tails were removed for 
genotyping (see Section 10.2.3) and the embryos were embedded (fresh, no 
fixation) in the sagittal or coronal orientation in OCT (optimal cutting 
temperature) mounting media (TissueTek, VWR). Samples were stored at -
80°C until such time as they were cryosectioned on an OTF 5000 Cyrostat 
(Bright, UK) at a thickness of 7 IJm onto charged (for immunohistochemistry) 
or non-charged slides (for laser capture microdissection) (both Superfrost, 
VWR). 
10.3.1.1 Staining Cryosections for Laser Capture Microdissection: 
Sections for laser capture dissection were stained using the following 
protocols at room temperature in an extraction hood using fresh reagents in 
coplin jars. SV129/B6 & Wnt1-Cre x LacZ: 70% EtOH 2 min, dH20 rinse, 
Mayer's Hematoxylin (Sigma) 2 min, dH20 rinse, Scott's Tap Water 
Substitute (Bluing Reagent) (Sigma) 1 min, 70% EtOH 10 sec, 95% EtOH 
10 sec, Eosin Y (Sigma) 20 sec, 95% EtOH 30 sec, 95% EtOH 30 sec, 100% 
EtOH 1 min (Sigma), 100% EtOH 1 min, Xylene (Sigma) 5 min, Xylene 5 
min, air dry 15 min. 
XZ-DR: 70% EtOH + 5:1000 DAPI (Invitrogen) 2 min, 95% EtOH 10 sec, 
95% EtOH 30 sec, 100% EtOH 1 min, 100% EtOH 1 min, Xylene 5 min, 
Xylene 5 min, air dry 2 min. 
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10.3.2 p-Galactagosidase Staining: j3-Gal staining of Wnt1-Cre x 
ROSA26LacZ permanently labels all cells in which the Cre-mediated 
excision has taken place; thereby allowing visualisation of all post-otic neural 
crest cells and their progeny. 
10.3.2.1 Whole Mount J3-Gal Staining: Wnt1-Cre+/- x Rosa26LacZ-I-
embryos were fixed in freshly prepared 4% buffered PFA on ice for 30 min 
with shaking, then rinsed twice with PBS. Next the sample was washed for 5 
mins at room temperature on a nutator with Solution A (0.1 M Phosphate 
Buffer pH7.4 (Sigma), 2 mM MgCI2 (Sigma), 5 mM EDTA (Sigma»; fresh 
solution A was then added for a further 25 min. The sample was then shaken 
for 10 min at room temperature in Solution B (0.1 M Phosphate Buffer pH7.4 
(Sigma), 2 mM MgCI2 (Sigma), 0.01 % Sodium Desoxyxholate in dH20 
(Sigma/GIBCO), 0.02% Nonidet (Sigma). Fresh, pre-warmed Solution B was 
then added for a further 10 min at 37°C. Solution B was then replaced with 
freshly prepared Solution C (Solution B supplemented with 5 mM 
Ferrocyanide (~Fe(CNa» , 5 mM Ferricyanide (K3Fe(CNa» and 1 mg/mL X-
Gal) and the sample was incubated overnight at 3rC in the dark. The 
following day, embryos were washed 2 x 10 min with Solution B, pre-warmed 
to 37°C, then post-fixed in 4% PFA for further storage. 
10.3.2.2 Cryosection J3-Gal Staining: Cryosections of fresh (un-fixed) 
sections were fixed in fresh 4% PFA for 10 min at room temperature, rinsed 
three times with PBS, then subjected to the following serial solutions: 
Solution A for 2 x 10 min at room temperature; Solution B for 20 min at room 
temperature; pre-warmed Solution B for 10 min at 37°C; Solution C overnight 
in the dark at 37°C. The following morning slides were washed in pre-
warmed Solution B, 2 x 10 min at 37°C. Slides where rinsed 2 x PBS, post-
fixed in 4% PFA for ten minutes, rinsed 2 x PBS and counterstained. 
Counterstaining consisted of: 2 min in Mayer'S Hematoxylin (Sigma), 2 min in 
Scott's Tap Water Substitute (Bluing Reagent) (Sigma) and mounted in 
Clarion (Sigma) or Mouwiol aqueous mounting medium. 
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Embryos and sections that were stained with I3-Gal were used for reference 
of the cellular origins of structures being subjected to LCM and for correlating 
pathognomic deficiencies with symptoms of Chiari (see below). 
10.3.3 Laser Capture Microdissection (LeM): Cells were captured from 
slides prepared as above using a PixCell II Laser Capture Microdissection 
microscope as described by the manufacturer; cells were captured onto 
clean caps from Molecular Devices. Cells were captured using the minimum 
power and duration necessary to isolate the cells; if necessary (for unusually 
thick or re-hydrated tissues) modifications from the standard were applied for 
optimal capturing. The amount of cells per capture was estimated from 
visual ising the cells on the cap (H&E and/or DAPI stain) and the regions 
being captured were photographically documented. 
10.3.4 cDNA Generation (modified from Tiejen et al. 2003): Post-capture, a 
microneedle in an RNAase-free environment was used to seed individually 
captured cells into thin-walled PCR tubes (Perkin-Elmer) containing 4 1-11 of 
ice cold lysis buffer (containing Nonidet P40 (USB), MMLV 1 st strand buffer 
(Fisher), RNAase inhibitor (Applied Bioscience), SO OD/mL pd(T)24 (Operon) 
and 12.S mM each of dATP, dCTP, dGTP, and dTTP (all Fisher». Cells were 
lysed at 65°C for 1 min followed by a S min room temperature incubation to 
anneal oligo-dT to RNA. First-strand cDNA synthesis was initiated by adding 
6:1 (vol:vol) MMLV (200 U/J..IL) and AMV (15 U/J..IL) reverse transcriptases 
(both Invitrogen) followed by 37°C incubation for 15 min then heat 
inactivation at 65°C for 10 min. poly(A) was added to the first-strand cDNA 
product via a tailing buffer (100 U Terminal Transferase (Roche) & TdT 
buffer (Invitrogen), plus dATP) at 37°C for 15 min, followed by 10 min heat 
inactivation at 65°C. PCR buffer was then added to sample (containing 2.5 
mM MgCI2, 100 IJg/mL BSA, 1 mM dNTPs, 0.05% Triton, S J..IG AL 1 primer 
(see table below for sequence) as well as 14 U AmpliTaq (Invitrogen». peR 
amplification was then performed as: 25 cycles of [1 min at 94°C, 2 min at 
42°C, 6 min at 72°C with 10 s extension per cycle]. An additional 5 U of Taq 
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polymerase was added before performing 25 additional PCR cycles (no 
extension time between cycles). Following first-strand synthesis, 10 uL of 
cDNA was run on a 1.5% agarose gel for 70 minutes at 80V to visualise the 
smear of DNA from 0.4 - 1.2 kB, confirming the success of the reaction. 
Initial cDNA amplification yields approx 10-20 I-Ig of cDNA from RNA of 
individual cells; re-amplification of 2.5-5 I-IL of each PCR-purified cDNA 
product is then undertaken (reaction contains 1-5 I-IL original cDNA plus 100 
I-IL PCR mix: 2.5 mM MgCI2, 0.2 mM dNTPs, 5 U AmpliTaq, and 5 I-Ig AL 1 
primer) with 30 cycles of [1 min 30 sec at 94°C, 2 min at 42°C, 3 min at 
72°C]. Samples are run in triplicate and the PCR product is purified (Qiagen 
kit according to manufacturer's instructions), eluted in 30 I-IL and pooled. 
cDNA concentration is measured using a NanoDrop Spectrophotometer; 
typical yield from the reamplification reaction is 30 I-Ig. 
OLIGOS (from MWGEurofins/Operon) 
AL 1 primer: ATT GGA TCC AGG CCG CTC TGG ACA AAA TAT GAA TTC (T)24 (0.2 
umol scale) 
Oligo dT24 (0.2 umol scale) 
10.3.5 Southern Hybridisation: Quality of cDNA was checked by Southern 
blot. 10 I-IL aliquots of cDNA, ladder marker and a positive control plasmid 
were run on 2% agarose gels for 2 hours at 80V. The gel was depurinated in 
a 0.2 N HCL solution for 25-30 mins, denatured in a 0.5 M NaOH + 1.5 M 
NaCL solution for 25 mins, and neutralised in 1. 5M NaCL+ 0.5 M Tris pH7.5 
solution for 25 mins. The gel was blotted on a pre-wet nylon transfer 
membrane (Hybond N+, Amersham) for 2 hours at constant pressure in a 
posiblotter (Stratagene). cDNA was UV crosslinked onto the membrane and 
cDNA transfer was confirmed under UV-light. 
The blot was and hybridized with DNA probes for the transgene of interest 
(LacZ), as well as the ubiquitously expressed gene GAPDH. 
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10.3.5.1 Generation of Probes for Southern Hybridisation: Probes were 
designed to correspond to the 3' region of the gene in question, in line with 
the 3' bias of the cDNA. The probe was generated using 5-9 IJL of gel 
purified DNA fragment (details of plasm ids and restriction digest (all New 
England Biolabs) in table below) brought to a volume of 24 IJL using dH20; 
10 IJL of random oligonucleotide primers were added to the fragment and 
boiled for 5 min then put on ice for 3-5 min; following chilling, 10 IJL of 5X 
Primer buffer was added and the solution was moved to the radioactivity 
suite. 
In the radioactivity suite, -250 ng of cDNA was radioactively labelled with 50 
IJCi of aP 32 dCTP via Klenow extension with Klenow enzyme (5 U/J..IL) 
(Roche). The probe-solution was incubated for 15 min at 37°C, purified on a 
NucTrap column (pre-wet with 80 J..IL of 1xSTE solution) in a BETASheild 
Push column device, and collected in a 1.5 mL Eppendorf tube. Probe 
labelling efficiency was measured using 1 IJL of labelled probe in 7 mL 
Ecoscint scintillation fluid on a Beckman counter. Probe labelling was 
considered a success with a count >250,000 cpm. Hybridisation (BUCK) 
Buffer was generated using Na2HP04, 20% SDS, BSA and dH20, to which 
boiled herring sperm DNA (Promega) was added 1:100. The nylon blot was 
pre-hybridised in native BUCK Buffer (no hot probe) for 30-60 min, after 
which the probe was boiled for 2-5 min and added to the Hyb solution in a 
final concentration of 1-2x106 cpm/mL. The membrane was hybridised with 
the hot probe overnight at normal stringency conditions (60 0 e). The next 
morning the nylon membrane was washed 2 x 20 min with the wash solution 
(0.5% SDS, 0.05xSSC in dH20) at the hybridisation temperature. The 
membrane was stored on x-ray film (Kodak Fujifilm) and was exposed for 
one night to one week in an x-ray cassette at -80°C, after which the film was 
developed. 
Gene Primers, Name: 5'·3' 
1 (Fwd}:TICMCATCAGCCGCTACAG 
LacZ 
4(Rev}:GCGGTTGGAA T AA TAGCGAG 
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Plasmid 
P128, pCRII 
TOPO 
REfor 
Digest 
EcoRI 
GAPDH N/A pCRIl TOPO, Gift EcoRI from K. Vance 
10.3.6 PCR: The presence of several genes in the cDNA was confirmed via 
PCR, conducted as in Section 10.1.2. Primers were designed as in Section 
1.7. Genes and their primers are detailed below. 
Gene Forward, Name: 5'-3' Reverse, Name: 5'-3' 
2: 
LacZ 1 :TTCAACATCAGCCGCTACAG TTTCCTTACGCGAAATAC 
GG 
3:TTCAACATCAGCCGCTACAG 4:GCGGTTGGAA T AA TAGCGAG 
6:CCAGCTGGCAGTTCAGGCC 7:AACGATCGCCAGTTCTGTAT 
AATCC GAACG 
Twist 1 : GCTGAGCAAGA TTCAGACCC 2:TTCTTCGTCAAAAAGTGGGG 
3:AA TTCACAAGAA TCAGGGCG 4:CAGTTTGATCCCAGCGTTTT 
Tlx 1 :GTGACACCAGGAGGGACAGT 2:ACTCCACCAAAA TCACCAGC 
GAPDH Fwd: Rev: GTGAGGGAGATGCTCAG CTTCACCACCATGGAGAAGGCC TGTTG 
10.3.7 qPCR: To evaluate the internal control, GAPDH, qPCR was carried 
out on an ABI PRISM 7000 Sequence Detection System, operating ABI 
Prism 7000 software (both Applied Biosystems). PCR reactions consisted of: 
1x TaqMan Gene Expression Master Mix (Applied Biosystems), 1x mouse 
GAPD (GAPDH) Endogenous Control (FAM/MGB Probe, Non-Primer 
Limited), 2 IJL reamplified cDNA, in a total volume of 20 1Jl. To generate 
standard curves that cover the same range of amplification as the laser 
captured samples, serial dilutions of a single, well-characterised sample 
were analysed, as well as an RT -negative control. All reactions were 
performed in triplicate. Results were analysed using Microsoft Excel 
(Microsoft). 
10.3.8 Tissue Culture (to Isolate control cDNA): All cell culture 
experiments were carried out using aseptic technique in a Class II 
Microbiological Safety Cabinet (Walker Safety Cabinets Ltd.). Commercially 
procured cell lines were maintained in their optimal media supplemented with 
fetal bovine serum (FBS) at 37°C in a 5% CO2 humidified Galaxy R Incubator 
(Wolf Laboratories). Once confluent or at their desired time-point, cells were 
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washed twice with phosphate buffered saline (PBS) and trypsinised with 1 x 
0.05% trypsin-EDT A. Cells were incubated at 37°C until rounded and 
detached then resuspended in 10mL growth medium. Cells suspension was 
then transferred to a sterile 50mL falcon tube and cells were pelleted at 1000 
rpm for 4 min at 21°C. At this point the cell pellet was used to harvest RNA 
and reverse transcribe cDNA (see 10.5.4.1 below), or for cell passage as 
follows. For passaging, the cell pellet was re-suspended in growth medium 
and cultured at an appropriate dilution. Cells for image analysis were grown 
on fresh, charged slides 0JWR); once cells reached their harvest time they 
were washed twice with PBS and stained using the protocols for 
immunohistochemistry (see 10.4.2 below). 
10.3.8.1 RNA Isolation from Cultured Cells: RNA was isolated from cell 
lines (approximately 1x107 cells/isolation) using an RNeasy mini kit (Qiagen) 
according to the manufacturer's instructions, with no modifications. Total 
RNA was eluted using RNAse/DNAse free water in a volume of 30 ~L and 
concentration was determined using a nanodrop (Section 1.1). RNA was 
stored at -80°C. 
10.3.8.2 eDNA Generation: First strand cDNA was synthesised from total 
cellular RNA using the SuperScript III First-Strand Synthesis Systems for RT-
PCR kit (Invitrogen), according to manufacturer's protocol with no 
modifications. 
10.3.9 Bioanalysis: Prior to microarray analysis, cDNA quality was analysed 
using a 2100 Bioanalyzer (Agilent Technologies). Samples of whole, 
unfragmented cDNA, as well as fragmented samples (prior to addition of 
Biotin) were measured. Samples were prepared with an RNA kit and the 
output consisted of the fluorescent intensity, the running time, RNA (cDNA) 
area and RNA (cDNA) concentration. Bioanalyzer traces were used to 
qualitatively characterise the neat (whole, unfragmented) sample, to quantify 
the concentration of cDNA hybridised to the microarray chip, and to assess 
the result of the fragmentation. 
318 
10.3.10 Mieroarray Hybridisation 
10.3.10.1 eDNA Fragmentation: Prior to microarray analysis, cells that have 
passed quality controls (Southern hybridisation, PCR and/or RT-PCR, 
Bioanalyzer) are fragmented as follows: 15-20 IJg of re-amplified, purified 
cDNA is combined with 10X One-Phor-AII Buffer (Amersham) and -1 U of 
RQ1 DNAse (Promega) in a total volume of 60 IJL. Samples are incubated at 
37°C for 13 minutes then heat inactivated at 99°C for 15 minutes, after which 
1.5 J.JL is taken for bioanalysis (see Section 10.3.9). 
10.3.10.2 Biotin Labelling: Using the entire 58.5 IJL fragmented sample, 
biotin end-labelling is achieved by adding 1.0 mM Biotin-N6_ddATP (Perkin 
Elmer), and -20 U Terminal Transferase (Invitrogen). The sample is 
incubated at 37°C for 90 minutes then heat inactivated at 65°C for 15 
minutes and stored at 4°C until hybridisation to microarray. 
10.3.10.3 Hybridisation: Biotin labelled samples were hybridized to 
Affymetrix Gene Chip 430 v2.0a microarrays due to the comprehensive 
nature of the chips which house 39,000 transcripts per array. Hybridisation 
by the Warwick University Molecular Biological Services Unit followed the 
standard Affymetrix protocol for Eukaryotic Target Hybridisation. 
Hybridisation cocktail consisted of: 58.5 IJL cDNA (containing approximately 
15-20 IJg), 3.3 J.JL Control Oligonucleotides (B2), 10 J.JL 20x Eukaryotic 
Hybridisation Controls (bioB, bioC, bioD, ere), 100 IJL 2x Hybridisation Buffer, 
2 IJL Herring Sperm DNA (10 mg/mL), 2 J.JL BSA, 20 J.JL DMSO (Sigma), and 
dH20 (Ultrapure™IGIBCO) to a total volume off 200 J.JL, of which 130 J.JL is 
used for hybridisation. 
The hybridisation protocol was as follows: arrays were warmed to room 
temperature and the hybridisation cocktail was heated to 99°C for 5 min 
followed by 45°C for 5 min then spun at 13,000 rpm for 5 minutes to remove 
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insoluble materials; the array was wet with 1 xhybridisation buffer and 
incubated for 10 min at 45°C with rotation, then buffer is removed from the 
array and the hybridisation cocktail is added. Hybridisation takes place 
overnight at 45°C for 16 hours, rotating at 50 rpm. The next day the sample 
is pulled off the array and the array is washed twice according to the 
standard Affymetrix protocol. 
10.3.11 Microarray Analysis (Statistical): Prior to gene expression 
analysis, background corrections on the arrays were performed using the 
GeneChip Robust Multiarray Average package (GCRMA; 
http://www.bioconductor.org/packages/2.2Ibioclhtmllgcrma.html), which 
removes any bias created due to the nucleotide content of the probes (Naef 
and Magnasco, 2003). AffyBatch Quality controls were run on all the arrays 
to assess the overall array intenSity, density, 3'/5' ratios, and the presence of 
negative and positive border elements; further analyses were also conducted 
to assess RNA degradation. Dr Sascha Ott (Warwick University) developed 
small R functions based on the tools of the Bioconductor package 
(http://www.bioconductor.org/; Gentleman et a/., . 2004) for principle 
component analyses, gene expression analyses, analyses of overlap and 
differential expression between arrays. 
10.3.12 Correlating pathognomic defiCiency with symptom: Symptoms of 
Chiari were compiled via a primary literature search (see Bibliography) and 
medical resource and patient support websites including: 
www.conquerchiari.org/index.htm. http://chiarione.org/symptoms.html. 
http://www.ninds.nih.gov/disorders/chiari/detaiLchiari.htm. Aetiology of 
structures involved in these symptoms was derived primarily from Matsuoka 
et a/. 2005, Le Dourain & Kalchiem 1999, and from lineage labelling 
experiments in this study (see Section 1 0.3.2 ~-Galactagosidase staining 
above). 
320 
1004. Analysis of Dermal Bone Development 
10.4.1 Sample Preparation 
10.4.1.1 Samples for Immunohistochemistry: Samples were prepared as 
in Section 10.3.1, with the following modifications: specimen from embryonic 
stage E16 onwards were fixed overnight in fresh 4% PFA at 4°C, with the 
exception of samples from the Wnt1-Cre x DR-XZ cross. All specimen for 
immunohistochemistry from embryonic stage E 16 onwards were cut to a 
thickness of 12-17 ~m onto charged slides. 
10.4.1.2 Flat-Mount Bone Preparation: The murine frontal bone from one 
wild-type mouse at post-natal stage P2 was flat-mounted onto a slide as 
follows. The specimen was culled via cervical dislocation (Schedule 1) and 
fixed in 4% PFA at 4°C for one week. Following fixation the specimen was 
decapitated, the dermis was removed and the frontal bone was isolated 
together with the parietal and part of the nasal bones to ensure the frontal 
bone was undisturbed. The brain and meninges were dissected out and the 
sample was treated with permabilisation (0.1 % Triton) and counterstaining 
(1: 10,000 DAPI) overnight at 4°C. The following morning sample was rinsed 
3 times with cold PBS. The frontal eminence was separated along the frontal 
suture and the pars orbitalis removed to obtain a flat surface and mounted 
onto a charged slide into two orientations (one lobe with L 1 up and the other 
with L3 up). The bone was mounted with mouwiol and the slide was sealed 
with vacuum grease. The slide was imaged as described in Section 10.4.4. 
10.4.2 Immunohistochemistry: Multiplex immunohistochemistry was 
performed on sections of embryos from all crosses listed above (Section 
10.2.2), prepared as described in Section 10.2.4.1. Slides were defrosted at 
room temperature for 5 min, fixed in 4% paraformaldehyde for 15 min at 
room temperature, rinsed 3 x in PBS and blocked with permabilisation for 1 
hour at room temperature. Blocking Solutions are listed below, with 20% 
Roche Western Block Solution (WBS) (Roche) + 0.1 % Triton used as the 
default. Following blocking, primary antibodies were incubated at 4°C 
overnight in the Blocking Solution. The next morning samples were washed 
for 1-2 hours(s) with the Wash Solution associated with the given Blocking 
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Solution (see table below), with changes every 5-15 min. Secondary and 
conjugated antibodies were then incubated for 1 hr at room temperature in 
the Blocking Solution, followed by 1-2 hour(s) of washes (with frequent 
changes) and a PBS rinse. Slides with tyramide amplification (~­
Galactogosidase (AbCam) and Hand2 (R&D) antibodies) had the following 
additional steps: quenching of endogenous peroxidases with 0.3% H202 
during blocking; tyramide amplification (Perkin Emler Kit) with 5 JJI 
conjugated (FITC, Cy3 or Cy5) tyramide in 500 ~L Arnpli-Buffer for 10-15 
min; stopping of amplification reaction with 4% PFA or 0.01 N HCI for 10 min 
and 3 x PBS rinse. All slides were counterstained with DAPI (Invitrogen), 
administered either at 1: 1 000 for 5 min, or 1 :2000 for 20 min with Rhodamine 
Phalloidin (Chemicon 1 :250). Slides were then rinsed a final time in PBS and 
mounted in Mouwiol + DABCO. Slides were cover-slipped and sealed with 
nail varnish. Details of antibodies used can be found below. 
- Mouwiol Preparation: The following are combined: 6 g Glycerol (Sigma), 
2.4 g Mouwiol 4-99 (Calbiochem), 6 rnL dH20, 12 rnL 0.2M Tris Buffer 
pH8.5. The solution is mixed slowly for >3 hr after which 12 mL 0.2 M Tris 
Buffer pH8.5 is added and the mixture is stirred overnight on a warm plate. 
The following morning the Mouwiol is incubated for 10 min at 55°C, 
centrifuged at 5000 g for 15 min or until supernatant is clear. Supematant 
was removed and 2.5% w/v DABCO (1,4-diazobicyclo-[2,2,2]-octane, Sigma) 
was added to prevent fading. Mouwiol aliquots were stored at -20°C until 
use, at which point the temperature was raised to 37°C. For all mountings, 
30 ~L of Mouwiol are used. 
Blocking Solution 
20% Fetal Bovine Solution (FBS) (Sigma) in PBS + 0.1% Triton (Sigma) 
20% Roche Western Blocking Solution (WBS) (Roche) in PBS + 0.1 % 
Triton 
Superbloc (3 part Maleic Acid Buffer MAB, 1 part FBS, 1 part WBS) + 
0.1 % Trition 
* Slides undergoing tyramide amplification had 0.3% fresh Hydrogen 
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Wash Solution 
2% FBS/PBS 
2%WBS/PBS 
TBST + 1xWBS 
Peroxide (H202) added to the blocking solution 
PRIMARY ANTIBODIES 
Protein 
a-SMA-FITC conjugated 
a-SMA-cy3 conjugated 
J3-Catenin 
J3-Catenin 
J3-Ga lactagosidase 
CD31 (PECAM) 
Collagen I 
Collagen I 
Collagen I 
Collagen II 
Col14A1 (Undulin) 
CRABP1 
Decorin 
Fibronectin 
GFP 
Hand2 
MMP9 
MMP9 
MMP13 (VIIIA2) 
MMP13 (Hinge-Region) 
Notch (activated) 
Osteocalcin 
Osteopontin 
Periostin (POSTN) 
Runx2 
von Willibrand Factor 
WntSa 
SECONDARY ANTIBODIES & 
COUNTERSTAINS 
Antibody 
Host 
Mouse, 
IgG2a 
Mouse, 
IgG2a 
Mouse, 
IgG1k 
Mouse,lgG1 
Chicken, 
IgGY 
Rabbit,lgG 
Mouse,lgG1 
Rabbit,lgG 
Rabbit,lgG 
Goat. 
polyclonal 
Mouse, 
IgG1k 
Mouse, 
IgG2b 
Mouse. 
IgG2b 
Rabbit,lgG 
Chicken, 
IgGY 
Goat, 
polyclonal 
Mouse.lgG1 
Rabbit,lgG 
Mouse,lgG1 
Rabbit,lgG 
Rabbit,lgG 
Mouse,lgG1 
Rabbit.lgG 
Rabbit,lgG 
Mouse, 
IgG2a 
Sheep, 
polyclonal 
Rabbit,lgG 
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Working 
Dilution Company Reference 
1:200 AbCam ab8211 
1:200 Sigma C6198 
1:100 Millipore 05-665 
1:100 BD 610153 
1:500+Amp1: 
1500 Abeam ab9361 
1:20 Abeam ab28364 
1:200 Abeam ab6308 
1:100 Abeam ab21286 
1:100 Abeam ab59435 
1:100 AbCam ab24128 
HOOO0737-
1:250 Stratech M01 
1:100 Abeam ab2816 
1:200 AbCam ab54728 
1:100 Sigma F3648 
1:400 Abeam ab13970 
1:50+Amp1:1 
500 R&D AF3876 
1:200 AbCam ab58803 
1:200 Abeam ab38898 
1:100 Abeam ab52128 
1:100 AbCam ab39012 
1:100 Abeam ab8925 
NB600-
1:100 Stratech 1528 
1:100 Abeam ab63856 
1:100 AbCam ab14041 
1:200 Abeam ab76956 
1:500 Abeam ab11713 
1:100 AbCam ab72581 
Working Dilution Company 
DAPI 1:1000 Invitrogen 
Rhodamine Phalloidin (F-Actin) 1:250 Chemicon 
Rhodamine Phalloidin-555 (F-Actin) 1:100 Universal Sio 
goat anti-Rabbit AlexaFluor 546 1:200 Invitrogen 
donkey anti-Rabbit AlexaFluor 555 1:200 Invitrogen 
donkey anti-Rabbit AlexaFluor 488 1:200 Invitrogen 
donkey anti-Rabbit AlexaFluor 594 1:200 Invitrogen 
donkey anti-Rabbit AlexaFluor 647 1:200 Invitrogen 
donkey anti-goat AlexaFluor 594 1:200 Invitrogen 
donkey anti-goat AlexaFluor 488 1:200 Invitrogen 
donkey anti-goat AlexaFluor 555 1:200 Invitrogen 
donkey anti-goat AlexaFluor 647 1:200 Invitrogen 
donkey anti-sheep AlexaFluor 488 1:200 Invitrogen 
donkey anti-sheep AlexaFluor 546 1:200 Invitrogen 
donkey anti-sheep AlexaFluor 647 1:200 Invitrogen 
goat anti-chicken AlexaFluor 488 1:200 Invitrogen 
goat anti-chicken AlexaFluor 647 1:200 Invitrogen 
goat anti-mouse IgG1 AlexaFluor 488 1:200 Invitrogen 
goat anti-mouse IgG1 AlexaFluor 555 1:200 Invitrogen 
goat anti-mouse IgG2a AlexaFluor 488 1:200 Invitrogen 
goat anti-mouse IgG2a AlexaFluor 555 1:200 Invitrogen 
donkey anti-mouse IgG AlexaFluor 488 1:200 Invitrogen 
donkey anti-mouse IgG AlexaFluor 555 1:200 Invitrogen 
donkey anti-mouse IgG AlexaFluor 647 1:200 Invitrogen 
10.4.2.1 Matrix Labelling: In some instances, prior to slide mounting 
(following the immunological staining or in its absence), mineral matrix of 
bone was stained with a labelling agent, either: Calcein, Xylenol Orange, 
Doxycyline, Calcein Blue, or Alazarin Complexone (All Sigma). Labelling 
agents were made into solution with PBS, with 5 mg/50mL an effective 
concentration of all agents to allow visualisation of labelling (for spectral 
acquisition see Section 10.4.4.1). Slides were dipped in the labelling reagent 
324 
for 10 sec - 45 sec (concentration and agent dependent), rinsed several 
times with PBS then mounted as described above (Section 10.4.2). 
10.4.3/n Situ Hybridisation: to detect mRNA from transcribed genes. 
10.4.3.1 Generation of Antisense RNA Probes for ISH: Plasmids for 
generating RNA probes for in situ hybridisation were generated either via: a) 
PCR (as described in Section 10.1.2) of mouse genomic DNA, sub-cloned 
into pCRl1 TOPO and fully sequenced (Section 10.1.8b), or; b) regrowth of a 
clone from the NIA 15K collection (as described in Section 10.1.8a). 5 IJg of 
plasmid were linearised overnight (as described in Section 10.1.10) with a 5' 
overhang and purified with QIAquick PCR Purification Kit (Qiagen) according 
to manufacturer's protocols, eluted in a final volume of 50 IJL in Ultrapure® 
dH20 (GIBCO). 
RNA probes were synthesised from linearised plasm ids using RNA 
polymerase T7 or SP6 (Roche Diagnostics) in a 2 hour synthesis reaction 
(37°C) containing: 1 x DIG or Fluorescein RNA labelling mix, 1 x 
Transcription Buffer (Roche), 0.1 M OTT (Invitrogen), 1 U/IJL RNAse inhibitor 
(Promega), in a total reaction volume of 20 IJL. Synthesis was confirmed by 
running 1 IJL of reaction mix on a 1 % Agarose Gel. RNA was precipitated for 
1 hr - overnight at -20°C after the addition of 2.51JL 4M LiCI and 60 IJL 100% 
EtOH. RNA was pelleted (centrifugation at 13,200 rpm for 20 min at 4°C) and 
the pellet was washed with 70% EtOH, centrifuged for 5 min (13,200 rpm, 
4°C) with the supernatant discarded, then air dried in an extractor hood until 
clear and re-suspended in 50 IJL Ultrapure® dH20 (GIBCO). 
Gene Plasmid RE Polymerse Detects Note 
Last Performed 
Hand2 pBR43 BamHI T7 Exon by B. Ryll 
Runx2 Type II pKJR211 Spel T7 Intron1 Fail 
Runx2 TypelnJ pKJR2UI Xhol SP6 Intron2 Fail 
10.4.3.2. Fluorescent RNA ISH on Mouse Cryosections: 
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Day 1: Acetylation, Pre-Hybridisation and Hybridisation: Single and double 
fluorescent RNA ISH was carried out using a protocol designed and 
optimised by X. Zhang, modified from Scharen-Wiemers and Gertin-Moser. 
Cryosections were prepared as in Section 10.3.1. Sections were defrosted, 
fixed in fresh 4% buffered PFA for 15 minutes and rinsed 3 x in PBS (3 min 
each) then incubated in Acetylation Solution (0.1M TEA, 0.02M NaOH, 
0.75mL Acetic Anhydride) for 10 min at room temperature. Sections were 
next washed 3 x in PBS and incubated for 2 hours at room temperature with 
Hybridisation Buffer (50% Formamide, 5x SSC [from stock 20xSSC = 3.0 M 
NaCL, 0.3 M Sodium Citrate], 5 x Denhardts [from stock 50xDenhardt's = 
1%w/v Ficoll400, 1% Polyvinylpyrrolidone (PVP), 1%BSA], 0.25 mg/mL 
Baker's yeast tRNA, 0.5 ~g/mL Herring Sperm DNA). The DIG, DNP or 
FITC-Iabelled RNA ISH probe (200-400 ng/mL per target gene) was boiled 
for 5 min, placed on ice, then added to the Hydybridisation Buffer. The 
sections were hybridised with 100-200 ~L Hyb Buffer (containing probe), 
coverslipped and placed in a humidified chamber (5xSSC, 50% Formamide) 
overnight at 68-72°C. Separate chambers were used for slides with different 
probes to avoid cross-contamination. 
Day 2: Post-Hybridisation Washes & Immunological Staining: Coverslips 
were removed in pre-heated (hybridisation temperature) 5xSSC. Slides were 
washed 2 x 30 min in pre-heated (hybridisation temperature) 0.2xSSC, then 
5 min 0.2xSSC at room temperature. Immunological staining was conducted 
as follows: slides were incubated for 5 min in Solution B 1 (0.15 M NaCl, 0.1 
M Tris pH7.5) then blocked for 1-2 hours with B2 (B 1 supplemented with 
10% Fetal Bovine Serum (FBS) (Invitrogen». Slides were next labelled by 
incubating them with 500 ~L B2 + antibody (1 :30,000 Anti-Fluorescin-POD 
(Jackson), 1 :4,000 anti-DIG-POD (Roche) or 1 :,1000 anti-DNP-POD (Perkin 
Elmer» at 4°C, overnight in a humidified chamber. The next morning slides 
are rinsed 3 x 5 min with PBS. 
Day 3- end: 
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Single Fluorescent ISH: Slides were washed 3 x 30 min at room temperature 
with B 1. Tyramide amplification was achieved using 3.2 IJL FITC/Cy3/CyS 
conjugated Tyramide in 200 IJL 1 xPlus Amplification Solution (Perkin Elmer); 
amplification was conducted at room temperature for a probe-dependent 
time ranging from 30 min - 2 hours. POD activity was then quenched with 
0.01 N HCL for 10 min, room temperature (dark). Slides were washed a 
further 3 x 3 min with B1*. Slides were counterstained for S min with 1:1000 
DAPI (7x10-4M, Invitrogen) in Utrapure® dH20 (GIBCO), washed 3 x dH20 
and mounted with Mouwiol and sealed with nail varnish. 
* For Double ISH, move to 'Double Fluorescent ISH' at this point. 
Double Fluorescent ISH: Double ISH were performed as above and Day 2 
is repeated using a second antibody (1 :30,000 Anti-Fluorescin-POD 
(Jackson), 1 :4,000 anti-DIG-POD (Roche) or 1 :,1000 anti-DNP-POD (Perkin 
Elmer)). Probes are typically developed in the following order: FITC, then 
Cy3, then CyS. 
Brightfield ISH on Mouse Cryosections: Protocol is the same as above 
with the following modifications: Day 2 Immunological Staining (overnight 
4°C) was achieved with B2 Solution containing 1/2000 anti-DIG-AP (Roche 
Diagnostics). On Day 3 the slides were washed 3 x 30 min at room 
temperature with B1 then S min with B3 (O.1Tis pH9.S, 0.1M NaCI and SOmM 
MgCI2). A development step is then completed with B3 supplemented with 
6.7S U/mL NBT and 3.S U/mL BCIP substrates (both Roche), in the dark for 
3 hrs to overnight. Development is quenched by washing the slides in B3 for 
10 min, then a PBS wash for 10 min, at room temperature. Sides were then 
mounted with Mouwiol. 
10.4.4 Image Acquisition: Confocal microscopy was performed at Warwick 
University using Leica TCS SP2 and SP5 systems using 10x, 20x, 40x, 63x, 
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and 100x lenses. Alexa Fluor 488 was excited at 488 nm and emission was 
measured around 500 nm on the FIlC channel; Alexa Fluors 546, 555, RPh 
and Cy dye 3 were excited at 543 nm and emission measured around 555 
nm (TRITC channel). Alexa Fluor 647 and Cy dye 5 were excited at 633 nm 
and emission measured around 655 nm. OAPI stain was excited at 364 nm 
and emission measured around 400 nm. Reflectance images were acquired 
by exciting with the 488 laser and collecting using PMT. The measurement 
range was optimised to guarantee no overlap or bleed-through between the 
channels. All image acquisition occurred in the x, y and z-planes, resulting in 
a z-series. The average z-series comprised a step size of -0.4-0.9 ~m and 
the entire depth of the section was imaged. Brightfield images were acquired 
at Warwick University under a dissecting microscope, in a single optical 
plane. 
10.4.4.1 Image Acquisition: Matrix Labelling 
Samples that had been subjected to mineralised matrix labelling were 
imaged with the following parameters to ensure no spectral overlap occurred. 
Labelling 
Agent Excitation/Emission 
Alizarin 
complexone 530-580 1624-645 
Calcein 495/517 
Calcein blue 373 1420-440: 
Doxycycline 390-4251 520-560 
Xylenol 
orange 440/570/610: 555 
10.4.5 Image Analysis 
SP5 Laser 
DPSS 561 
Ar 100 mW 
(488) 
Diode 20 mW 
(DAPI) 
Diode 20 mW 
(DAPI) 
DPSS 561 
SP2 Laser 
HeNe 1.SmW 
(543) 
Ar 100 mW 
(488) 
Diode 20 mW 
(DAPI) 
Diode 20 mW 
(DAPI) 
HeNe 1.5mW 
(543) 
Overlaps: 
FITC 
DAPI 
RPh 
10.4.5.1 Image Analysis, 20: 20 image reconstructions were completed 
using LeicaLiteAS and Adobe Photoshop softwares. Images were either of 
individual optical sections from a z-series, or collapsed maximal or average 
projections of z-series. Image files from the confocal were converted into 
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colour and channels were superimposed. Adjustments for brightness and 
contrast were made, in a linear fashion to the entire image, as needed. 
10.4.5.2 Image Analysis, 3D: All 3D reconstructions of z-series were 
created using the freeware BiolmageXD developed by the Universities of 
Jyvaskyla and Turku in Finland and the Max Planck Institute of Germany: 
World Wide Web http://www.bioimagexd.net. 
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11. Technical Appendices 
11.1 Technical Appendix: Determining the emission spectra of in vivo 
labels for the biomineralised matrix 
Prior to in vivo experimentation, described in Chapter 3.3, the emission 
spectra, as visible on a Leica SP2 confocal microscope, was determined for 
each of the potential labelling agents that could be used in the study. A total 
of nine chelating agents were successfully used in previously published 
studies of in vivo analyses of endochondral biomineralisation: alazarin 
complexone, SAPTA, calcein, calcein blue, doxycycline, rolitetracycline and 
tetracycline hydrochloride (published dosages, and the expected 
excitation/emission spectra of each are found in Table 11.1.1). For the 
purpose of the current study, I chose to focus on four of these labelling 
agents: alizarin complexone, cal cein, xylenol organe and doyxcyline. To 
confirm it is possible to image the labelling agents without overlap, previously 
untreated slides from wild-type mice were subjected to histological addition 
of each agent (at in vivo concentrations) and imaged. The resulting 
wavelength (A) range of the emission spectra, when excited with various 
wavelength lasers, was documented and extensive overlap was seen 
between the four compounds. The total detectable emission spectra for each 
compound is shown in Figure 11.1.1, with the optimal range indicated with a 
bold bar. For each agent, the optimal detection range (as well as the total 
range in which the dye is visible) was determined on the laser that 
corresponded to the recommended excitation range, as published. Once the 
optimal wavelength range for detecting the labelling agent (denoted OPT) 
was determined, I measured the bleed-through to other channels, as well as 
the emission detected in the OPT range when the agent was excited by the 
other lasers on the SP2 confocal microscope. The resulting images of these 
investigations (with the compound, excitation laser and wavelength detected) 
are presented in Figures 11.1.2 to 11.1.7. 
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Alazarin 
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Doxycycline 
ExcitationfEmission 
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Figure 11 .1.1: The emission wavelengths of 4 chelating agents as 
determined experimentally 
The recommended in vivo dosage was histolgically added to sections of wild-
type, newborn mice. Maximal range indicated by line, OPT (optimal range for 
detection) indicated by bar. Emission spectra is significantly wider than reported 
in the literature. 
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Alazarin 405 laser, 
AOPT 
Alazarin 488 laser, 
AOPT 
Alazarin 496 laser, 
AOPT 
Alazarin 514 laser, 
A OPT 
Figure 11.1.2: Emission spectra of alazarin complexone 
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I 
I 
Alazarin 543 laser, A. 
OPT 
Alazarin 633 laser, A. 
OPT 
Alazarin 543 laser 
A. 610-670 
Figure 11.1.3: Emission spectra of alazarin complexone 
continued 
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Calcein 476 laser, 
AOPT 
Calcein 488 laser, 
A 500-550 OPT 
Calcein 476 laser, 
A 480-500 
Calcein 496 laser, 
AOPT 
Calcein 488 laser, 
A 490-500 
Calcein 488 laser, 
A 570-600 
Figure 11.1.4: Emission spectra of calcein 
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Calcein 488 laser, 
A 576-600 
Doxycycline 405 
laser, 
).. 520-560 OPT 
Doxycycline 405 
laser, 
)..470-510 
Doxycycline 405 
laser, 
Doxycycline 405 
laser, 
).. 450-470 
Doxycycline 405 
laser 
A 470-490 
Doxycycline 405 
laser 
).. 470-490 
Doxycycline 405 
laser, 
).. 500-520 
Figure 11.1.5: Emission spectra of doxycycline 
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Doxycycline 458 
laser OPT A 
Doxycycline 496 
laser OPT A 
Doxycycline 478 
laser OPT A 
Doxycycline 514 
laser OPT A 
Doxycycline 488 
laser OPT A 
Figure 11.1.6: Emission spectra of doxycycline continued 
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Xylenol 543 laser 
" 580-650 OPT 
Xylenol 405 laser, 
" OPT 
Xylenol 488 laser, 
" OPT 
Xylenol 543 laser, 
" 570-590 
Xylenol 458 laser, 
" OPT 
Xylenol 496 laser, 
" OPT 
Xylenol 543 laser, 
" 600-630 
Xylenol476 laser, 
,\ OPT 
Xylenol 514 laser, 
,\ OPT 
Figure 11.1.7: Emission spectra of xylenol orange 
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11.2 Technical Appendix: Optimising the single cell transcriptome 
analysis protocol 
The protocol used for the single cell transcriptome analysis study described 
in Chapter 8 was modified from one pioneered by Koentges et al. described 
in Tietjen et al. 2003. This technical appendix details the modifications and 
optimisations to the 2003 protocol that were conducted to yield the current 
laboratory protocol (referred to herein as "Updated Protocol"), which can be 
found at the end of this Appendix. Alterations to the 2003 protocol were 
necessitated by reagent availability, to introduce new quality controls and to 
optimise the protocol for the specific project at hand. All procedures 
described herein are detailed in Materials & Methods, Chapter 10. 
11.2.1 Laser Capture Microdissection (LCM) 
Embryonic samples were isolated without modification to the 2003 protocol, 
briefly: specimen were isolated and embedded fresh (without fixation) in 
tissue tek mounting media before being cryo-sectioned at a thickness of 7-10 
~M onto alternating charged (for LCM) or non-charged (for IHC) slides, which 
were kept at -80°C until they were used for laser capture microdissection (for 
this study, a period of no more than a few days). Slides were prepared for 
LCM as follows, according to the genetic background of the sample: 
Wnt1-Cre+l• X ROSA26 LacZ-l- (E13) samples: Adjacent sections to those 
being subjected to LCM were X-gal stained to visualise the (3-Galactosidase 
(+) cells, indicating their neural crest origin. Samples for LCM were prepared 
using a standard histopathological hematoxylin and eosin stain to visualise 
the nuclear and cytoplasmic boundaries. All stains were performed in coplin 
jars that had been cleaned to be RNAse/DNAse free. Optimisation of the 
staining protocol was necessary as the objective was to completely 
dehydrate and stain the samples, using the minimal preparation necessary to 
curtail RNA degradation. Due to the physical location of the PixlCell II LCM 
microscope (in a room that also contains a live-cell imaging system that 
involves fluid injection and yields a high humidity), the slides were re-hydrate 
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quickly, which prohibited successful laser capturing. As such, the duration of 
the dehydration steps were increased and the air-drying decreased and 
individual slides would be subjected to capturing for no more than 1 hour or 
until capturing became confounded by tissue rehydration. 
Wild-type (E9-10), non-transgenic samples: prepared as above with the 
omission of the parallel ~-gal staining. 
Wnt1-Cre+l- x XZ-DR-1- (E18.S) samples: Slides were prepared using a 
modified protocol including a nuclear counterstain (DAPI) but no other 
histological preparation. The GFP reporter (indicating the neural crest cells) 
was a soluble molecule, quenched during aqueous preparations, therefore, 
the staining protocol was optimised to achieve successful dehydration and 
DAPI staining without impinging visualisation of the GFP+ cells (which was 
possible in the fluorescent channel of the LCM without any enhancement or 
immunohistochemistry). 
The successful staining protocols are described in Table 11.2.1; for images 
from LCM see Chapter 8. 
11.2.2 Modifications resulting from enzyme availability 
The single cell transcriptome study relies on the successful reverse 
transcription of cDNA from total RNA, the re-amplification of the cDNA, and 
the fragmentation and subsequent biotinylation of the fragmented cDNA; 
these steps are all mediated by enzymes, some of which had become 
unavailable or were altered (yielding new cloned or recombinant forms) in the 
interim between the 2003 protocol being generated and the current study. 
Specifically, the updated protocol contains modifications in: 
- the cellular lysis step following single cell isolation, due to one RNAse 
inhibitor (RNA guard) no longer being available and the second RNAse 
inhibitor currently having a higher activity level than the 2003 enzyme; 
- the initial RNA reverse transcription to cDNA step to account for a new AML 
reverse transcriptase having a higher activity level than the 2003 enzyme; 
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_ the fragmentation step as strict adherence to the old protocol generated 
overly-fragmented cDNA (less than 25-mer fragments that could not be 
expected to anneal to the 25 bp probes of the microarray, or >500-mer 
fragments that could also have difficulty annealing), despite the activity level 
of the enzyme not changing between 2003 and the current study. 
The modifications to the protocol ensure the same number of enzymatic units 
mediate each step of the updated protocol as they did in the 2003 protocol. 
The enzymes used in the 2003 and updated protocols are described in 
Table 11.2.2. 
11.2.3 Quality controls 
The 2003 protocol recommends using Southern hybridisations as a control 
for the cDNA quality and to confirm the cellular identity of the single cells 
captured (which can also be checked via PCR). The updated protocol has 
modified the quality controls as follows: 
- The lineage origins of the cells are confirmed in samples from Wnt1-Cre+l- x 
R26lacZ-I- mice by PCR for the lacZ transgene after the reamplification of 
the cDNA; while lineage of the cells in samples from Wnt1-Cre+l- x XZ-DR-I-
samples is confirmed at the time of capture by visualising the captured cell 
on the cap using fluorescence (GFP+ neural crest cells are green) (For 
images see Chapter 8). 
- The presence of the housekeeping gene GAPDH is confirmed with peR 
after the reamplification of the eDNA (For images see Chapter 8). 
- After both the initial cDNA transcription and subsequent reamplification, an 
aliquot of the sample is run on an agarose gel to confirm the length of the 
product and the relative concentration of cDNA (For images see Chapter 8). 
Notably, there is no strict criteria for what is considered "good" but a 
successful experiment should yield several micrograms of cDNA around 
1000 bp in length (which is 3' biased due to the nature of the reverse 
transcription). 
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- Southern hybridisations are no longer used as a primary quality control as 
the cDNA quality is assessed with a Bioanalyzer (see below) and the lineage 
origin confirmed as above. Southern hybridisations were deemed, therefore, 
to be an unnecessary and time-consuming use of the very limited sample 
material. 
- The quality and concentration of the neat (unfragmented) cDNA was 
confirmed on an Agilent 2100 Bioanalyzer (Figure 11.2.1). Bioanalysis was 
also used to check the successful fragmentation of the cDNA prior to 
hybridisation to microarrays (Figure 11.2.1). The Genomics Facility of 
Warwick University's School of Life Sciences conducted the bionanalysis of 
the single cell cDNA, a quality control that was used by the Genomics Facility 
in studies conducted by other laboratories using cDNA or RNA from pools of 
cells. Bioanlysis of cDNA from single cells had not previously been examined 
at the on-site facility and results were loosely comparable to results from 
pools of cells, although it required trial and error was used to determine what 
was a "good" result. Specifically, a good sample was one that had a nice 
curve of cDNA with a long migration time (indicating cDNA length) and a high 
concentration. Samples whose neat cDNA was more of a peak than a curve 
and had short migration time were considered to be poor quality. 
- Quantitative PCR (qPCR) of the GAPDH housekeeping gene was also 
used to analyse the overall quality of the cDNA. Standard curves were 
generated from serial dilutions (2.5 nanograms/~L to .25 picograms/J..lL) of 
cDNA generated from whole RNA of the mouse osteoblastic cell line MC3T3-
E1. As a second control, high quality reamplified cDNA from a different study 
(conducted by Dr Keith Vance (KV), unpublished), generated using the 2003 
protocol, was concurrently analysed. Results indicate that all the samples 
generated in the current study using the updated protocol have GAPDH in a 
low abundance (in amounts between the 2.5 picogram/J..lL and 0.25 
picogram/J..lL controls from MC3T3-E1 cells); however, the curves generated 
are, for the most part, comparable or more robust than those from the KV 
sample. The KV sample (which yielded 12.3% present calls when hybridised 
to microarrays concurrently with samples from the present study) may have 
experienced degradation in the 4 year gap between its amplification and 
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qPCR analysis; alternatively, the majority of the samples isolated in the 
current study can be considered to be of equal or higher quality than the KV 
control sample. Notably, the curves did not start to spike until many cycles 
into the qPCR (approximately 35/40) and the results are not used for any 
quantification purposes, merely to discriminate the quality between the 
various samples. As such, there is a clear distinction between the samples 
that have superior versus inferior curves (Figure 11.2.2). 
11.2.4 Validating microarray results: AffyBatch Report 
A total of 26 samples sufficiently passed quality controls prior to hybridisation 
and were selected for further analysis. As a means of comparison I also 
hybridised some samples that had failed the Bioanalyzer quality controls 
(being over-fragmented n = 2, poorly-fragmented n = 2) and a blank sample 
(no cell material added to initial cDNA reverse transcription step, blank was 
subsequently re-amplified, n = 1) to confirm the protocol had successfully 
discriminated between samples that would produce good quality microarray 
results and those that would not. 
Prior to gene expression analysis, background corrections on the arrays 
were performed using the GeneChip Robust Multiarray Average package 
(GCRMA; http://www.bioconductor.org/packages/2.2/bioclhtmllgcrma.htrnl), 
which removes any bias created due to the nucleotide content of the probes 
(Naef and Magnasco, 2003). AffyBatch Quality controls (Bioconductor) were 
run on all the arrays to assess the overall array intenSity, 3'/5' ratios of 
housekeeping genes, and the presence of negative and positive border 
elements. Because the QC report was designed to analyse standard 
microarray experiments of cDNA/RNA from pools of cells, the report was 
used largely to inter-compare the single cell samples to each other. 
The ac report indicated that the overall intensity of the majority of the arrays 
was acceptable and even comparable to the ac report standard generated 
for pools of cells (aC standard mean intensity = 6-8; single cell sample mean 
intensity = -6); the Bioanalyzer-failed arrays had a reduced intensity as did 
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several arrays that had been deemed "borderline" based on Bioanalyzer 
results as they had a sharp peak of cDNA, where "good" samples had a 
characteristic curve. For the purposes of gene expression analyses, the 
microarrays with diminished brightness and questionable Bioanalyzer results 
were removed from the analysis (See Chapter 8). This highlighted the 
importance of being strict with the Bioanalyzer controls, as neat cDNA quality 
directly correlated with samples having poor overall intensity and low array 
coverage. 
The 3' to 5' ratio of the housekeeping genes GAPDH and J3-Actin were, for 
the most part, beyond the range recommended by the ac standard (GAPDH 
recommended ratio of 1, J3-Actin recommended ratio under 3). As the 
recommended range of ratios is between 1 and 3, the ac report only 
indicates if a ratio is within a good range (-3 to 3), in a borderline range (>3 
or <-3) or significantly outside of this; no absolutely values are given (Table 
11.2.3). Among our 26 "good" samples, for J3-Actin, 12/26 (46%) were within 
the good to borderline range, 10/26 (39%) were significantly beyond the -3 to 
3 boundaries and 4/26 (15%) had ratios that were not computed (presumably 
due to missing probe values); comparatively 4/5 control (Bioanalyzer-failed) 
samples (80%) were within the good to borderline range. For GAPDH, 11126 
(42%) of the Ilgood" samples were within the plotted rangel 8126 (31 %) were 
outside the recommended range and 7126 (27%) had uncomputed ratios. 
Comparatively, 100% of the "bad" arrays had GAPDH 3' to 5' ratios that were 
within the acceptable range. The discrepancy whereby poor quality samples 
gave ostensibly better 3' to 5' ratios than "good" samples is accounted for by 
the fact the ac report scales the intensities to determine the ratio; even 
though the intensity of the overall IIbad" arrays was diminished, scaling the 
intensity to calculate the ratios would indicate a hit for a housekeeping gene 
that might not actually be above background. I confirmed this by examining 
the present hits on the IIbad" arrays, where I found that of the 3 probes for 
GAPDH and 3 probes for J3-Actin, only 1 sample (of the 5) had a single J3-
Actin hit, while 2 samples had a single GAPDH hit. Contrasting this, 20 of the 
26 "good" samples had at least 1 present hit for J3-Actin (of which 10 had 2/3 
present calls) and 19/26 Ilgood" samples had at least 1 present hit for 
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GAPDH (2/26 had triple hits, and 7126 had double hits) (Table 11.2.4). 
Additionally, the overall intensity of the housekeeping genes was significantly 
higher in the "good" arrays compared to the 3 present hits in the Bioanalyzer-
failed samples. 
The 3' to 5' ratios being beyond the recommended limits of the ac standard 
in the "good" samples was unsurprising given the 3' bias of the cDNA 
generated in the current protocol and short length of the cDNA transcripts 
generated in the initial reverse transcription step (approximated to be 
between 500-1000 bp). As a comparison, a published report of single cell 
transcriptome analyses from laser captured samples hybridised to 
microarrays indicate a GAPDH 3' to 5' ratio of a mean 6.76 and I3-Actin 3' to 
5' ratio of a mean 57.92; comparatively, in the same report, unfractionated 
pooled cells that were isolated and also hybridised to m icroarrays had 3' to 5' 
ratios of 0.89 and 1.44 for GAPDH and I3-Actin, respectively (Seshi et a/. 
2003). These results indicate the ratios in the current study are not beyond 
the acceptable limit for published studies. 
The aspects of the QC report relating to the intensity across the arrays (as 
determined by examining the positive and negative border elements) were 
not deemed to be useful in the current study as the low percentage of 
present hits may be perceived by the software to be a bias in the 
hybridisation. A cursory examination does show, however, that among all the 
"good" arrays, the intensities cluster toward the middle of the plot (indicating 
unbiased hybridisation), while in the Bioanalyzer-failed and blank sample the 
intensities cluster in a corner of the plot (Figure 11.2.3). 
In addition to the AffyBatch QC report, further analyses were also conducted 
to assess RNA degradation. RNA degradation analysis compares the 
intensity of 3' versus 5' probes among genes described as present in the 
array. little RNA degradation will yield a straight line, while extensive RNA 
degradation will have a sloped line. Reassuringly, the plots for the "goOd" 
samples indicate very little RNA degradation (Figure 11.2.4); although the 
validity of using this control for QC in reamplified cDNA from single cells has 
not been examined in published reports. 
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11.2.5 Validity controls from previously published reports 
Following AffyBatch quality controls and RNA degradation analysis, the 
microarrays were subjected to further quality controls in line with quality 
controls reported in previous studies, see below (Kamme et al. 2003; Seshi 
et al. 2003; Tietjen et al. 2003; Esumi et al. 2008). 
11.2.5.1 Representation of transcriptome complexity 
Following AffyBatch aCt 9 samples were removed from further analysis due 
to an overall diminished brightness of the arrays combined with the 
borderline/questionable Bioanalyzer result from those samples. Among the 
remaining 17 samples, array coverage ranged from 1.7-14.9% present, with 
a mean coverage of 5.8%; among the blank array and the four control "bad" 
Bioanlyzer-failed samples, array coverage ranged from 1 % (blank) to 2.6%, 
with a mean coverage of 1.9%. For comparison sake, among the 9 arrays 
removed for having questionable Bioanalyzer quality and low intensity as 
indicated by the AffyBatch QC report, the range of coverage was 1.7-5%, 
with a mean of 3.7% (Table 11.2.5). 
Previous studies analogous to our own, using microarrays to interrogate the 
transcriptome of LCM-isolated single cells from rodent tissues, reported array 
coverage ranging from 5.6%-13.9%. Other published studies using 
dissociation as a means to isolate single cells report higher array coverage, 
and one study reported extremely high array coverage from LCM dissected 
single cells (28-41 % present, mean 36%), however, this was on a custom 
designed array which would be expected to have more bias toward genes 
that are predicted to be expressed in the cell type studied (Seshi et al. 2003). 
Notably, I was unable to determine how many genes are "expected" to be 
expressed in any given single cell, as this value would vary based on the cell 
type, stage in the cell cycle, and innumerable other factors. 
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I, therefore, decided to use 4% as the cut off to include arrays for further 
analyses, which further reduced the experimental cohort by 5 arrays to 12, 
with % present ranging from 4-14.9% and a mean % present of 9.1%. 
The technique described herein for isolating single cells is robust enough to 
capture single cells; however, in highly dense areas, some cellular material 
from adjacent cells might also be captured. Furthermore, the thickness of the 
sections were designed to ensure only a single cell plane, however there 
were inevitably times when the capture was not a clean single cell. I was 
diligent in recording this and quantifying the exact number of cells captured 
(as indicated by both the nuclear stain and the margins of cells on the 
histopathological presentation) and as a default I indicated a 2-cell capture 
unless an absolute clean margin around the entire cell was visible. I 
observed also that published reports of single cell LCM studies that display 
their captures in figures are analogous to my own and most appear to have 
more than one cell; I accept that "single cell" has become nomenclature for a 
tiny volume of no more than a few cells. I was anxious to examine the effect 
of increased cell volume on the final data output. While the technique should 
not be biased toward samples that have more than one cell, I correlated the 
number of cells captured with the array coverage in the final cohort of 12 
arrays and found no relationship between them (R2 = 0.0931) (Figure 
11.2.5). I also confirmed that the amount of cDNA hybridised to the array did 
not correlate with the array coverage; this was true using the [hybridised] as 
either the concentrations of the neat cDNA (R2 = 0.0006) or the fragmented 
cDNA (R2 = 0.1124), as determined by the Bioanalyzer (Figure 11.2.5). 
When I included the total cohort of the initial 26 samples, including those that 
had been excluded due to poor intensity/Bioanalyzer results, there was still 
no relationship between cell number and array coverage (R2 = 0.0289), neat 
cDNA concentration (R2 = 0.0304) or fragmented cDNA concentration (R2 = 
0.1741) (Figure 11.2.6). 
11.2.5.2 Clustering analyses 
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Clustering analyses can be used to group cells based on whole-
transcriptome expression profiles (Kamme et al. 2003); the expectation is 
that cells of a similar type should cluster more closely to one another than to 
cells of another type. I use principle component analysis (peA), conducted 
by Dr Sascha Ott, as my clustering method (see Chapter 8) and find that the 
neural crest cells giving rise to non-vascular structures cluster more closely 
to each other than to vasculature cells; and peA could not discriminate 
between neural crest versus mesodermal vasculature (Figure 11.2.7). 
Notably, the clusters could also be seen to represent stages of 
differentiation, as samples from E13 were more closely aligned to each other 
than those from E18.5, with the exception of sample 87. 
The microarrays were run in two main batches and when the samples are 
analysed with PCA, the first cohort clusters nicely, while the other (containing 
the 9 samples with diminished intenSity -circled in red-) did not (Figure 
11.2.7). To confirm that the arrays with overall intenSity did not cluster well, 
and the lack of clustering was not an artefact of including samples with 
extremely low array coverage, peA was run on all samples with % present 
>2.5%; and the clusters were not recapitulated. 
I, therefore, conclude that the peA confirmed the arrays with low intenSity 
and low % present had transcriptomes unlike biologically similar and 
adjacent cells (Figure 11.2.8). 
I could not determine, using peA, to what extent the clusters were 
biologically relevant, however, they were a useful tool to confirm the 
transcriptomes of the E13 analgen to structures affected in Chiari were 
dissimilar to the transcriptomes of terminally differentiated vasculature of the 
cranial base in E18.5 specimen. 
11.2.5.3 Hybridisation effiCiency 
Studies of single cell transcriptomes often use analYSis of well-characterised 
genes, specific to the cell-type of interest, to confirm the capture and validate 
the microarrays (Kamme et al. 2003; Seshi et a/. 2003; Tietjen et al. 2003; 
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Esumi et a/. 2008). I confirmed the lineage of the capture as described 
above, as well as using peR to detect the presence of the LacZ transgene in 
the E13 samples and the GAPDH housekeeping gene in the 18.5 samples. 
The samples from neural crest cells in the E 13 specimen were from 
condensed mesenchymal anlagen to structures affected in Chiari, the 
majority of which were precursors to bony structures. I was hesitant to 
confirm the fate of cells from these regions with genes expected to be 
expressed given the study of dermal bone development described in Part I 
indicated that gene expression in bone development is complex; furthermore, 
the condensed mesenchymal precursors to the bone structures would be 
expected to contain both vascular and osteoblastic lineages and may be at 
various stages of terminal differentiation. We did, however, examine the 
expression of some markers associated with certain cell fates and confirmed 
the samples from the E18.5 vasculature expressed vasculogenic markers, as 
well as various collagens and adhesion molecules and some 
muscle/fibroblastic markers- presumably confirming these are endothelia 
and/or pericytes (Table 11.2.6). Among the E 13 samples, those from the 
anlagen to the posterior cranial fossa/tentorium had similar profiles (among 
the limited genes examined) to both the E18.5 vascular samples and the 
condensed mesenchyme from the other sub-populations of E13 neural crest 
cells (Table 11.2.6). This explains why the PCF samples cluster closely to 
the other E 13 sub-populations, but on the perimeter of the cluster toward the 
E18.5 samples. Additionally, samples 87, from the clivus/pharyngeal 
constrictor region, has a similar profile to the vascular cells from the E18.5 
samples (confirmed with cluster analysis), indicating it may be a precursor to 
the vasculature in the mesenchymal condensation at the cranial 
base/pharyngeal interface. Examining this limited cohort of markers further 
emphasized how diverse the expression profiles of the cells were and 
reiterated that many markers are not confined to being expressed by cells of 
a single fate; a future study, to increase the experimental cohort and produce 
statistically significant expression profiles from the various regions explored 
in this pilot study is warranted. 
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In studies categorising differential gene expression between groups of cells, 
the ultimate confirmation of the present calls on microarrays includes either 
quantitative real-time PCR (qRT-PCR) or in situ analysis of the mRNA 
expression in the adjacent tissues to those captured. In the current study, 
differential analysis between groups was prohibited by the low number of 
samples from each group in the 12 microarrays that ultimately passed all 
quality controls. Any differential expression would be statistically invalid as 
there were not three replicates in each group. As such confirmation of gene 
expression with in situ is planned once future studies increase the cohort. 
11.2.5.4 Further controls 
In the current study, the abundance of the transcripts of expressed genes 
was not examined; the study was binary in nature and the microarrays were 
not used to quantify gene expression levels. This obliterated the need for 
quality controls relating to confirming the accuracy of in how far the cDNA 
represented the distribution of RNA (ex: qRT -PCR, spiking in RNAs, dilution 
experiments ). 
There were, however, two controls not included in the current study that 
would be recommended in future studies: reproducibility of the arrays (cDNA 
from the same cell hybridised in duplicate) and controls for the labelling 
efficiency in the biotinylation step. 
A reproducibility analysis was conducted early in the study, prior to 
optimisation of the fragmentation step, in sample #8, which was found to be 
over-fragmented based on Bioanalyzer results. Among the three replicates, 
only 30-40% of the present hits were shared between all three arrays 
(depending on the overall % present), 10-15% were shared between any two 
of the arrays, and 47-51% were unique present calls among one of the 
replicates. Comparing the three replicates of sample 8 to the blank sample, 
run in the same batch, revealed 93% of the present calls in the blank were 
not shared with any of the replicates of sample 8. This indicated that the 
three repeats were not reproduCible, but most probably contained "real" hits, 
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but the over-fragmentation had indiscriminately split the cDNA such that only 
2-2.6% of the genes on the array were indicated to be expressed (compared 
to the 1 % array coverage of the blank sample). Low expression levels in the 
arrays could also be attributed to incomplete biotin labelling, such that there 
was no "tag" on the cDNA annealed to probes that would allow the scan to 
detect the .hybridisation. In the future, controls for labelling would be 
recommended and optimisations undertaken as necessary; issues of 
labelling were not raised in the Tietjen et al. 2003 protocol, and the terminal 
transferase enzyme conferring the biotin label has not been altered (cloned, 
recombined, altered activity level, etc) since the 2003 study. However, the 
finding that the fragmentation needed optimisation despite no discernible 
changes to the RQ1 DNAse enzyme supports the idea that all steps involving 
enzymatic reactions should be checked with a quality control and not 
assumed to be successful. 
11.2.6 Discussion 
The aim of the optimisation to the 2003 protocol was to create a workflow 
that would enable me to explore the transcriptomes of single cells isolated by 
laser capture microdissection. An ideal workflow would be able to distinguish 
between samples that would generate good data, from those whose poor 
quality is prohibitive to further analyses. We hybridised 26 "good" samples 
that had passed pre-microarray quality controls and an additional 5 "bad" 
samples, which had failed QC or were blank. The final experimental cohort, 
following the post-hybridisation controls, included only 12 samples, or 46% of 
the original 26 (excluding 56%). It is impossible for us to know how this 
compares to published studies as the process of optimisation is never 
included in the final literature report. Crucially, in hindsight I should not have 
hybridised 9 of the arrays with questionable bioanalyser results, which would 
have reduced the % of arrays excluded from the final cohort to the 30% with 
extremely low array coverage. Although the samples with low % present may 
be perfectly valid, and represent more quiescent cells, I chose to err on the 
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side of caution and not include samples with less than 4% coverage in 
analyses for the study. 
Within the 12 final samples, those that were captured from E13 samples (n = 
7) had a % present range on the array of 4-8.9% with an average of 6.6%; 
the E18.5 samples (n =5) have a % present range from 7.5-14.9%, with an 
average of 10.7%. I attribute this difference to the fact that the E13 samples 
were the first to be captured and used to optimise the protocol, and the 
E18.5 samples were isolated at a later date under the most optimised 
conditions, with minimal time for degradation prior to hybridisation. If this is 
the case, future studies should expect to yield similar results to the E18.5 
samples using the optimised protocol. Alternatively, the cells at E13 may 
have less genes being expressed due to the stage of cell differentiation or 
the nature of the tissues from which they were isolated. 
Overall, I am satisfied that the current updated protocol can be used to 
successfully conduct single cell transcriptome analyses, provided strict 
adherence to quality controls is followed. Further optimisations to confirm 
reproducibility and biotin labelling efficiency will further enhance the current 
protocol. 
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Table 11 .2.1: Histological preparations for tissues subjected to laser capture microdissection (LCM). Protocols 
were optimised according to genotype to identify cell lineage and morphology, thoroughly dehydrate the tissue and 
minimise RNA degradation. 
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Table 11 .2.2: Enzymes used in the single cell transcriptome analyses. Enzymes with modifications (due to 
availabil ity, activity, properties, etc.) between the 2003 and updated protocol are indicated in red. 
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Figure 11.2.1: The spectrum of results of the Bioanalyzer quality control 
A variety of results from Agilent Bioanalyzer results of whole (neat) and fragmented cDNA. 
A. Example of a sample (#8) with good neat cDNA results, top, (a long curve), but poor results after fragmentation, 
bottom. DNAse over-fragmented the cDNA leading to a remarkably diminished overall intensity, concentration and 
length of the product which would be too short to anneal to the microarray probes. When run on a microarray as a 
control, this sample had 2.6% array coverage. 
B. Example of a sample (#45) with "borderline- neat cDNA results: a peak as opposed to a nice curve and the height 
of intensity closer to 25 than 4000 (indicating a short cDNA). The fragmentation was successful, however, this 
sample was among those whose overall intensity on the microarray was poor, presumably due to poor initial cDNA 
quality. 
c. Example of a sample (#4) with good quality neat eDNA and good fragmentation. This sample had 9.7% array 
coverage. 
* Conditions for sample preparation can be found in Materials and Methods. 
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Figure 11.2.2: Quantitative peR as a pre-hybridisation quality control 
Quantitative PCR for the housekeeping gene GAPHD can be used to discern between samples with high or low 
abundance GAPDH, used as a proxy for cDNA quality. 
A. Standard curves generated using cDNA reverse transcribed from RNA from mouse osteoblastic cell line MC3T3-
E1. Notably, the curves would not be sufficient for quantification purposes but were only used to estimate the 
abundance of GAPDH in the highest quality samples from the LCM study. 
B. Three replicates of eDNA from a previous study conducted by Keith Vance (cDNA from this sample hybridised to 
microarray had over 11% array coverage). The three replicates indicate intense variability among aliquots from the 
sample re-amplified sample. 
c. Results of qPCR for GAPDH showing high quality samples have curves somewhere between the standard curves 
for the 2.5pg/1JL and .25pgllJl controls. All curves were significantly better than the water control. 
* Conditions for sample preparation can be found in Material and Methods. 
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Table 11.2.3: Quality control results from AffyBatch QC report 
for the 5 control (samples which failed pre-array quality controls) 
and 26 experimental samples. Cell 10, region from which cell was 
captured, array intensity and 3' to 5' ratios of two housekeeping 
genes are indicated. Values outside the recommended range 
(based on arrays of pools of cells) are indicated in red . 
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Figure 11.2.3: Results of AffyBatch quality controls for border element clustering 
The results of the clustering of the positive and negative border elements for the "good" microarrays (A) versus the 
abad" Bioanalyzer-failed control microarrays (8) demonstrates the poor clustering among the controls. 
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Figure 11 .2.4: RNA degradation analysis of the 
single cell transcriptome samples 
RNA degradation plots indicate the vast majority of 
the samples had little difference in the mean 
intensity of the 5' versus 3' probes in the 
microarrays, which should imply there is little RNA 
degradation among the samples; furthermore, the 
eDNA was long enough to not be too biased 
toward the 3' probes. The validity of using RNA 
degradation plots as a quality control for single-cell 
transcriptome analyses has not been raised 
previously in the literature. 
Table 11.2.5: Properties of samples from microarray analyses. Properties of the 5 control (samples which failed 
pre-array quality controls) and 26 experimental samples. Cell 10 and region from which the cell was captured are 
indicated. QC results from Bioanalyzer include: concentrations of 1 IJL of neat and fragmented cDNAs, as well as the 
length of the fragmented product (ideally 25-500 bp), the intensity of the fragmented product, and the characteristics 
of the neat cDNA (ideally a curve from 500-1000 bp). The intensity on the arrays is also indicated, as well as the array 
coverage (% present hits). Samples in red have passed all pre and post-array QC; samples in blue have passed QC 
but have low % present and were excluded from further analyses; arrays in green had questionable Bioanalyzer 
results and poor array intensity, result ing in their exclusion from further analyses. 
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Figure 11.2.5: Correlating microarray coverage with various characteristics of the single cell samples 
Among the 12 samples that passed all pre and post-hybridisation quality controls , and had over 4% array coverage, 
there is no statistical correlation (as indicated by the R2 value) between array coverage and the number of cells 
captured (A), the concentration of in itial neat cDNA (8 ), nor the concentration of the fragmented cDNA hybridised to 
the chip (C). Concentrations for these analysis determined by Bioanalyzer results. 
361 
A 16 8 16 C 16 
• • R2-0Q3JM_ • R2 = 0.1741 14 L.02&L 14 14 
12 12 12 
• • ~ 10 ..- 10 ..- 10 c c C a.> a.> C/l 8 C/l • a.> 8 a.> a.> 8 C/l ... ... 
• a.> D.... D.... ... 6 D.... 6 ~ ~ 6 ~0 0 ~ 4 0 4 4 
2 .... ~ ... II 2 2 o I 
/I 0 0 5 10 0 0 200 400 600 0 500 1000 1500 2000 
# Cells 
" [neat cDNA) 
" 
[fragmented cDNA) 
__ Linear (number of cells vs. Linear (concentration neat cDNA II Linear (concentration frgamented 
array coverage) vs. array coverage)c cDNA vs. array coverage)c 
Figure 11 .2.6: Correlating microarray coverage with various characteristics of the single cell samples II 
Among the total 26 sample cohort (including samples that failed subsequent post-hyrbidisation quality controls and/or 
had array coverage under 4%), there is no statistical correlation (as indicated by the R2 value) between array 
coverage and the number of cells captured (A), the concentration of initial neat cDNA (8) , nor the concentration of the 
fragmented cDNA hybridised to the chip (C). Concentrations for these analysis determined by Bioanalyzer results. 
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Figure 11.2.7: Principle component analysis plot of the transcriptomes single cell samples 
A. Following all pre and post-hybridisation quality controls, the transcriptomes of the first cohort of 12 samples were 
subjected to clustering analysis. A plot of principle components 1 and 2 (accounting for 99% of the variability within 
the samples) clearly divides the samples into two sets along the X and Yaxes. To the left are the vascular samples 
from the E18.5 mice; versus all the non-vasculature samples from the E13 mice are to the right. Interestingly, the 
transcritpomes of mesodermal versus neural crest derived vasculature do not segregate the lineage origins. Among 
the E13 samples, principle component 1 clusters the three sub-regions of neural crest cells, which may reflect region 
variation in the transcriptomes. 
B. The transcriptomes of the final cohort of 14 samples was subjected to principle component analysis, ignoring the 
diminished intensity of the samples circled in red. There is no significant clustering. 
c. The total group of all samples from both cohorts (including those failing post-hybridisation quality controls) was 
subjected to principle component analysis and the transcriptomes showed no significant clustering. 
* Sample preparation, hybridisation conditions and descriptions of statistical analyses can be found in Materials and 
Methods. 
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Figure 11.2.8: Principle component analysis of the 
samples passing both pre- and post-hybridisation 
quality controls 
Following all pre and post-hybridisation quality controls, 
the four samples with acceptable overall intensity were 
added to the first cohort of 12 samples and the 
transcriptomes of the 16 samples were subjected to 
clustering analysis. A plot of principle components 1 and 
2 (accounting for 99% of the variability within the 
samples) clearly divides the samples into two sets along 
the X and Y axes, with only sample 87 as an outlier 
(yellow box in left cluster). To the left are the vascular 
samples from the E18.5 mice; versus all the non-
vasculature samples (bar #87) from the E13 mice are to 
the right. Notably, the samples to the bottom right most 
corner, comprising samples from 3 sub-regions of neural 
crest cells, have the lowest overall array coverage and 
this clustering may be due to that fact. For further 
analysis, only 12 sampled that successfully pass all QC 
and have %present > 4% were included in the analysis. 
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Table 11.2.S: Expression of genes characteristjc of certa in lineages within the final experimental cohort of 12 
samples. P, present; A, absent. 
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11.2.7 SINGLE CELL MICROARRAY PROTOCOL: FROM 
SAMPLE PREPARATION TO MICROARRAY HYBRIDISATION 
The following protocol was used to perform Affymetrix microarray analysis of 
single cell cDNAs. The generation of single cell cDNA is modified from Tiejen 
et al. 2003, itself a modification (Dulac and Axel 1995). Single cells are 
obtained by laser capture microdissection. Several micrograms of amplified 
cDNA are then synthesized by lysing the cell, reverse transcribing the total 
cellular RNA after oligodT priming, polyA tailing the 5' cDNA end, and finally 
amplifying the cell cDNA with a unique polyT primer. The reverse 
transcription is performed in limiting conditions of nucleotides and time in 
order to generate cDNA of uniform size (between -500 bp and 1 kb), which 
are then more likely to be uniformly amplified. This allows the amplified 
cDNA to reflect an accurate representation of the various cell RNAs. This 
cDNA synthesis can be done on single cells, groups of cells, as well as very 
small amounts of RNA purified from several hundred cells by the RNAzol 
procedure. The single cell cDNA is usually re-amplified to provide enough 
material for the microarray experiment, digested into smaller fragments with 
DNAsel, and then end labelled with a biotinylated ddATP. Hybridization to 
Affymetrix arrays and the subsequent washing steps then follows the 
standard hybridization procedures. It is critical to check the quality of the 
cDNA generated as well as the nature of the cell picked by performing the 
quality controls (OCs) described herein. We typically use only 10% of our 
single cell samples on microarray experiments, carefully choOSing only high 
quality cDNAs. Common cells, such as fibroblasts, can be used as a pilot to 
check for the quality of the cDNA, to gain familiarity with the protocol and to 
control for the quality of the reagents. 
Reagents and materials (for single cell isolation and cDNA synthesis) 
Dissecting scope 
~7°C and 65°C water baths 
Perkin Elmer DNA thermal cyler 
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Multiwell PCR Machine 
Arcturus PixCeli \I LCM 
Agilent Bioanalyzer 
NanoDrop Spectrophotometer 
- AL 1 primer: ATT GGA TCC AGG CCG CTC TGG ACA AAA TAT GAA 
(T)24 (0.2 \Jmol scale) MWGEurofins/Operon 
- Amplitaq 5000, with 10X buffer, Applied Biosystems 5U/ul #N8080-156 
- AMV reverse transcriptase 100U, 15 U/IJI, Fisher UK 
- Arcturus Capsure LCM caps 
- Autoclaved thin walled reaction tubes, Applied Biosystems #N8010611 
- BSA molecular grade 20 mg/ml, Roche #711454 
- dNTP set, 100 mM each Roche #1277049 
- H20, RNAse, DNAse free, Cell & Mol Tech #TMS006C 
- Mineral oil, molecular biology grade Sigma #M5904 
- MMLV reverse transcriptase + buffer 5X, 40,OOOU, 200U/ul Fisher UK 
#BPE3208-5 
- Nonidet P40 (NP40), 500 mL USB #19628 
- Oligo dT24 (0.2 \Jmol scale) MWGEurofins/Operon 
- Qia-quick PCR purification kit, Qiagen #28704 
- RNAse inhibitor, 2500 units, Applied Biosystems #0032005.357 
- Terminal transferase buffer 5X, Invitrogen #16314-015 
- Terminal transferase, 8000 U, 400 U/\JI Roche #3333566 
- Triton X100, RNAse and DNAse free Sigma #T8787 
I. Isolation of Single Cells 
Embryonic day E9.5 & E10.5 wild-type mice, E13 Wnt1-Cre+I• x 
ROSA26LacZ·I. transgenic and E18.5 Wnt1-Cre+I• x XZ-DR/· transgenic mice 
were dissected and embedded without fixation in Tissue-Tek OCT 
compound, cryosectioned into 7-10 lJm thick parasagittal sections, placed on 
permafrost coated glass slides (non-charged), and frozen immediately on dry 
ice before storage at -SO°C. 
The slides are taken through the following dehydration series immediately 
from the -BO°C freezer; make sure all staining jars (coplin jars or 
disposable mailing jars) are thoroughly cleaned to be DNAse/RNAse free 
prior to staining: 
Wild-type & ROSA26LacZ XZ-DR 
70% EtOH 2 minutes 70% EtOH + 5:1000 DAPI 2 min 
H20 5 sec 95% EtOH 10 sec 
Mayer's Hematoxylin 2 minutes 95% EtOH 30 sec 
H20 5 sec 100% EtOH 1 minute 
Bluing Reagent 1 minute 100% EtOH 1 minute 
70% EtOH 10 sec Xylene· 5 min 
95% EtOH 10 sec Xylene· 5 min 
Eosin Y 20 sec air dry 2 min 
95% EtOH 30 sec 
95% EtOH 30 sec 
100% EtOH 1 min 
100% EtOH 1 min 
Xylene· 5 minutes 
Xylene· 5 minutes 
air dry 2 minutes 
• Xylene kept in coplin jars in hood as Xylene dissolves plastic. 
- Single cells were dissected using a PixCell II Laser Capture 
Microdissection microscope, as described by the manufacturer. The single 
cells were captured into Arcturus Capsure caps, using minimal power and 
duration to reduce spot size to capture single cells. 
- Using a very clean (RNAse free: Wipe clean with RNAse Away or other 
appropriate solution. Keeping these tools under UV-light prior to use can 
also minimize contamination.) micro-scalpel or microdissection needle, the 
single cells were removed from the Capsure caps under a dissection 
microscope. This is done by cutting the plastiC cap around each single cell 
with the micro-needle. 
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- Using the micro-needle to lift the sample, place the dissected single cell 
into the bottom of a thin-walled PCR tube. Samples then stored at -80°C 
until the lysis step. 
- Prepare the single cell lysis buffer; for 25 reactions mix on ice: 
MMLV buffer 5X (the "1 st strand buffer") 25 J.lL 
NP40 5% 0.625 J.lL 
PrimeRNase inhibitor(= 60 U) 2 J.lL 
stock primer mix 2.5 \JL 
dH20 95J.1L 
Stock primer mix (aliquot and store at -20°C) 
100 mM dATP, dCTP, dGTP, dTTP solutions (12.5mM final) 10 J.lL each 
50 OD/ml pd(T)24* [0.050D/\JL1 10 \JL 
H20 30 J.lL 
- Aliquot 4 J.l1 of this buffer into a thin-walled PCR reaction tube (Perkin 
Elmer) for each sample (Important: don't forget a zero control tube with no 
cell in it). 
-Spin immediately for 30 seconds, to make sure the cell is indeed in the lysis 
buffer. Keep the collected cells on ice. Proceed to Part II. 
" eDNA Synthesis and Amplification 
-Lyse the cells by transferring the PCR tubes containing lysis buffer mix and 
cells from ice to a 65°C water bath for 2 min. 
- Keep several minutes at room temperature to allow the oligo-dT to anneal 
to the RNA. 
- Put back on ice. Spin 2 min at 4°C. 
- Prepare the 1:6 AMV:MML V reverse transcriptase master mix; for 25 
reactions mix on ice: 
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MMLV-reverse transcriptase (50 U/cell) 
AMV-reverse transcriptase (0.625 U/cell) 
6.25 ~L 
1.05 ~L 
- Add 0.3 ~L of the reverse transcriptase mix to the cell mix and incubate for 
exactly 20 min at 37°C (no longer). 
- Inactivate 10 min at 65°C. 
- Put back on ice. Spin 2 min at 4 DC. 
- On ice, add 1 OU terminal tranferase (0.3 ~L) to 4.5 ~I 2X tailing buffer and 
add to cells: 
stock 2X tailing buffer: 
5X terminal transferase buffer (Invitrogen) 
100 mM dATP 
800 ~L 
30 ~L 
1.17 mL H20 
- Incubate at 37°C for 15 min. 
- Inactivate at 65°C for 10 min. 
- Put back on ice. Spin 2 min at 4°C. 
- Add 90 IJI of ice cold PCR buffer (keep all reagents and PCR mix on ice 
to avoid primer dimer formation): 
10X PCR buffer" 
MgCI2 25 mM 
BSA 25mg/mL 
each 100mM dNTP 
5% Triton (250 IJI Trition + 4.75 mL dH20) 
AL1 primer 
H20 
AmpliTaq 
1 or 2 drops of mineral oil 
10 ~L 
10 ~L 
1 IJL 
1 ~L 
1 IJL 
5 ~g 
to total vol 90 IJL 
2 IJL 
(Note: If using thermocycler with heated lid, mineral oil is not necessary) 
- Hot start PCR reaction on a Perkin Elmer DNA Thermal Cycler [holds up to 
48 samples] 0/Ve have also used the Perkin Elmer geneamp PCR system 
2400). Perform 25 cycles: 
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94°C for 1 min 
42°C for 2 min 
72°C for 6 min with a 10 sec extension time added each cycle 
- When these 25 cycles have finished, add 1 ~I of AmpliTaq directly in each 
tube (see a cloud when Taq is added). 
- Perform 25 more cycles with the same program, except do not add the 
extension time, end with 4°C Hold. 
- Once completed, keep on ice/store at -20°C. 
lIa. QUALITY CONTROL: 
1. Run a 5 ~L aliquot of each sample on a 1.5% agarose gel and confirm 
there is a thick band of cDNA at the bottom and a faint smear or corners of 
the band, ideally reaching 0.4-1.2 kB. There may be a smear in the zero 
control due to minor bacterial contaminants in the enzyme solution. 
- The best samples from Part II are used to proceed to Part III. 
III. Re-Amplification of Single Cell cDNA 
Re-amplify the single cell samples to generate large amounts of single cell 
cDNA. 
- Per reaction, make up the following solution on ice: 
Ultrapure H2O 80 ~L 
10X PCR buffer II 10 ~L 
10X MgCI2 10 ~L 
100 mM dATP 0.2 ~L 
100 mM dCTP 0.2 ~L 
100 mM dGTP 0.2 ~L 
100 mM dTTP 0.2 ~L 
AmpliTaq 1 ~L 
AL-1 primer 5~g 
Each cell gets five reactions, so if three cells are to be re-amplified, make 16 
reactions worth (3 cells x 5 + blank DNA control = 16). 
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- Add 100 J,JL to a negative control tube. 
- Add 100 IJI to each tube for each single cell reaction, then add 2 IJI of 
single cell cDNA . 
- Add mineral oil to each tube (if using PCR machine without heated top). 
- On the PCR machine, run the following for 30 cycles: 
94°C 
42°C 
72°C 
followed by 72°C 
4°C 
1 min 30s 
2 min 
3 min 
20 min 
until ready to process 
- PCR purify using Qiagen PCR purification kit. Each column can hold 10 
IJg of cDNA, so 2 reactions can be purified/column. Elute each column in 30 
J,JL, generating -20 IJg of each single cell reaction in 60 IJL total volume. 
Use a spectrophotometer to measure the concentration of cDNA. 
Following this procedure, we typically get between 20-50 J,Jg of single cell 
cDNA. 
lila. QUALITY CONTROL 
1. Run a 5-10 J,JL aliquot of each sample on a 1.5% agarose gel and confirm 
there is a thick smear of cDNA reaching >500 bp in length. There may be a 
faint smear in the zero control due to minor bacterial contaminants in the 
enzyme solution. 
2. Confirm the presence of the transgene, or highly expressed housekeeping 
genes (such as GAPDH) with peR. Primers must correspond to 3' most end 
of the genes as the cDNA generated are mostly <1 kB. 
3. Test the quality of the cDNA using quantitative PCR for GAPDH. Run each 
sample in triplicate and also run a re-amplified sample from single cell cDNA 
that has previously successfully generated good microarray results: compare 
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the results to an RT -negative control, the standard curves generated from 
cDNA of known concentration (such as from a cell line), and each other. 
qPCR should be used to discriminate between the quality of the individual 
reamplificates and not for quantification. I 
I 
4. Run a 1 IJL aliquot of each single cell re-amplified cDNA on Agilent I 
Bioanalyzer to confirm concentration, cDNA length, and quality. Neat cDNA I 
should generate a long curve. Compare the results of "good" and "bad" 
samples from previous OC to become familiar with the results expected from 
high and low quality samples (and the zero control). ** No cDNA should be 
hybridized to microarrays unless they pass Bioanalyzer OC! 
- Based on these control experiments, it is possible to find a number of high 
quality samples that can be used for a microarray experiment in Part V 
V. Labeling of Single Cell cDNA and Microarray Hybridization 
Additional materials and reagents: 
One Phor-AII Buffer, Amersham, but no longer available #27-0901-02 
RNAse free DNAse, R01, Promega 1000 U, #M6101 
Biotin-N6 ddATP, Perkin Elmer #NELS08 
Terminal Transferase, sao U, Invitrogen #10S33-016 
---------------------------------------------------------------
(Note: all volumes are scaled up 1.SX to avoid evaporation problems. This 
ensures enough volume for multiple hybridizations with the same sample to 
standard Affymetrix Genechips.) 
- In an eppendorf tube, mix the following reaction for each single cell cDNA 
to be analyzed: 
20 IJg* of re-amplified, purified single cell cDNAx IJL 
10X One-Phor-AII buffer 6 IJL 
0.7 U RQ1 DNAse 0.751JL 
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Eluate buffer (Tris from Qiagen kit) up to 60 I-IL 
Total rxn: 60 1-11 
* note: standard Affy protocol will only use 2/3 of reaction for hybridization, 
therefore using 20 I-Ig of cDNA will mean 15 I-Ig is hybridized. Less cDNA can 
be used, Affymetrix recommends no less than 7-10 I-Ig. 
- Incubate the samples at 37°C for 13 minutes (sharp). 
- Heat Inactivate the DNAse at ggoC for 15 minutes (ALWAYS cap the 
samples). Spin briefly in microfuge. 
- Remove 1 I-IL aliquot of sample for Bioanalyzer quality control. 
- Using the entire 601-11 sample of fragmented DNA, add: 
Biotin-N6_ddATP (1.0 mM) 
Terminal Transferase (15 U/I-II; Invitrogen) 
- Incubate at 37°C for 1.5 hours. 
1.51-1L 
1.251-1L 
Heat inactivate reaction at 65°C for 15 minutes. Put on ice for 5 minutes. 
**At this point, protocol essentially merges with the standard Affymetrix 
protocol for preparing samples for microarrays. 
Va. QUALITY CONTROL 
1. Run the 1 I-IL aliqot of fragmented cDNA on an Agilent Bioanalyzer to 
confirm the cDNA has been successfully fragmented. Over fragmented 
samples will be less than 25-bp length and under-fragmented samples will 
still be around 500 bp in length. After fragmentation the concentration is 
reduced, but should still be >250 ng/l-lL; the fragmented cDNA appears as a 
peak, not a curve. ** No cDNA should be hybridized to microarrays unless 
they pass Bioanalyzer aC! 
- Based on these control experiments, it is possible to find a number of high 
quality samples that can be hybridised to microarrays 
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